 
  
 
 
 
 
 
 
 
 
 
 
 
 
The Respi[INVESTIGATOR_466877]  
 
[STUDY_ID_REMOVED]  
 
May, 17, 2018  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  2  The Respi[INVESTIGATOR_466878], PI, 214 -648-9022, Lew Radonovich, PI,  
  
  
Incidence of Respi[INVESTIGATOR_466879]: The 
ResPECT Study  
Principal Investigators   
 Lew Radonovich, MD  Trish M. Perl, MD, MSc  
 Senior Physician Scientist  Jay P Sanford Professor of Medicine  
 National Personal Protective Technology  Departments of Medicine  
 Laboratory  UT Southwestern Medical Center  
 National Institute for Occupational Safety and  Dallas, TX  
 Health  Adjunct Professor of Medicine  
 Centers for Disease Control and Prevention  Johns Hopkins School of Medicine and Bloomberg   
 [ADDRESS_598753]   School of Public Health  
 Building 40, Room 109  Baltimore, Maryland  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]   
    
Sponsors:  
CDC (DHQP), NIOSH, BARDA and VHA  
Revision:  May 17, 2018  

The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   3  Disclaimer: The opi[INVESTIGATOR_466880], the Centers for 
Disease Control and Prevention, the National Insti tute of Occupational Safety and Health, Johns Hopkins 
Health System, UT Southwestern Medical Center, or any other employers or affiliates of the study team.   
      
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598754]  ......................................................................................................... ...................... 7   
 A2  PRIMARY HYPOTHESIS  ......................................................................................................................... 7   
B BACKGROUND ...................................................................... ........................................................... 8   
 B1  PRIOR LITERATURE AND STUDIES  ........................................................................................................... 8   
 B2  RATIONALE FOR THIS STUDY : THE 2009 -10 H1N1 INFLUENZA PANDEMIC ......................................... 14   
C STUDY OBJECTIVES ............................................................................................................ ............ 17   
 C1  PROTECTIVE EFFECTS  ........................................................................................................................ 17   
1.a Primary ............................................................................................................................. ....... 17   
1.b Secondary: ............................................................................................................ .................. 17   
 C2  INCIDENCE DETERMINATION  ............................................................................................................... 17   
2.a Primary................................................................................. ................................................... 17   
2.b Secondary: .................................................................................................................. ............ 18   
D STUDY DESIGN AND METHODS ................................. ..................................................................... 18   
 D1  OVERVIEW  ............................................................................................................................. ......... 18   
 D2  STUDY SITE SELECTION AND  RANDOMIZATION SCHEME  ........................................................................... 19   
 2.a  Cluster Randomization Scheme: Clinical Unit of Analysis and Eligibility ................................. [ADDRESS_598755] SELECTION : ........ ....................................................................................................... [ADDRESS_598756] RECRUITMENT PLAN AND CONSENT PROCESS  ............................................................................ 21   
 D5  RESPI[INVESTIGATOR_6709] /FACIAL PROTECTIVE DEVICES  .......................................................................................... 23   
5.a Data on respi[INVESTIGATOR_466881] ........ ......................................................................................... 23   
5.b Fit testing ................................................................................................................. ............... 24   
 D6  ATTITUDES AN D OPI[INVESTIGATOR_272876]  ................................................................................................................. 24   
 D7  ADHERENCE TO RESPI[INVESTIGATOR_466882]  ................................................................. 24   
 D8  RISKS AND BENEFITS  ......................................................................................................................... 25   
 D9  EARLY WITHDRAWAL OF SUBJECTS /DATA/FOLLOW -UP FOR WITHDRAWN SUBJECTS  ................................. ... 26   
 D10  STUDY DATA COLLECTION TOOLS  ......................................................................................................... 26   
10.a Pre-study Inclusion/Exclusion screening ................................................................................. [ADDRESS_598757] METHODS , STORAGE AND SHIPPI[INVESTIGATOR_1645]  .................................................... 29  
11.a Blood Specimen Collection .................................................................................... .................. 30  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   5  11.b Respi[INVESTIGATOR_466883] .............................................................................................  30  
11.c Study Specimen Storage and Shippi[INVESTIGATOR_007] .................................................................... ................ 31   
E STUDY PROCEDURES ............................................................................................................ ......... 31   
E1 CERTIFICATION AND REGISTRATION OF THE CLINICAL SITES/CLUSTERS : ........................................................ 31  E2 
SCREENING FOR ELIGIBILITY  ................................................................................................................ 31   
E3 SCHEDULE OF STUDY ASSESSMENTS  ..................................................................................................... 32  1) 
Pre-study Period assessments .................................................................................................... . 32 2) 
Interventio n Period Assessments: ............................................................................................... 33   
 3)  Post -Study Period Assessments ...................................................................................................  [ADDRESS_598758] (DSMB) ...... ...................................................................... 37   
F STATISTICAL PLAN ............................................................................................................ ............. 38   
 F1  STUDY OUTCOME DEFINITIONS  ............................................................................................................... 38   
 F2  STUDY OUTCOME MEASUREMENTS : ........................................................................................................ 39   
2.a Measurement of the Protective Effects: ................................................................................. [ADDRESS_598759] ........................................... .............................................. 46   
 I1  NEW KNOWLEDGE  ............................................................................................................................. ... 47   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  6   I2  PUBLICATIONS AND REPORTS  ....................... ........................................................................................... 47   
 I3  SIGNIFICANCE  ............................................................................................................................. ......... 47   
J STUDY ADMINISTRATION ........................................................................................................... ... 47   
 J1  ORGANIZATION AND PARTICIPATING CENTERS  ............................................................................................ 48  
1.a Study Site and the Data Coordinating Center (DCC): Johns Hopkins Health System ............... 48  
1.b Study Administration: the National Center for Occupational Health and Infection Control ... 50 
1.c Study Administration: North [LOCATION_012] Foundation for Research and Education (NFFRE): ........ 
50 
1.d Study Administration: Veterans Health Administration Network o f Medical Facilities: ......... 50  
1.e Study Site: VA [LOCATION_001] Harbor Healthcare System............................................................... 51   
1.f Study Site: VA Eastern Colorado Healthcare System ....................................................... ............ 
53  
1.g Study Site: VA Michael E. DeBakey Medical Center ................................................................ 53   
1.h Study Site: VA Washington DC Medical Center ....................................................................... 55   
1.i Study Site: Denver Health & Hospi[INVESTIGATOR_54686] .......................................................................... 
56  
1.j Study Site: Children’s Hospi[INVESTIGATOR_20161] .................................................................................... . 
[ADDRESS_598760]  ......................................................................................... 62   
 J3  COMMITTEES /SCIENCE BOARD  ...................................................................................... .......................... 62   
K PUBLICATION PLAN ............................................................................................................ ........... 63   
L REFERENCES ......................................................................... ......................................................... 64   
M ATTACHMENTS ................................................................................................................. ............. 72   
M1 TABLES  ............................................................................................................................. .............. 72  
Table1  Protocol Activities by [CONTACT_10585] .................................................... Error! Bookmark not defin ed. 
Table2  Case Definition* of Acute Respi[INVESTIGATOR_19269] ..................................................................... [ADDRESS_598761] of potential ILI pathogens ............................................................................................ 74   
 Table4   Power analysis of the sensitivity to the 4 -year attack rate: ............................................... 75   
M2 APPENDICES  ....................... ............................................................................................................. 78  
Appendix  A  Cluster Randomization Scheme ................................................................................. 78  
Appendix  B  Recru itment Flyer ....................................................................................................... 79  
Appendix  C   Inclusion/Exclusion Screening ................................................................................... 81   
Inclu sion/Exclusion Screening .................................................................................................... .......... 81   
 Appendix  D   Baseline Survey ...................................................................................... .................... 82   
 Appendix  E   Pre-Study Survey ........................................................................................................ 85   
 Appendix  F   Daily Exposure Form (Monday, Tues, etc.)..................................... ............................ [ADDRESS_598762] in the use of 
facial protective equipment (FPE) – medical masks (MMs) or N95 respi[INVESTIGATOR_13530] (N95s) - as a 
key component of personal protective equipment (PPE) when faced with seasonal influenza, 
epi[INVESTIGATOR_466884]. Patient isolation, cohorting, and healthcare 
personnel (HCP) use of PPE , including FPE, have been found important. However, their 
relative protective effect is unknown, especially in the outpatient setting.  In 2003, the 
Severe Acute Respi[INVESTIGATOR_23223] (SARS) outbreak and the role of healthcare -associated 
transmission stimu lated a series of evaluations examining which interventions were critical 
in decreasing spread of this respi[INVESTIGATOR_466885]. While data emerged supporting 
the use of respi[INVESTIGATOR_466886] a risk of extensive exposure to respi[INVESTIGATOR_466887], the need for such respi[INVESTIGATOR_466888]. Studies from epi[INVESTIGATOR_466889] -based. Public health groups and healthcare delivery 
organizations are uncertain about appropriate respi[INVESTIGATOR_466890]. To plan for such an 
even tuality and to best manage limited supplies of FPE, evidence is needed to guide 
planning activities and policy makers. This project aims to answer a key question about FPE 
use: How do respi[INVESTIGATOR_13530] (N95s) protect HCPs in the outpatient setting against influe nza, 
influenza -like illness, acute respi[INVESTIGATOR_4375], and other respi[INVESTIGATOR_466891], 
as compared to medical masks (MM)? This study will have the following outcomes:  
  
• An analysis to determine the more effective facial protective equipment, N95s or MM, to 
prevent disease transmission in the outpatient setting during a seasonal influenza outbreak, 
epi[INVESTIGATOR_466892].  
• An analysis of the incidence of organism -speci fic rates of respi[INVESTIGATOR_466893].  
• Occasional secondary analysis that use de -identified or limited data sets from the 
ResPECT database to support the central objectives of the stud y and to extend the scope of 
the project.  
  
  
A2 Primary Hypothesis  
Null Hypotheses:  The incidence of (1) laboratory confirmed influenza (LCI) or (2) influenza -like 
illness (ILI), acute respi[INVESTIGATOR_4375] (ARI), laboratory confirmed respi[INVESTIGATOR_4375] (LCRI) and 
laboratory detected respi[INVESTIGATOR_4416] (LDRI) will not be different between HCPs who practice 
2007 guidelines (medical masks) or 2009 guidelines (N95 respi[INVESTIGATOR_13530]).     
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   9     
Alternative Hypothesis:  The incidence of (1) laboratory confirmed influenza (LCI) or (2) 
influenza -like illness (ILI), acute respi[INVESTIGATOR_4375] (ARI), laboratory confirmed respi[INVESTIGATOR_4375] 
(LCRI), and laboratory detected respi[INVESTIGATOR_4416] (LDRI) will be  different between HCPs who 
practice 2007 guidelines (medical masks) or 2009 guidelines (N95 respi[INVESTIGATOR_13530]).    
  
B  Background  
  
B1 Prior Literature and Studies  
Introduction: Despi[INVESTIGATOR_466894] U.S. healthcare 
workplace, there is limited and inconclusive clinical evidence that respi[INVESTIGATOR_466895].   Scientific investigation of this issue has be en quite complicated, 
primarily because the use of respi[INVESTIGATOR_466896] "the standard of care" for protection 
against airborne diseases in some instances, even without sufficient evidence to support their 
use. The key question remains: How well do respir ators prevent airborne infectious diseases?  
The answer to this important question has medical, public health, political and economic 
implications.   
  
Key challenges posed by [CONTACT_467210][INVESTIGATOR_466897] .  This lack of 
knowledge posed pragmatic challenges and became source of controversy during the [ADDRESS_598763] may also help gain understanding about modes of viral transmission, because 
respi[INVESTIGATOR_466898].   
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  10  Bacterial superinfection is a common, morbid, and potentially mortal complication of influenza 
(Chertow, 2013). Autopsy studies demonstrated bacterial infection in nearly all deaths resulting 
from the 1918 influenza pandemic.  During the 2009 H1N1 influenza pandemic, bacterial 
superinfection complicated 55% of fatal cases. Palacios et al  found that presence of  
 S. pneumoniae  in a nasopharyngeal swab specimen correlated with severe disease in previously 
heal thy, low risk patients with 2009 pandemic strain influenza (Palacios 2009). There is clinical 
concern for bacterial superinfection after other respi[INVESTIGATOR_77881], but the supporting 
evidence is limited (Randolph 2004). As noted, the data on bacte rial superinfection is gleaned 
largely from autopsy series and cases of severe disease. Less is known about the events 
occurring early in bacterial colonization and infection of humans with influenza.   
  
Colonization of the nares or pharynx with Streptoco ccus pneumoniae, Staphylococcus aureus, 
Hemophilus influenzae, Streptococcus pyogenes , and other bacterial pathogens is presumed to 
be the antecedent to infection (Wertheim 2005; Simell 2012). Changes in the resident 
microbiota following viral infection ma y present an opportunity for more pathogenic bacteria to 
invade. To date, studies of bacterial superinfection have focused on the epi[INVESTIGATOR_466899], or on the pathophysiology of single pathogens. We propose to characterize 
the bacterial co mmunities of the nares and oropharynx in healthy subjects prior to, during, and 
after natural infection with influenza and other respi[INVESTIGATOR_4398]. We will use culture 
independent methods to comprehensively profile bacterial diversity in all specimens.  
  
The Veterans Health Administration (VHA) and the Centers for Disease Control and Prevention 
(CDC) have a vested interest in the results of this clinical trial, with both providing funding and 
sharing resources for its implementation.  The CDC is charged with providing guidelines to 
protect HCPs from infectious diseases while the VHA employs a large population of HCPs.  The 
results stand to have broad health policy implications that will reach well beyond the funding 
organizations on a global scale. The Jo hns Hopkins University (JHU) (Baltimore, MD) served as 
the initial Data Coordinating Center (DCC) for this clinical trial. We will transfer the DCC to the  
University of [LOCATION_007] Southwestern Medical Center (Dallas, TX) where the co -Principal Investigator  
(TMP) is now on staff.   
  
Historical Context:  Influenza, respi[INVESTIGATOR_299989] (RSV), coronavirus and other respi[INVESTIGATOR_466900], 
especially among the frail and chronically il l.  Human -to-human spread of respi[INVESTIGATOR_466901], including the transmission characteristics of these viruses, 
the population density of ill patients in healthcare settings, the types of exposures within 
healthcare set tings, and the administrative and physical structure of healthcare facilities.  These 
influences on transmission were evident during the 1918 influenza pandemic and became 
increasingly evident during the 2009 H1N1 influenza epi[INVESTIGATOR_466902] 2003 SARS outb reak 
(caused by a coronavirus). Additionally, patients in healthcare facilities who acquire influenza, 
RSV and other respi[INVESTIGATOR_4398], suffer increased morbidity and mortality. During the 
pandemic of 1957, influenza A impacted a Chicago hospi[INVESTIGATOR_307], causin g one -third of the patients 
and staff -members on affected units to become ill with influenza. Leclair et al.  found that the 
incidence of nosocomial RSV increased with the intensity of hospi[INVESTIGATOR_466903].  Sartor and 
colleagues describe a small outbreak on a  23-bed internal medicine unit where 41% of the 
patients and 23% of the HCPs developed influenza.  The authors noted that [ADDRESS_598764] $34,179, approximately $3,[ADDRESS_598765] that students miss about 22 to 189 million school days annually 
due to upper respi[INVESTIGATOR_10711], commonly called "colds”.   Acc ordingly, parents miss about 
[ADDRESS_598766] of cold -related work loss exceeds $[ADDRESS_598767] influenza is transmi tted from person -to-person via large 
respi[INVESTIGATOR_466904], several recent exhaustive reviews of the world’s literature suggest routes 
of transmission are variable, depending on virus characteristics, host -virus interactions, and 
environmental conditions.  Many studies indicate that that the predominant mode of 
transmission is via large droplets that are generally greater than [ADDRESS_598768] and small droplets (sometimes called aerosols) that are generally less than 10 microns in 
diameter, typi[INVESTIGATOR_466905] “dr oplet nuclei,” and may be 
inhaled deep into pulmonary tree.  In addition, this later form of transmission may be more 
likely in the setting of procedures which potentially aerosolize secretions.   
  
It is generally agreed that the predominant mode of trans mission for most other contagious 
respi[INVESTIGATOR_13531], such as RSV and corona virus, is via large  droplets, with small droplets 
(aerosols) playing a much smaller but clinically significant role.   Indirect contamination from the 
environment (e.g., fomite s) or direct contact [CONTACT_369142] (e.g., hand -to-hand or hand to 
conjunctiva)  may also be important with many respi[INVESTIGATOR_13531].     
  
Prevention Strategies:  Healthcare facilities face challenges in preventing transmission to HCPs 
who are exposed to i nfectious patients, colleagues and family members.  Unfortunately, some 
pathogens, including influenza, can be transmitted when the infectious person is asymptomatic, 
although symptomatic transmission is believed to be the more common route.  The timing of  
when transmission is most likely to occur has not been defined for many respi[INVESTIGATOR_13531].  
  
For many of these pathogens, vaccines or chemoprophylaxis may not be available, requiring 
institutions to use other infection prevention techniques.  Recomme nded prevention and 
control methods for the pathogens in this study include both primary strategies (e.g., 
vaccination, chemoprophylaxis, use of barriers), when available, and secondary strategies (e.g., 
hand hygiene, isolation, environmental disinfection,  screening and cohorting). 
Nonpharmacologic interventions are promoted by [CONTACT_467211], patient isolation, and respi[INVESTIGATOR_102492]. The 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598769] for healthcare epi[INVESTIGATOR_466906] (1) determining t he most appropriate types of PPE for HCPs, (2) delivering data 
to HCPs that will help convince them to comply with infection control recommendations, and (3) 
actually implementing FPE usage, taking economic, logistical, and occupational factors into 
consid eration.  The first issue is central to determining policy recommendations at institutional, 
national and international levels.  At a local level, these decisions determine planning and supply 
chain needs for healthcare facilities for both seasonal and pan demic respi[INVESTIGATOR_466907].   
  
Among non -pharmacologic interventions, there is continued interest in the use of "facemasks" 
as a key component of personal protective equipment (PPE).   While masks were used in the 
Middle Ages (between the approximate years of 400 and 1500 A.D.) to prevent transmission of 
plague, it was not until the mid -1980’s  that Hall et al.  demonstrated that the use of masks and 
goggles decreased healthcare -associated transmission of RSV.  Control measures for influenza in 
long term care settings have focused primarily on two methods: immunoprophylaxis for 
generally healthy HCPs and chemoprophylaxis for patients.  Still, the importance of patient 
isolation, cohorting, and use of FPE by [CONTACT_467212].    
  
Gaps in Knowledge:  The relative importance of face masks (medical masks), respi[INVESTIGATOR_466908] (without masks or respi[INVESTIGATOR_13530]) has not been definitively proven, prompting 
disagreement and controversy in the scientific and health policy communities.  In 2003, SARS 
and the role of healthcare -associated transmission stimulated a series of evaluations to identify 
which interventions had been critical in decreasing spread of the SARS coronavirus among HCPs.  
Jefferson et al.  summarized studies that evaluated the utility of non -pharmacologic 
interve ntions used during the SARS epi[INVESTIGATOR_901]. Transmission was reduced 55% by [CONTACT_467213], 78% by [CONTACT_467214], 57% by [CONTACT_467215] 77% by [CONTACT_467216].  Still, with 
only one exception, these studies did not determine the protective effect of N95  respi[INVESTIGATOR_466909]; the word "masks" were either undefined or represented 
by [CONTACT_467217][INVESTIGATOR_13530].  One study that is often cited as showing a 
statistically significant decrease in infections with N95 respi[INVESTIGATOR_466910].   
  
In 2007, the World Health Organization (WHO) proposed draft guidance recommending a 
complement of strategies that included t he use of medical masks for many respi[INVESTIGATOR_46264], including novel influenza strains and the SARS coronavirus.  These recommendations 
were based on the experiences of several countries to prevent and control SARS infections and 
the lack of data showin g superiority of respi[INVESTIGATOR_466911]. Data emerged 
from the SARS events supporting the use of respi[INVESTIGATOR_466912], such as 
intubations, which are known to produce aerosols of respi[INVESTIGATOR_171919].  While these data 
were v aluable, they focused narrowly on infection control measures for SARS.  Similar studies 
are needed in the setting of other pathogens, such as influenza.    
  
MacIntyre and colleagues recently published a prospective cluster -randomized trial that 
compared m edical masks and non –fit-tested respi[INVESTIGATOR_466913] (no masks) in 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   13  preventing ILI in households (MacIntyre et al . 2009). Among 286 adults, from 143 households, 
who were exposed to children with clinical respi[INVESTIGATOR_4375], self -reported adhere nce to mask 
or respi[INVESTIGATOR_466914] -associated infection, but only in the subset 
of the population reporting adherence to mask or respi[INVESTIGATOR_466915].  However, adherence with 
mask or respi[INVESTIGATOR_466916]; <50% of participant s wore masks or respi[INVESTIGATOR_466917].  Across the entire study population, including those who were not adherent, 
the authors reported that household use of face -masks or respi[INVESTIGATOR_466918].   What is not known, however, is whether the 
observed ineffectiveness was due to non -compliance or insufficient respi[INVESTIGATOR_466919].  Unfortunately, new knowledge gained from completion of this Australian study 
was limited.  This study lacked the power to compare any effects of masks with those of 
respi[INVESTIGATOR_13530].  Thus, it was not informative on this issue.    
  
MacIntyre et al . also conducted a study among 1936 front -line hospi[INVESTIGATOR_466920], initially 
reporting t hat use of N95 respi[INVESTIGATOR_466921] (MacIntyre et al . 2011).  However, due to low outcome 
incidence, the study lacked the power to address influenza, either from the stand point of 
laboratory -confirmed respi[INVESTIGATOR_269449], clinical respi[INVESTIGATOR_4375], and influenza -like 
illness.  It was also initially reported that fit -testing did not improve N95 effectiveness, perhaps 
because a large proportion of the population wa s documented to have a good fit with the 
initially -chosen respi[INVESTIGATOR_13521]. However, the authors later retracted their findings, citing 
methodological, analytic, and sample size limitations.   
  
The most recent research continues to fuel the debate over appropri ate prevention against 
influenza and respi[INVESTIGATOR_13531].  Loeb et al . (2009) conducted a trial comparing influenza 
rates among 446 Canadian nurses individually randomized to wear either an N95 respi[INVESTIGATOR_466922] a 
surgical/medical mask, finding that masks we re no less effective at preventing 
laboratoryconfirmed influenza than N95 respi[INVESTIGATOR_13530].  However, nurses randomized to the use of 
masks did experience a strong trend ( p = 0.06) towards higher level of influenza -like-illness and a 
statistically significantly  higher level of fever ( p = 0.007) compared to those wearing N95s.    
  
Although the Loeb study found no significant differences in the prevention of 
laboratoryconfirmed influenza, many of the cases were identified by [CONTACT_467218].  A main goal of proper FPE usage is the 
prevention of symptomatic influenza, resulting in the current study’s emphasis on obtaining 
data quickly on  symptomatic individuals.  Loeb et al. acknowledged frequent non -occupational 
(e.g., home and community) exposures to influenza -like illness in both arms, but no analysis was 
done to assess the levels of risk associated with these home exposures.  Addition ally, Loeb et al.  
conducted their study in a cohort of HCPs with relatively low influenza vaccination rates, did not 
directly assess exposure risks by [CONTACT_467219][INVESTIGATOR_4375], and was unfortunately termin ated prematurely (April 23, 2009) when, in 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  14  response to growing concern about the H1N1 outbreak, the Ontario Ministry of Health and Long 
Term Care recommended N95 respi[INVESTIGATOR_466923].   
  
Perl & Srin ivasan’s (2009) simultaneously published editorial in JAMA stressed that the lack of 
clinical trials on the transmission of influenza hampers the appropriate authorities from making 
definitive recommendations for PPE.   Two cluster randomized trials of med ical masks versus 
N95 respi[INVESTIGATOR_466924], China. The first trial 
(McIntyre 2011) was conducted from December 2008 to January 2009 and enrolled 1441 
healthcare workers. The second trial (McIntyre 2013), conduct ed from December 28, 2009 to 
February 7, 2010 enrolled 1669 healthcare workers. These trials found no significant difference 
between groups assigned to medical masks or N95 respi[INVESTIGATOR_466925]. The incidence of influenza d uring the study periods was low, limiting the power of the 
trials to identify significant differences. A meta -analysis (Smith 2013) of the three available RCTs 
also identified no significant difference in influenza like illness or laboratory confirmed infl uenza.  
  
Importantly, based upon numerous laboratory studies, most scientists believe that N95 
respi[INVESTIGATOR_466926].  After all, respi[INVESTIGATOR_466927], 
inhalable particulates while medical masks are not.  However, considering all published studies 
to date, the clinical data produced thus far by [CONTACT_467220].  One possibility that may help explain this gap between 
expectations and contemporary clinical evidence is pragmatic in nature: HCPs, in general, may 
not tolerate respi[INVESTIGATOR_466928], prompting them to remove respi[INVESTIGATOR_466929] r periods and/or more frequently, possibly increasing the likelihood of exposure and 
infections.  Of note, removing respi[INVESTIGATOR_466930] (non -compliance).   Imp ortantly, in the 
context of this limitation with respi[INVESTIGATOR_13530], it is conceivable that medical masks could provide the 
same or higher levels of protection than N95 respi[INVESTIGATOR_13530].    
  
Unfortunately, clinical trials conducted in real patient -care environments during a respi[INVESTIGATOR_466931] (“flu season”) are lacking.  Accordingly, the public health recommendations for 
respi[INVESTIGATOR_466932], in part, based on expert opi[INVESTIGATOR_1649], sometimes leading to 
controversy.  A key challeng e posed by [CONTACT_467221][INVESTIGATOR_466933].  To 
plan for such an eventuality and to be able to best manage limited supplies of respi[INVESTIGATOR_13530], 
evidence  is needed to guide policy developers and decision -makers.  One of the most important 
lessons learned from the SARS crisis was the importance of protecting HCPs with appropriate 
personal protective equipment.  It is important to recognize that in Toronto, a SARS commission 
convened by [CONTACT_467222] 72% of SARS cases occurred in a hospi[INVESTIGATOR_111483], 43% of cases involved HCPs, and of the 100 healthcare providers who became infected 
with SARS, three died.  Since this time, Suwantarat et al . found that another coronavirus causing 
Middle Eastern Respi[INVESTIGATOR_23223] (MERS) has been associated with significant transmission 
to HCPs, further supporting the importance of solving this issue. Transmission in several settings 
in Middle East settings  has resulted from conflicting recommendations issued by [CONTACT_467223][INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598770] appropriate.  
  
B2 Rationale for this Study:  THE [ADDRESS_598771] frequently discussed and debated topi[INVESTIGATOR_1102].  Many healthcare organizations found 
themselves without sufficient N95 respi[INVESTIGATOR_466934]/or local guidelines for use. 
Perhaps worse was a highly variable difference in the number of N95 respi[INVESTIGATOR_466935]; some hospi[INVESTIGATOR_466936].  The uncertainty and lack of 
evidence -based respir atory protection policies, in part, caused organizations to prepare 
differently, resulting in disparate levels of access to N95 respi[INVESTIGATOR_466937], in some cases, 
interference with healthcare operations.    
  
In in midst of the [ADDRESS_598772] instances 
the use of medical masks for HCPs exposed to H1N1 -infected patients (except during 
aerosolgenerating procedures), while the CDC took a somewhat contradictory stance, 
recommending instead that HCPs wear N95 respi[INVESTIGATOR_13521] s in most instances.  The notoriety of this 
contradiction increased when many state and local health departments in the U.S. sided with 
the WHO.  In an open letter published on November 5, 2009, the Society for Healthcare 
Epi[INVESTIGATOR_128456] (SHEA), ID SA, and the Association for Professionals in Infection Control 
and Epi[INVESTIGATOR_623] (APIC) jointly expressed their dissatisfaction with the CDC position.   Increasing 
the controversy, the National Academy of Sciences Institute of Medicine (IOM) issued findings 
from a consensus meeting that called for (a) HCPs to favor N95 respi[INVESTIGATOR_466938] H1N1 influenza and (b) intensive research without delay to determine which is more 
effective. Although the CDC initially recommended and later reiterate d its position that medical 
facilities should favor the use of N95 respi[INVESTIGATOR_13530], on a practical level, large sectors of the US 
healthcare workforce continued to essentially ignore these guidelines, wearing medical masks, 
and in some instances no protection.     
  
In October 2009, The CDC issued Interim Guidelines that addressed the insufficient supplies of 
N95 respi[INVESTIGATOR_466939].  This updated guidance recommended that supply shortages 
should prompt prioritization of FPE usage at the institutional l evel, calling for HCPs to wear 
devices at least as protective as N95 respi[INVESTIGATOR_466940] -risk settings such as when performing 
aerosol -generating procedures.  In lower risk settings when there were clear shortages or 
impending shortages of respi[INVESTIGATOR_13530], fac ilities were permitted to use medical masks as a primary 
means of HCP protection against influenza. Facilities were advised to make a “good faith” effort 
to procure an adequate supply of respi[INVESTIGATOR_13530], and continue to implement a hierarchy of 
controls, inclu ding source control, engineering, and administrative measures, encourage 
vaccination, and continue other work practices recommended by [CONTACT_6750].    
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598773] been, infected with 2009 H1N1 
influenza.  This modification occurred after CDC posted in the Federal Register a notice that 
proposed a change such that (a) medical masks would be the primary means of respi[INVESTIGATOR_466941] (b) devices at least as protective as N95 
respi[INVESTIGATOR_466942] (or help perform) procedures that produce 
bioaerosols (e.g., intubation, suction).  The [ADDRESS_598774] influenza, per CD C recommendations.  All HCPs are no 
longer required to wear N95 respi[INVESTIGATOR_466943]/suspected influenza, allowing the current study to proceed.  Subsequently, the CDC 
guidelines have remained largely unchanged. Patient s with respi[INVESTIGATOR_466944] a healthcare setting, HCPs should 
don a medical mask when entering the room of a patient with suspected or confirmed influenza, 
and HCPs performing aerosol -generating procedures should wear an N95 or equivalent.  If 
facilities or organizations wish to provide a different type of FPE (e.g. to meet evolving CDC 
guidance and local policies) than the standard medical mask, it should at least provide the same 
protect ion of the nose and mouth as a facemask (e.g., N95, PAPR, etc.).   
  
Despi[INVESTIGATOR_466945], most who opi[INVESTIGATOR_466946] [ADDRESS_598775] would be one that bases 
respi[INVESTIGATOR_466947].  The National Academy of Medicine 
(formerly the Institute of Medicine or IOM) articulated its position in multiple documents, 
including its [ADDRESS_598776], Director of the 
National Institute of Occupational Safety and Health (NIOSH), and [CONTACT_467323], Chair of the  
IOM Committee on Respi[INVESTIGATOR_101748] f or Health Care Workers in the Workplace against  
H1N1 Influenza, who both wrote letters in support of this clinical trial. Although the H1N1 
20092010 influenza pandemic has ended the need for this research remains essential.  This 
study will focus on the r elative protective effects of the CDC’s 2007 seasonal influenza guidelines 
versus the CDC’s 2009 H1N1 pandemic influenza guidelines.    
  
Since this time, further controversy has developed around the appropriate prevention practices 
for Middle Eastern Resp iratory Syndrome (MERS) caused by a novel coronavirus with differences 
between the CDC and the WHO guidelines (CDC 2015; Chung 2014; Hsu 2014; WHO 2015).  The 
emergence of another pathogenic respi[INVESTIGATOR_466948].  
  
 Non -Compliance with Respi[INVESTIGATOR_466949]:  The CDC and other influential public 
health organization s recommend in most scenarios that HCPs utilize droplet precautions when 
caring for patients who are ill with respi[INVESTIGATOR_3748].  Only a few diseases require airborne 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598777] of a gown, gloves, eye protection (glasses o r goggles) 
and a medical mask.  Exceptions include tuberculosis, measles and a small set of diseases known 
to be capable of airborne spread, in which case a respi[INVESTIGATOR_13521] (N95 respi[INVESTIGATOR_466950]) is 
recommended.  On a practical level, this means HCPs sh ould wear a medical mask whenever 
they enter a room of a patient with respi[INVESTIGATOR_1856], unless the worker is certain the 
patient is not infected (no mask needed) or the patient is suspected or known to have 
tuberculosis or one of the less common airbor ne diseases (respi[INVESTIGATOR_466951]).  However, it is 
widely acknowledged that HCPs often do not fully adhere to these recommendations; 
compliance rates with personal protective equipment recommendations are near 30%.  
Interestingly, lower rates of FPE complian ce are often observed among senior staff and longtime 
employees, possibly due to a feeling of increased invulnerability.  This trend is also reflected in 
lower hand hygiene and vaccination rates among more senior HCPs.  Limited tolerability may 
also play a  role.    
  
Attitudes/Opi[INVESTIGATOR_6153]/Beliefs : There is minimal data on the impact of attitudes and opi[INVESTIGATOR_466952]. An IOM report 
concluded that “Experience with… efforts to improve infection control… have demonstrated 
that the efficacy of an intervention alone does not guarantee its success. The best respi[INVESTIGATOR_466953] w ho refuses, or who misunderstands how… 
to use it correctly.”   
  
Despi[INVESTIGATOR_466954], 
few studies have examined seasonal respi[INVESTIGATOR_466955], 
individual  HCP attitudes and beliefs about FPE use, or the specific impact of safety climate in this 
setting. In a recent comprehensive review of the infection control literature regarding protecting 
workers from respi[INVESTIGATOR_13531], The British Columbia Interdisc iplinary Respi[INVESTIGATOR_466956] “organizational and individual factors can explain much of 
the variations in self -protective behavior in health care settings, especially with respect to 
applying universal [standard] precautions. It s eems likely that these factors were also important 
safety determinants during the SARS outbreaks but they have not been extensively studied”. 
This group also noted that “safety climate is being increasingly recognized as one of the most 
important determina nts of safe work practice in terms of preventing exposures to [blood and 
body fluids] but has been little studied in other types of nosocomial transmitted diseases. 
Respi[INVESTIGATOR_466957], in particular, have not been well studied in this regard.” Thus , it 
would be interesting to collect data on HCPs attitudes and opi[INVESTIGATOR_466958]. This data could possibly 
lead to policies that improve knowledge about FPE use amon g HCPs, especially in an outpatient 
setting.  
  
Number of Study Arms: The consequences of widespread non -compliance among HCPs and the 
impact on the efficacy of measures remain controversial.  On the surface, therefore, it would 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598778] of non -compliance. To 
make an unbiased assessment of FPE e ffectiveness, a randomized clinical trial would ideally 
include three arms: a respi[INVESTIGATOR_466959], a medical mask arm and a negative control (no respi[INVESTIGATOR_466960]) arm.  However, there is often a dearth of evidence, in part, because the ideally 
designed cl inical studies ( e.g., randomized, double -blind trials) are challenging to conduct in a 
clinical (operational) context.    Ethical considerations often preclude designs that randomize 
individuals to “no protection” when the standard of care (or operational policy) calls for some 
level of protection.  This challenge has been discussed elsewhere in detail.  With this ethical 
limitation in mind, the protocol that follows is designed with two arms, not three.  
  
HCP Exposure Risk Assessment: This study will also  investigate the relationship between HCP 
infection rates and their reported exposure to patients with suspected or confirmed respi[INVESTIGATOR_228851], aerosol -generating procedures, or household members with respi[INVESTIGATOR_466961].  Loeb et al.  (2009) b ears several important parallels to the current study but did not 
directly assess exposure risk by [CONTACT_467224] a higher risk for infection.   Studying this relationship may reveal important 
informat ion concerning transmission, prevention, and absolute and relative risks of respi[INVESTIGATOR_466962]. The proposed study aims to assess and account for the frequency and level of risk 
associated with non -occupational exposures.   
  
C  Study Objectives  
This study aims to determine the relative effectiveness of two interventions to protect HCPs 
against infections and illnesses caused by [CONTACT_467225][INVESTIGATOR_13531].    
  
C1  Protective Effects   
1.a  Primary  
To determine and analyze the magn itude of the change, if any, in incidences of laboratory 
confirmed influenza in HCPs wearing N95 respi[INVESTIGATOR_13530] (2009 guidelines) compared to medical 
masks (2007 guidelines).    
1.b  Secondary:   
• To determine and analyze the magnitude of the change, if any, in incidence of ARI, ILI, 
LCRI and LDRI in HCPs wearing N95 respi[INVESTIGATOR_466911].    
• To examine the relationship between incidence and possible risk factors, including 
complianc e, attitudes and opi[INVESTIGATOR_466963].  
C2  Incidence Determination   
2.a  Primary  
• To improve understanding about the burden of infections and illnesses caused by 
[CONTACT_467225][INVESTIGATOR_466964].  
2.b  Secondary:   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   19  • To measure the incidence of ARI, ILI, LCRI, and LDRI in selected outpatient settings.  
• To measure the changes in the participant’s nasal/oropharyngeal microbiome over the 
course of the study.  
  
D  Study Design and Methods   
  
D1 Overview   
This study will assess and compare the effectiveness of respi[INVESTIGATOR_466965] a variety of geographic/climatic conditions.    
We propose a study with a prospective timeline (Appendix L), no n-blinded, cluster randomized 
interventions (with the unit/clinic as the unit of randomization), a two -arm, “head -to-head” 
comparison, multiple sites and multiple geographic locations, with longitudinal cohorts recruited 
for multiple years.    
  
This study will be conducted in outpatient clinics, emergency departments and/or urgent care 
settings in multiple geographic locations.  The outpatient setting has been chosen because it is 
the front line in the event of an influenza epi[INVESTIGATOR_901].  Patients ty pi[INVESTIGATOR_466966], urgent care facility or the emergency department for respi[INVESTIGATOR_58776].  It has been shown that the highest rate of infection in healthcare workers is in this 
outpatient setting. The Study Team ai ms to balance the sites to include medical, pediatric and 
VA study sites.  We will employ stratified randomization for FPE assignment, to assure 
generalizability of results across clinic types.  The types of clinics/clusters included will be 
dependent on t he clinics that meet the requirements and agree to participate in the study, but 
we will attempt to recruit a variety of outpatient clinics to ensure a generalizable study group.   
Each study site will utilize a Master Study Protocol with synonymous text t o produce a local IRB 
application.  
  
Subjects will be recruited and randomized to one of two study arms, medical masks (2007 and 
2010 CDC seasonal influenza guidelines) or N95 Respi[INVESTIGATOR_13530] (2009 N95 pandemic influenza 
guidelines).  Sites will be randomized  each flu season such that sites may use different types of 
FPE each flu season.  The duration of the intervention (mask wearing) period of the study is 
dependent on surveillance and incidence of viral respi[INVESTIGATOR_466967].  The 
intervention pe riod may potentially be shortened due to site -specific/regional incidence and 
surveillance, but it is not anticipated to extend longer than [ADDRESS_598779] will agree to participate in 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  20  the study for up to 16 weeks per flu season, in which the “pre -study period” is a screening and 
educational period.  During the pre -study period, participant demographic information will be 
collected (baseline sur vey), a survey on knowledge, attitudes, and beliefs regarding FPE will be 
administered (pre -study survey), a blood sample will be collected for baseline serology testing, 
and subjects will be educated about the study, including the fit testing process.  We eks 1 -16 are 
the “intervention period.”  A cluster -randomized design will be utilized such that a group 
(“cluster”) of approximately 16 people will be assigned (randomized) to wear the same device 
(Medical Mask or N95) for up to 16 weeks (potentially short er) while working in the study site 
location (Appendix A).  Participants will also be asked to provide upper respi[INVESTIGATOR_466968].  During this time, the research team will also observe 
participants’ adherence to mask use and  hand hygiene.   Two weeks after the final week of 
wearing FPE (hereafter referred to as “post -study period”), subjects will be asked to provide a 
final serological sample and to complete a post -study survey.   Participants may participate in 
successive fl u seasons until the study is completed.  
  
Being able to wear OSHA -compliant and NIOSH -approved respi[INVESTIGATOR_466969] a pre -employment condition for all study sites under 
consideration.  Therefore, the  potential participants should have experience wearing medical 
masks and respi[INVESTIGATOR_466970].  It is expected that a small percentage of subjects will be excluded because 
they h ave facial hair that precludes OSHA -accepted fit testing (likely < 5% of eligible subjects), or 
they will have been advised by [CONTACT_467226][INVESTIGATOR_466971]  (likely < 1% of eligible 
subjects).    
  
D2 Study Site Selection and Randomization Scheme  
2.a  Cluster Randomization Scheme: Clinical Unit of Analysis and Eligibility  
Previous studies utilized a traditional individually randomized design (in a healthcar e setting) or 
cluster, randomized design (in a home setting), a methodological tool that may be utilized in 
suitable circumstances.  For this study, a “cluster design” will be used.    
  
A group of people (a “cluster”) will serve as one unit of randomizati on as described in the 
General Methods  section of this protocol (Appendix A).  Ideally, most or all staff working in 
selected clinic locations will agree to participate via informed consent.  All HCPs (subjects) within 
that cluster will wear the same type of device (Medical Mask or N95) for the intervention 
period.    
  
This study focuses on illness and infection in the healthcare workplace, a setting known for 
propagating influenza outbreaks.  The principal and co -investigators believe a clusterrandomized 
design is essential to optimize the validity, reliability and generalizability of the results.  Others 
have proposed individual randomization schemes in which each person (not each clinical unit) is 
randomized to one of the intervention arms.  Justificatio n has often centered on an individually 
randomized study often requiring fewer subjects to achieve statistical significance.  In this 
setting, staff working alongside each other in the same clinic would routinely wear different 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598780], in which all subjects on the same clinical unit are outfitted with the 
same type of pr otective devices.   Although the model of N95 may vary at each study site and 
within each cluster, the type of respi[INVESTIGATOR_13521] (NIOSH -certified, negative pressure, N95 filtering face 
pi[INVESTIGATOR_6928]) will not change.  
  
Selection of clinic sites will be based on the size of the clinic.  Each cluster/clinic will have a 
median of approximately [ADDRESS_598781] -level and enthusiasm of the HCP -subjects and the nu mbers of patients who present for 
healthcare with a diagnosable respi[INVESTIGATOR_4375].  For purposes of this study, “primary care” will 
be defined as “a healthcare delivery site at which family practice, internal medicine, emergency 
medicine, or general prac tice clinicians (or nurse practitioners and physician assistants with 
similar training) evaluate and treat patients who typi[INVESTIGATOR_466972] (not via 
referral) and from which referrals to subspecialty services are typi[INVESTIGATOR_466973]” (See 
Appendix K).  While most clusters will naturally consist of consented HCP -subjects who work in a 
particular clinic location, some large clinics may be designed in functional partitions that are 
amenable to this study’s analysis scheme.  When deemed appropr iate by [CONTACT_3476], large 
clinics may be further sub -divided into more than one cluster for study purposes.     
  
The participating center would register their clinical sites/clusters with DCC who meets the 
eligibility criteria for the cluster as descr ibed above. The clusters would be assigned to one of 
the two arms using a system established by [CONTACT_15791]).  
  
D3 Study Subject Selection:  
  
Seven institutions have been identified as participating centers: the Johns Hopkins Health  
System (JHHS) in Baltimo re, MD; Denver Health Medical Center, and Children’s Hospi[INVESTIGATOR_466974] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  22  Colorado in Denver, CO; and the Department of Veterans Affairs (VA) sites in Denver, CO;  
Washington, DC; NY, NY; and Houston, TX. Additional sites need to be added.   Additional sites 
will be assessed by [CONTACT_467227] (Appendix K) and must have an adequate number of 
outpatient visits/clinics (at least 25 that employ 20 or more HCPs), history of collaboration with 
other sites on large clinical trials, and research infrastructure experie nce with clinical studies.  
We aim to recruit at least 500 participants per study site per influenza season, based on a 2530% 
dropout rate.  Depending on the capability of selected study sites to accrue subjects, up to 10 
(ten) sites may be included altoge ther.    
3.a  Inclusion Criteria  
  
(1) Clinical site leadership has agreed to have one or more staff participate in the trial   
(2) Subject meets the definition of “healthcare personnel”  
(a) Provides healthcare to patients and/or  
(b) Typi[INVESTIGATOR_287670] 6 feet of patients (“close contact”) and (c) Is a full -
time employee (average of ≥ 24 hrs/week) working 75% of the time at a study site (and not 
employed at another location where the study is being conducted).  
(3) Subjec t able to read and sign informed consent  
(4) Subject agrees to all requirements of the protocol, including fit testing and diary keepi[INVESTIGATOR_007]  
(5) Subject’s age 18 or greater  
(6) Subject passes fit testing for one of the study supplied respi[INVESTIGATOR_466975] (if in the respi[INVESTIGATOR_466959]).  
3.b  Exclusion Criteria  
  
(1) Subject self -identified as having severe heart, lung, neurological or other systemic disease 
that one or more Investigator believes could pr eclude safe participation.  
(2) Known to not tolerate wearing respi[INVESTIGATOR_466976].  
(3) Facial hair, or other issue such as facial adornments, precluding respi[INVESTIGATOR_466977] -compliant fit 
testing or proper mask fit during the study period  
(4) Advised by [CONTACT_467228] (or other qualified clinician) to not wear the same or similar 
respi[INVESTIGATOR_466978].  
(5) In the opi[INVESTIGATOR_689], may not be able to reasonably participate in the trial for 
any reason ( e.g. anatomic changes to nose).   
(6) Self-identified as in, or will be in the third trimester of pregnancy, during the study period.  
(7) Subject rotating in [ADDRESS_598782] study clinic sites /clusters during the study period.   
(8) Subject works less than 24 hours/week in the cluster/clinic in which they are recruited.    
(9) Subject work less than 75% of the intervention period in that clinic.   
(10) Subject is a previous participant of the ResPECT Study, but does not consent for data from 
previous flu season(s) to be linked.   
  
Subject Recruitment Plan and Consent Process  
HCP -subjects in each clinic will be made aware of the study through emails (Ap pendix V), 
telephone calls (emails and telephone calls will be used to contact [CONTACT_467229][INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598783] previously participated in study), posters (“flyers”) 
distributed at each potential study location, the primary refe rral hospi[INVESTIGATOR_466979], and other locations HCPs frequent (Appendix B).  Participants will receive emails and 
telephone calls throughout the study to alert them of study updates, planned times for 
specimen collection, and to address iss ues that the participants have. Another social medium we 
may use to optimize recruitment and retention is a ResPECT Study Facebook page occasionally 
posting information such as survey reminders, blood draws, or swab timing for clinics (example 
post: “We ar e nearing the half -way point! Please make sure you complete your Weekly Diary 
and Days Worked Surveys by <date>!! If you have questions, contact [CONTACT_467230] 
[EMAIL_8934]  or (410) 614 -6206.)” The point is to leverage our social media cont acts and 
widen the scope of information systems with which to communicate updates and important 
events to participants (see Appendix AA). The Facebook page will protect privacy by [CONTACT_7466] a 
unidirectional information source – staff will post notifications, b ut participants will be unable to 
post messages on the page. The caveat being participants “liking” the page will show up in their 
news feed depending on their own privacy settings. We will have the following disclaimer on the 
page informing participants o f the privacy policy:  The Johns Hopkins Health System and Johns 
Hopkins University School of Medicine do not edit or control the content of posted comments 
by [CONTACT_467231]. However, Johns Hopkins reserves the right to remove any such 
postings that contain objectionable or inappropriate content.  The Facebook page and email 
addresses will be deactivated at the end of the study.  
  
The protocol, forms, and all written materials about the study will be approved by [CONTACT_467232](s). The definition of eligible “healthcare personnel” for the purposes 
of the study will be any person who is a full -time employee (average of ≥ 24 hours/week), at 
least [ADDRESS_598784] s with patients.  
Interaction in this context will mean the provision of clinical care, typi[INVESTIGATOR_466980] 6 feet of patients, or entering into a small -enclosed airspace shared with patients, such as 
a typi[INVESTIGATOR_466981] (e.g. , “close contact”).  We will cover all operating hours of 
participating clinics.  Covering clinics such as emergency departments may require staffing 
outside of standard operating hours.  
  
Subjects will be recruited by [CONTACT_467233]/her des ignee or self -referred to the 
Study Coordinator in a response to emails, telephone calls, or flyers.  Initial recruitment will 
mainly occur through educational meetings.  Consent forms will be distributed to clinic directors 
prior to these meetings for dis semination among interested individuals.  Research staff will 
present the project during staff meetings, change -of-shift meetings, and other meetings/visits at 
the participating clinics.  The research staff will go over the consent forms to ensure particip ants 
fully understand the meaning of the forms, answer any questions, and ensure that each 
potential participant has adequate time to review the forms.  If any potential participants would 
like additional time to review the forms or consider enrolling, res earch staff will arrange to 
follow up with them later.  During these educational meetings, the research staff will explain to 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598785] the risks of wearing a respi[INVESTIGATOR_466982]. Visual 
demonstrations of study requirements (e.g. how to properly put on, wear, and take off a 
respi[INVESTIGATOR_13521]/mask; nasal and throat swab procedures) will also be presented to ensure that 
potential participants understand all study requirements before they agree to consent.  Study 
staff may also provide paper  copi[INVESTIGATOR_466983]/or bring computers to show participants what the e -mails they’ll receive from the study will 
look like, as well as how to access and complete the weekly and daily surveys.  
  
D4 Respi[INVESTIGATOR_13521] y/Facial Protective Devices  
4.a  Data on respi[INVESTIGATOR_466984].  They were selected because these models:  
(a) Are commonly used by [CONTACT_467234]  
(b) Are commonly used by [CONTACT_467235], Denver Health and the Children’s Hospi[INVESTIGATOR_466985]  
(c) Are commonly used in many settings from across the U.S.  
  
N95 Respi[INVESTIGATOR_13530]:  
1. 3M Corporation 1860, 1860S, and 1870 models  
2. Kimberly Clark Technol Fluidshie ld PFR95 -270, PFR95 -274  Medical 
Masks:  
1. Precept [ZIP_CODE]   
2. Kimberly Clark Technol Fluidshield [ZIP_CODE] (preferred)  
  
(a) Data provided by [CONTACT_467236]: 3M 1860: 0.72% avg. penetration  
(b) 3M 1870: 0.32% avg. penetration  
(d) (c) Kimberly Clark PFR95 -170: 1.38% avg. penetration Precept model [ZIP_CODE]: 12.9% avg. 
penetration  
(e) Kimberly Clark Technol Fluidshield [ZIP_CODE]: 10.3% penetration.  
  
NIOSH N95 approval criterion is ≤ 5% penetration ( i.e., ≥ 95% efficiency), suggesting the practical 
difference between 0.32% and 1.38% penetration is negligible.    
  
The filter airflow resistance for the medical mask was 4.1 (Precept) and 4.5 mmH2O (Kimberly  
Clark), while the filter airflow resistances for the N95 filtering face pi[INVESTIGATOR_466986] 
8.[ADDRESS_598786] difficulty detecting differences between these low levels of airflow 
resistance.  Eac h study site will purchase the appropriate FPE each flu season to ensure 
availability of the FPE models in the study at the participating clinics/clusters.    
  
FIGURE 1       Basic* Elements of Recommended Personal Protective Equipment   
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598787] Precautions  
   Droplet Precautions           Airborne Precautions   
   Medical Mask               N95 Respi[INVESTIGATOR_466987]   
  
*This figure is for quick comparisons; for further details, see the original sources: references [ADDRESS_598788] as the use of  a protocol to qualitatively or quantitatively 
evaluate the fit of a respi[INVESTIGATOR_466988].  In compliance with JHH/OSHA regulations, 
subjects will be required to fill out an amended version of the 1910.134 OSHA Respi[INVESTIGATOR_466989] (Appendix M). Subjects randomized to the N -[ADDRESS_598789] kit (i.e., 3M™ FT -[ADDRESS_598790] Paul, MN, [LOCATION_003]) that 
meets the m anufacturers’ instructions for fit -testing.  The fit -tests used at each facility may vary 
but all will be OSHA -accepted.  As participants will change masks frequently during the course of 
a work shift, subjects will be educated about how to properly perfor m seal checks on their 
masks to ensure a proper fit.  Participants will be asked to refrain from eating or drinking for [ADDRESS_598791]; males will be asked to be freshly shaven, and to remain without facial 
hair for the duration of the study (A ppendix Q).  Instructions will be given as to how to properly 
don, doff, and adjust FPE, and manufacturer -recommended fit checks will be explained.  
Participants will be given specific instructions regarding when to reuse and replace their FPE.  
Participan ts will be instructed to don new respi[INVESTIGATOR_466990] -contact [CONTACT_4490] a 
patient with suspected or confirmed respi[INVESTIGATOR_466991]. Subjects will be allowed to 
choose which N95 respi[INVESTIGATOR_466992] – either 3M 1860 (regular or sm all), 3M 1870, or 
PFR95270/PFR95 -274 Kimberly Clark N95 (regular or small). In instances in which subjects who 
are fittested using either qualitative or quantitative methods cannot detect the Saccharin 
solution, Bitrex will be used instead.  Subjects who f ail all N95 respi[INVESTIGATOR_101731] -tests or cannot 
detect either Bitrex or Saccharin will be considered screening failures and will be excluded from 
the study.  Alternative respi[INVESTIGATOR_466993].   
D5 Attitudes and Opi[INVESTIGATOR_466994].  A standardized form will be used (Appendices E & H).  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598792] FPE use and 
number of respi[INVESTIGATOR_13521]/mask changes required.  Participants will be instructed to don a new 
respi[INVESTIGATOR_13521]/mask each time they come into close contact (within 6 feet) of a patient  with 
suspected or confirmed respi[INVESTIGATOR_466991].  Hand hygiene frequency will also be 
observed.  Unannounced observations will occur in each clinic throughout the intervention 
period of the study; these visits will take place during all operati ng hours of each participating 
clinic.  A standardized system will be used to measure FPE and hand hygiene compliance 
(Appendices I and Z) using HandyAudit compliance measurement iPad application.  These 
observations may be made using paper or electronic m ethods but must ultimately be submitted 
via HandyAudit.  
  
As discussed, a patient -based observation system (see Appendix Y) may also serve as an 
additional method for assessing HCP compliance with FPE and HH, especially when these 
observations are difficu lt or impossible to attain by [CONTACT_464] (i.e. behind closed doors or in 
areas with limited visibility).  
  
To encourage and remind participants of mask wearing, study sites may hang posters with a 
“Mask Up” slogan (see Appendix BB) in clinics and high tr affic areas of the hospi[INVESTIGATOR_307].  These 
posters reiterate CDC mask wearing guidelines for HCPs in close contact [CONTACT_467237][INVESTIGATOR_4416]. The intent of this campaign is to maximize 
mask -wearing compliance among study participants.  
    
D7 Risks and Benefits  
Respi[INVESTIGATOR_466995]; therefore, any subject may remove 
his/her respi[INVESTIGATOR_466996].  While 
CDC guidance specifies (and OSHA regulation enforces) the settings and c onditions in which 
these protective devices are to be worn, employees are afforded the right to remove the 
equipment.  Still, it is the subjects’ best interest to remove these devices at appropriate times, 
such as during break periods or when not interacti ng with patients.  
  
POSSIBLE RISKS:  The problems posed by N95 respi[INVESTIGATOR_466997].  The risks of wearing a respi[INVESTIGATOR_466998].  
Subjects wearing respi[INVESTIGATOR_466999] -level exertion, the type typi[INVESTIGATOR_467000], should not experience limits of endurance or exertion capacity.  Subjects who exert 
themselves at a moderate or high -level workload for a prolonged period (highly unusual for 
HCPs) may need to remov e their protective equipment for all or some of the remaining study 
session.  While the risks of ischemic events, such as a myocardial infarction or cerebrovascular 
accident, cannot be completely excluded, the risks of these events have been conventionally  
understood to be extremely low.  Studies quantifying the risks of such rare events while wearing 
respi[INVESTIGATOR_467001].  However, HCPs who 
can perform the occupational duties required to care for patients a re believed to be capable of 
wearing a respi[INVESTIGATOR_467002].   
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598793] trimester of pregnancy during the 
study period are excluded from the study.  
  
Mild discomfort is the primary risk associated with upper respi[INVESTIGATOR_467003] (throat 
and nasal swabs).  Gagging or aspi[INVESTIGATOR_467004], although the in vestigators are 
not aware of well -documented cases in the public domain.  Other rare occurrences may include 
bleeding or emesis.   
  
There is a risk associated with the collection and handling of PHI. All PHI data will be coded at 
the earliest opportunity, transmitted and stored according to institutional guidelines, and the 
code key will be destroyed at the end of the study.  
  
Risks a ssociated with having blood drawn are slight but may include excessive bleeding, fainting 
or feeling light -headed, hematoma, and rarely, infection. Trained personnel will collect blood for 
serological testing.  
  
POSSIBLE BENEFITS:  The study is designed to  help answer an important question regarding the 
safety of all HCPs.  All participants will meet fit -testing criteria (as determined by [CONTACT_941]  
“Inclusion/Exclusion” protocol).  They will also be fit -tested for the N95 respi[INVESTIGATOR_467005].   The fit -testing documentation provided by [CONTACT_467238] a clinic’s mandatory fit -testing renewal 
requirement.  Because OSHA -designed fit -testing provides a means for education about 
respi[INVESTIGATOR_467006] -testing can help equip HCPs with a safe work environment, the 
study could offer the benefit of enhanced workplace safety.  Otherwise, there is no known 
direct, immediate benefit to subjects.   
  
D8 Early Withdrawal of Subjects/Data/F ollow -up for Withdrawn Subjects   
If a participant is unable to complete the study, due to illness (other than a respi[INVESTIGATOR_467007]) or non -compliance with the data collection and sampling required for this study, they 
will be removed from the st udy. If participants fail to submit more than three entire weeks of 
surveys (i.e. no weekly survey and no daily surveys) and/or fail to comply with three warnings 
from study personnel during observations (i.e. improper use of FPE, failure to correct HH) th ey 
will be subject to an administrative withdrawal at the discretion of the site PI.  
In the event a participant becomes ineligible but is still willing to participate (i.e. – changes 
location but still willing to be involved with the study) AND has comple ted at least eight weeks 
of the study intervention period, the final blood collection and post -study survey will be 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598794] -study collections will be reviewed and 
completed at the discretion of the site PI.    
  
D9 Study Data Collection tools  
The data will be collected on electronic data capture forms (HandyAudit and REDCap). Findings 
may be validated with a telephone call, email, or a face -to-face contact [CONTACT_467239].    
  
  Forms  Study time 
point  Appendix  Filled by  
a)  Pre-study Inclusion/Exclusion  
Screening   Pre-study  C  Research 
team/participant  
b)  Baseline Survey  Pre-study  D  Participant  
c)  Preliminary Survey  Pre-study  E  Participant  
d)  Amended Fit -testing Medical  
Questionnaire  Pre-study  M  Participant  
e)  HSE Fit Test Evaluation Form  Intervention  Q  Research Team  
f)  Enrollment Checklist  Pre-study  P  Research Team  
g)  Weekly Diary  Intervention  G  Research Team  
h)  Daily Exposure Form  Intervention  F  Participant  
i)  Symptomatic Event Report  
Form  Intervention  N  Participant/Research  
Team  
j)  Subject Compliance Monitoring 
Forms:   
FPE Observation Form          Intervention  I, Y, Z  Research Team  
k)  Subject Compliance Monitoring 
Forms:  
Hand Hygiene Observation  
Form  Intervention  I, Y, Z  Research Team  
l)  Post Study Survey  Post -study  H  Participant  
m) Supplemental Vaccination  
Questions  Post -study  CC  Participant   
9.a   Pre-study Inclusion/Exclusion screening  
All potential participants will be required to complete a pre -study screening form to determine 
their eligibility to participate in the study (Appendix C). If HCPs are determined to not be eligible 
to participate in the study due to a potentially complicat ing health condition, they will be 
provided information about proper respi[INVESTIGATOR_467008] (Appendix J).  
9.b  Baseline Survey  
The baseline survey (Appendix D) will collect contact [CONTACT_3031], demographic information, 
recent exposure (risk factor) histo ry, vaccination status, smoking status, history of systemic 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   29  disease (respi[INVESTIGATOR_696]/heart/neurological) and information about medication use.  Participants 
will be required to complete this survey prior to the study intervention period.   
9.c  Preliminary Sur vey  
The pre -study attitudes, beliefs, and opi[INVESTIGATOR_467009] (Appendix E) will collect participants’ 
knowledge, attitudes, beliefs, and opi[INVESTIGATOR_467010].   Participants will be required to complete 
this survey prior to the study intervention period.      
9.d   Amended Fit -Testing Medical Questionnaire  
In compliance with OSHA regulations, subjects will be required to complete an amended version 
of the 1910.134 OSHA Respi[INVESTIGATOR_467011] (Appendix M) prior to being 
fit tested.  
9.e  HSE Fit -Test Evaluation Form  
This form will be completed by [CONTACT_467240]. 
(Appendix Q)  
9.f  Enrollment Checklist  
This will be a checklist (Appendix P) to ensure that the participants enrolled in the stud y 
intervention period meet the study entry criteria. The data collected during the pre -study 
assessments including; Inclusion/Exclusion criteria, Fit -testing, and Baseline survey will 
determine if a participant can be enrolled into the study or is a screen  failure.  
9.g  Weekly Diary   
During the intervention period (Table 2), the information will be collected once weekly  
(Appendix G) updating their influenza vaccination status, symptoms, treatment and exposure.    
  
9.h  Daily Exposure Form   
  
A daily exposure form (title “Monday Exposure Form, Tuesday Exposure Form, etc; Appendix F) 
will be used to help participants recall and record exposure risks, signs and symptoms of 
respi[INVESTIGATOR_467012]. The daily exposure form  will ask about 
respi[INVESTIGATOR_467013], work colleagues and other contacts.  Participants 
will complete the daily exposure form every day to track the existence or absence of respi[INVESTIGATOR_467014] -like symptoms on each date worked a t the study site.    
  
While data from this study will be kept confidential and will not be reported to managers and 
will not be used to enforce furloughs for ill participants, we will encourage participants who 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  30  become ill to consult with their local occupational/employee health  departments concerning 
their illness.  
  
9.i  Symptomatic Event Report Form  
Subjects who self -identify as having any sign(s) or symptom(s) of influenza (as defined in Table 3) 
will be asked to complete a Symptomatic Event Report Form (Appendix N).  Train ed study staff 
will then determine if the subject should undergo an upper respi[INVESTIGATOR_467015]/throat swabs for data collection purposes.    
  
Participants reporting signs or symptoms of respi[INVESTIGATOR_3765] (including influenza) in t heir 
weekly symptom diary/daily exposure diary will be contact[CONTACT_467241][INVESTIGATOR_467016] (throat and nasal swabs). Those participants who are not 
working or are unable to come to work will be instructed to use thei r take -home kit (Appendices 
R, S, T, and U).  
  
9.j  Subject Compliance Monitoring Forms   
  
Data will also be gathered on FPE compliance and hand hygiene (HH) compliance.  Data will be 
collected by [CONTACT_467242] 
(https://www.handyaudit.com/)  or using standardized forms if the HandyAudit system is 
unavailable (Appendix I, Appendix Z).  FPE and HH compliance data collection will occur during 
unannounced observation visits within clinic operating hours. This information will be used to 
analyze the relationship between levels of compliance with FPE and H H and incidence of 
respi[INVESTIGATOR_3765].  Participants will be asked to wear FPE whenever they have close contact 
(within 6 feet or sharing a small enclosed airspace) with an individual with suspected or 
confirmed ILI.  They will also be asked to don new FP E before each new close -contact [CONTACT_467243].   The study team will aim to achieve five FPE and five HH observations per site, per 
week. These data were collected using HandyAudit (Handimetrics, Toronto, 
CAhttps://www.handyaudit.com/handyaudittechno logy.html).  
9.k  Post -Study survey  
After the intervention period, there will be a post -study period when the participants will 
complete a post -study survey regarding attitudes, beliefs, and opi[INVESTIGATOR_467017]. 
(Appendix H).  
9.l  Adverse Event Submission Form  
An adverse event (AE) is any adverse change from the patient’s baseline (pre -study) condition, 
which occur during the course of the study and, after the consent form has been signed, 
whether the event is considered to be rela ted to the study intervention or not. The research 
team will complete an AE submission form (Appendix O) upon reporting of such events.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598795] of this study requires prioritization of achievable endpoints and target data.     In an 
effort to optimize the use of available funds, a subset of lab tests for identification of  respi[INVESTIGATOR_467018] (more information is  available in 
the section on funding source). The lead study team (principal and lead site  investigators) 
determined that all sites will send remaining samples to UT Southwestern (UTSW)  and the VA 
North [LOCATION_007] for storage. Future sample testing will be determined by [CONTACT_467244].  
Samples from VA sites will be stored in space leased by [CONTACT_467245]. All  storage 
facilities are in compliance with VA North [LOCATION_007] requireme nts.   
  
Excess samples remaining after study tests have been completed may be released to ResPECT  
investigators for analyses of other respi[INVESTIGATOR_467019], after approval by [CONTACT_467246]. As new respi[INVESTIGATOR_467020], specimens may be used for  
additional testing as dictated by [CONTACT_467247][INVESTIGATOR_623]. According to record retention policies,  
the VA requires that records are retained until six years after the end of the calendar year in  
which the study closed. The lead study team will comply with the record retention policies at  the 
VA, as well as the policies at each individual site.   
  
10.a Blood Specimen Collection  
Blood samples will be collected by [CONTACT_467248]; one at the beginning of 
the intervention period and second at the end of the intervention period. The samples collected 
were originally stored for serology testing and sent to [CONTACT_467324] at Saint Louis  
University at agreed upon interval s for analysis. [CONTACT_467325]’s lab operates in a VA -leased space at 
Saint Louis University and complies with all VA St. Louis Healthcare System regulations. To 
maintain data integrity and ensure study longevity, the lead study team determined that all sites  
will send remaining blood samples to UTSW and the North Dallas VA for storage. VA samples will  
be stored in space leased by [CONTACT_467249].  As new respi[INVESTIGATOR_467021], specimens may be used for additional testing as dictated by [CONTACT_467247][INVESTIGATOR_623].   
10.b Respi[INVESTIGATOR_467022].  The respi[INVESTIGATOR_467023]. No nasopharyngeal aspi[INVESTIGATOR_467024].  If it is 
determined that subjects are unable to come to work and participate in specimen collection 
when they experience respi[INVESTIGATOR_467025], participants wil l use “take -home” 
specimen collection kits, which will be provided to them upon enrollment, (Appendix R) and 
procure a respi[INVESTIGATOR_467026].  The kits will include instructions on dangerous 
goods shippi[INVESTIGATOR_007] (Appendix S), self -specimen collection ( Appendix T), and shipment packaging 
(Appendix U) so that the specimens can be sent to the research lab.   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598796] Methods   
  
Respi[INVESTIGATOR_467027] (secretions/swabs in viral transport medium) will be processed and stored  
within 48 hours at each study site. Frozen samples will stored at Johns Hopkins University and  
the Denver VA/the University of Colorado at agreed upon intervals. Stora ge and laboratory  
testing will occur at both Johns Hopkins and the Denver VA/the University of Colorado. Samples  
will then be sent to UTSW for storage, where they will be stored for future use.    
  
Nucleic Acid Extraction, PCR    
Samples will be processed f or nucleic acid extraction using multiplex PCR assay(s) at JHU to  
identify human respi[INVESTIGATOR_13531] (Table 4). St. Louis testing is done using assays to  
determine serum hemagglutination inhibition (HAI) antibodies to multiple strains of Influenza A  
and B viruses.  Excess samples were stored for further analysis by [CONTACT_467250]. These will be transferred to UTSW where they will be used for additional  
studies based on the determination of ResPECT investigators.  Samples may be destroyed at the  
discretion of the lead study team.   
    
10.c Study Specimen Storage and Shippi[INVESTIGATOR_467028]. Perl, study co -PI [INVESTIGATOR_467029], has left  
JHU for UTSW, the study lead team has  determined that all respi[INVESTIGATOR_467030]. UTSW will house and  
catalogue the samples according to good laboratory practices in a freezer farm in the  
institution’s ID Division and  space leased by [CONTACT_467251]. Samples will be stored in one of  
several -80°C upright freezers. Protocols for specimen cataloguing and storage will be developed  
with the Johns Hopkins University under the direction of Charlotte Gaydos, who also now s erves  
as the lead site investigator at JHU. A laboratory based, inventory database and tracking system  
will be put in place and will be used to track samples. Freezer temperatures will be monitored  
daily for temperature deviations. A materials transfer agr eement (MTA) has been signed by [CONTACT_1050],  
UTSW and the [LOCATION_001] VA. The study team will check with individual site IRBs to ensure this  
MTA suffices for all sites.    
  
  
E  Study Procedures   
E1 Certification and Registration of the clinical Sites/Clusters:  
  
The participating sites will certify (Appendix K) and then register these clusters with DCC. DCC 
will then randomize the clusters to one of the two arms and send the randomization scheme to 
the participating site.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   33  E2 Screening for Eligibility  
The anticipated duration of this study is four respi[INVESTIGATOR_467031].  Enrollment of subjects 
will commence as soon as possible after IRB approval, with the intention that the study will 
cover four respi[INVESTIGATOR_467031].  The start of the actual in tervention period will be 
determined by [CONTACT_467252], as well 
as state and regional health departments. The clusters would be assigned by [CONTACT_467253] a system established by [CONTACT_15791] .  
  
HCPs who agree to participate will be asked to provide written informed consent and agree to 
participate for up to 16 weeks with the option to voluntarily withdraw at any time, for any 
reason.   
  
Once consented, participants will be screened for excl usion (Appendix C), and to ensure that 
they are healthy enough to participate in the study. Non -English speakers and those with a 
language or hearing impairment will be excluded from the study.  Once participants are 
consented, they will be asked to fill o ut the baseline survey and preliminary 
attitudes/opi[INVESTIGATOR_6153]/beliefs survey, will provide their initial blood draw, and will be fit -tested if 
they are being recruited at a site that has been designated as an N95 -wearing clinic.  Ideally, all 
these (pre -study assessments) initial procedures will occur during their initial enrollment but 
may have to be performed later date in the study. During the pre -study period, fit testing will be 
done to confirm eligibility of participants at the site randomized to wear N95  respi[INVESTIGATOR_13530]. There 
will not be a pre -participation physical examination. However, during the informed consent 
process, the Study Coordinator will explain to each potential subject the risks of wearing a 
respi[INVESTIGATOR_467032] o f collecting upper respi[INVESTIGATOR_92814].  
  
Contact[CONTACT_467254] (but is not limited to) following up with participants about 
form compliance, fielding questions, ensuring payment and scheduling, and contact[CONTACT_467255].   The list of participating HCPs 
and the intervention schedule will be kept confidential to protect HCPs from repercussions for 
either declining or accepting participation in the study.    
  
E3 Schedule of Study Assessments  
1) Pre-study Period assessments  
Prior to the initiation of the intervention period, participants will be expected to provide an 
initial serological sample for comparison with their final serological sample for influenza titers.  
Study preparation/screenin g and education will also take place during this time.  Participants 
will also be required to complete a baseline survey and preliminary attitudes, beliefs, and 
opi[INVESTIGATOR_467009].  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  34    
i. Consent form: After explaining the study to the potential participant as di scussed in the 
previous section, consent from the agreeing participant would be obtained. The study 
participant will sign two copi[INVESTIGATOR_79642], one for the study use and other 
would be given to the study participant for their record.  
ii. Pre-study I nclusion/Exclusion screening   
iii. Enrollment checklist iv.       Baseline survey  
v. Preliminary survey  
vi. Fit-testing: Fit testing will include education on how to properly don and doff FPE, 
perform user seal checks, and when masks should be reused or replaced.  Education on 
donning and doffing respi[INVESTIGATOR_467033] a nd one -on-one discussion during the fit -testing process. In compliance with 
JHH/OSHA regulations, subjects will be required to fill out an amended version of the 
1910.134 OSHA Respi[INVESTIGATOR_467011] (Appendix M).   We will 
only include  clinics whose managers/leaders have agreed to the inclusion of their 
clinical site(s) in the study.  The researcher will complete a fit test evaluation form 
(Appendix Q) to assess if the participant passes the fit testing requirement.  
vii. Initial blood draw:  approximately [ADDRESS_598797] for 
baseline (at enrollment) influenza titers. Blood for serum titers will be drawn, 
processed and stored per laboratory protocol.  
viii. Educational component: All subjects will be counseled on infl uenza vaccination per 
their local policy if they have not received it for the current season. Subjects wishing to 
be vaccinated will be encouraged to do so at the earliest possible time, so that 
seroconversion occurs by [CONTACT_467256].  All subjects will be counseled on influenza 
vaccination in accordance with local policies and procedures ( e.g.,  no change in 
recommendations despi[INVESTIGATOR_467034]). All subjects will be educated about 
standard precautions.    
2) Intervention Period Assessments:  
The i ntervention period will consist of 12 -16 weeks of participants wearing their assigned FPE.  
Depending on the observed incidence of viral respi[INVESTIGATOR_3765], the intervention period may 
be extended (or otherwise modified) if the incidence of influenza rema ins significantly elevated.   
  
As discussed in the methods section, the duration of the intervention (mask wearing) period 
may be shortened or lengthened based on incidence and surveillance data available from each 
site.  Flexibility in adjusting the dura tion of the intervention period is vital to allow for the 
maximum capture of data during viral respi[INVESTIGATOR_431883], which may be different at each site, 
each year. Consenting HCPs in each of the included clinics will be enrolled for the duration of the 
intervention period and will be asked to follow the cluster randomization scheme.    
  
i. Daily Exposure Form:   All participants will be asked to complete the daily exposure 
diary for each day during the intervention period regardless of whether the participant 
worked that day.  This diary will collect participant symptom information, participant 
exposure to symptomatic patients/co -workers, hand hygiene frequency, and frequency 
of wearing N95s/medical masks.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   35  ii. Weekly Diary:  All participants will be asked to complet e the weekly diary.  This diary 
will capture participant symptom information, participant exposure to symptomatic 
household members, and flu vaccination status  
iii. Symptomatic Event Report Form:   If a participant develops respi[INVESTIGATOR_696]/flu -like 
symptoms, a symp tomatic event report form will be completed by [CONTACT_467257]/research staff.  
iv. Respi[INVESTIGATOR_467035]:   All subjects will be asked to consent to respi[INVESTIGATOR_467036], regardless of respi[INVESTIGATOR_1856]. Specimens from the upper respi[INVESTIGATOR_467037], that may include a nasal and throat swab, will be collected from participants 
during this time.  No nasopharyngeal aspi[INVESTIGATOR_467038].  Randomized upper 
respi[INVESTIGATOR_467039] 2 -6 times during the study period: [ADDRESS_598798] up to 75% of 
asymptomatic cases, serology cannot identify infection with organisms other than 
influenza.  PCR testing of samples from participants with signs or symptoms of influenza 
will allow us to accurately determine the organism that is causing the symptoms.  
v. FPE/Hand Hygiene Compliance Monitoring:   During unannounced visits to study clinics, 
research assistants will complete the subject compliance forms and may verbally 
correct participants  who are observed donning/doffing/wearing FPE incorrectly or who 
are not following proper hand hygiene procedures to maximize compliance and 
protection of healthcare workers and patients. We may also be employing an additional 
patient -based hand hygiene an d FPE monitoring system to assess practices on a clinic -
wide basis (see Appendix Y). Forms may be distributed to participating sites asking their 
patients to record the HH and FPE practices of HCP during interactions. This information 
will be collected ano nymously with respect to HCP and the patients.  
  
Subjects with signs or symptoms of respi[INVESTIGATOR_467040]/employee health department as per institutional guidelines. In many cases the 
Occupational Health Clinic would be expected to recommend employee sick leave for a short 
period (1 or more days).  When absent from duty, subjects will be asked to continue completing 
their exposure and symptom forms.  However, we plan t o have an online survey/form system 
that will be integrated into the data collection scheme within the first flu season. When the 
subject -employees return to work (e.g., the Occupational/Employee health Department permits 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  36  the employee to return to duty), s /he will resume donning of the assigned protective devices 
and will resume their testing.     
  
3) Post -Study Period Assessments  
Two weeks after the conclusion of the intervention period, a post -season serological sample will 
be collected and a post -study  survey will be completed.  Although participants will only be 
required to wear FPE, provide upper respi[INVESTIGATOR_92814], and be observed for the initial 
intervention period, the entire course of the study will continue for two weeks after the 
intervention period to allow for the final visit for final serology and the post -study survey.  It is 
anticipated that study participants will enroll for subsequent respi[INVESTIGATOR_467031]. However, 
if participants withdraw prior to the completion of [ADDRESS_598799] -Study Survey: All participants will be asked to complete a post -study survey.  This 
form will collect participants’ post -study attitudes, behaviors, and opi[INVESTIGATOR_467041].     
ii. Final Blood draw: Approximately [ADDRESS_598800] at the 
end of the study (before termination). Blood for serum titers will be drawn, processed 
and stored per laborato ry protocol.    
iii. Supplemental Vaccine Questions: All participants will be asked  to complete an 
additional survey about selected vaccinations for preventable diseases that can be 
acquired in the healthcare environment, in addition to the questions asked in t he pre - 
and post -study surveys.   
iv. Sub-study consent: Participants who participated in the main portion of the study will 
be asked to take part in a study extension, in which any additional respi[INVESTIGATOR_467042] d for respi[INVESTIGATOR_13531].  
E4 Subject Stipends or Payments   
Subjects will be compensated for the time necessary to complete the entire study, resulting in a 
maximum possible compensation of $599 (Appendix W).  HCPs’ compensation will be prorated 
by [CONTACT_467258], contingent on the completion of the nasal and throat swabs, 
preliminary and post -study surveys, daily exposure diaries, weekly symptom diaries, and 
serological testing at the beginning and end of the study.  Subjects who voluntarily  withdraw 
from the study or are removed from the study mid -week, because of illness or other 
investigator -identified issue will receive compensation prorated according to completed study 
requirements.  Subjects who do not meet eligibility requirements at s creening will not receive 
compensation and will be withdrawn from the study. Receipt of the final $[ADDRESS_598801] withdrawn from the study before t he endpoint, voluntarily or at the direction of the 
investigator, will not receive the additional $135. The compensation will be issued to study 
participants via checks mailed to their home addresses and will be issued twice during the study 
period, once a fter the 6th week of intervention and again after all study activities are complete.  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598802] compliance, etc.  
  
E5  Study Timetable  
  
See Table 2  
  
E6 Safety and Adverse Events   
6.a  Definitions and Classification of Adverse Events  
Definition of Adverse Event:   An adverse event (AE) is any adverse change from the patient’s 
baseline (pre -study) condition, which occurs during the trial, after the consent form has been 
signed, whether the event is considered related to study procedure or not.  
  
i Relationship  
At eac h site, the principal investigator [INVESTIGATOR_467043], based on available information, using the following as guidelines:  
a) Unrelated: No temporal association, or the cause of the event has been identified; or 
the study procedure cannot be implicated  
b) Probably not related: the cause of the event has been identified;   
c) Possibly related: Temporal association is present, but other etiologies are likely to be 
the cause; however, involvement of the study procedures cannot be excluded   
d) Probably related: Temporal association is present; other etiologies are possible, but 
unlikely  
e) Related: Tem poral association is present  
f) Other: unknown  
  
ii Severity and Expectedness  
The following AE definitions will be used:  
Unanticipated/Unexpected Event : (Any untoward event that is not identified with the current 
investigator brochure or study protocol) Awar eness of sign, symptom, or event, but discomforts 
enough to cause interference with usual activity and may warrant intervention.  
  
Serious Adverse Event : Any untoward medical occurrence that results in death, is life -threatening, 
requires patient hospi[INVESTIGATOR_11298], prolongs existing hospi[INVESTIGATOR_059], results in persistent or 
significant disability/incapacity, or is a congenital abnormality.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  38  6.b  Data Collection and Reporting Procedures for Adverse Events  
  
Data collection procedures for adverse events    
Any event experienced by a participant in a given week will be documented in the weekly diary.  
Participants will complete the weekly symptom diary, and any event experienced during that 
week will be noted. The Research team will assess if the reported eve nt meets the definition of 
adverse event. If the Study Coordinator or Principal Investigator [INVESTIGATOR_467044], an Adverse Event 
Submission Form will be completed (Appendix O). Information regarding the type of report will 
be collected initial and a follow -up, the date and description of the AE.  All adverse events and 
Serious Adverse Events between the time of study entry (consent) and the end of post -study 
period will be co llected and reported.  Patients will be monitored for all ongoing unresolved 
adverse events until they are either resolved, or in the opi[INVESTIGATOR_1237], the 
patient is medically stable.  
  
Reporting procedures : All serious adverse event s and unexpected/unanticipated events(s), will 
be submitted to local IRB according to their reporting policy. In addition, a summary of the 
adverse and serious adverse events will be sent to the sponsors/agency/DCC annually.  
  
6.c  Data and Safety Monitor ing Board (DSMB)  
  
Three independent researchers will constitute a Data Safety Monitoring Board (DSMB).  The 
members of the board are expected to include the following members. The board composition 
could change at any time. Members with similar qualifica tions will be included to replace exiting 
members.   
• [CONTACT_467326], MD is a psychiatrist and bioethicist. She is the Director of the Montefiore - 
Einstein Center for Bioethics.   Previously she has been the Executive Director of the  
[LOCATION_001] State Task Fo rce on Life and the Law, and the Director of Clinical Ethics at  
Columbia -Presby[CONTACT_24021][INVESTIGATOR_467045].  She graduated from Harvard  
University and Yale Medical School.  She was a member of the Institute of Medicine 
Committee that reviewed a CDC and OSHA request to clarify the recommended 
guidelines for protection of HCPs exposed to novel H1N1 influenza.  
• [CONTACT_467327], PhD is an Assistant Professor with joint appointments 
at the Johns Hopkins School of Medicine in the Department of Anesthesiology and 
Critical Care Medicine (ACCM) and at the Johns Hopkins School of Public Health in the 
Department of Biostatistics.  She is a member of the Quality and Safety Research Group 
within ACCM.  She earned her PhD at the Johns Hopkins Bloomberg School of Public 
Health of the Johns Hopkins University, her MS in Statistics at North Carolina State 
Unive rsity and her BS at Virginia Tech.    
• Daniel Morgan MD, MS is a physician and epi[INVESTIGATOR_467046], Maryland. He is 
Associate Professor of Epi[INVESTIGATOR_467047], Chief Hospi[INVESTIGATOR_467048] t he Baltimore VAMC and a fellow at the 
Center for Disease Dynamics, Economics and Policy (CDDEP). His work is funded through 
the Department of Veterans Affairs, the Centers for Disease Control and Prevention 
(CDC), the National Institutes of Health (NIH), a nd the Agency for Healthcare Quality and 
Research (AHRQ).   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   39  DSMBs typi[INVESTIGATOR_467049]/modification to avoid exposing 
subjects to an inferior intervention.  This often occurs when the study results pass a statistical 
thresho ld demonstrating one arm to be inferior. In this context, the DSMB will be charged with 
identifying an appropriate time for protocol termination/modification based on available interim 
data about the incidence of influenza and respi[INVESTIGATOR_18073].  If o ne respi[INVESTIGATOR_467050] a clinically significant fashion (e.g., p=0.05), 
the DSMB will weigh the risks and benefits of continuing or prematurely terminating the study.  
The DSMB will meet approximatel y yearly for respi[INVESTIGATOR_467031] 1 and 2, and on an as 
needed basis after that time (e.g., December, May).  One member of the team will be selected 
to be the primary liaison with the DSMB.  
  
  
  
F  Statistical Plan   
  
F1 Study Outcome Definitions   
    
The following definitions align with the definitions in the study’s analysis plan, posted on  
clinicaltrials.gov here:   
https://clinicaltrials.gov/ct2/show/ study/[STUDY_ID_REMOVED]?show_desc=Y#desc . The most recent 
analysis plan was uploaded and registered to ClinicalTrials.Gov in June of 2017.   
  
Laboratory -confirmed influenza illness (LCI):  A laboratory -confirmed influenza illness is defined 
as laboratory confirmation of influenza infection by [CONTACT_5640]: (A) detection of influenza virus by 
[CONTACT_467259][INVESTIGATOR_467051] [ADDRESS_598803] within seven days of symptom onset or (B) influenza seroconversion defined 
as a 4fold rise in hemagglutination inhibition antibody titers from the pre - to post -season 
serological samples.  
  
Acute Respi[INVESTIGATOR_19269] (AR I): The first secondary outcome is the incidence of ARI as a clinical 
syndrome. ARI is defined as the occurrence of signs or symptoms of respi[INVESTIGATOR_4416], as 
defined by [CONTACT_50489] 2 in the published protocol, with or without laboratory confirmation.   
  
Influenza -Like Illness (ILI): The second secondary outcome is the incidence of ILI as a clinical 
syndrome. ILI is defined as temperature of 100°F [37.8°C] or greater plus cough and/or a sore 
throat, with or without laboratory confirmation.  
  
Laboratory Conf irmed Respi[INVESTIGATOR_19269] (LCRI): The third secondary outcome is LCRI 
attributable to any of the pathogens listed in Table 4. LCRI is defined as ARI combined with 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  40  laboratory confirmation by [CONTACT_937] -PCR of any of the pathogen listed in Table 4 in an upper 
respir atory specimen swab after symptoms were reported and within seven days of the original 
symptomatic report. Events with multiple viruses detected will count as a single event of LCRI.  If 
a swab that tested positive but was not associated with a symptomatic  event (i.e. was not 
collected between symptom onset and seven days after symptom onset) then the incident does 
not count as a LCRI event. If an individual seroconverts to influenza, had symptoms at some time 
during the study, and does not have a PCR -confi rmed pathogen event already, then we will 
assign them a single LCRI event.   
  
Laboratory Detected Respi[INVESTIGATOR_60623] (LDRI): The fourth secondary outcome is LDRI 
attributable to any of the pathogens listed in Table 4. For a participant with or without 
symptoms, an LDRI is defined as: 1) detection of a respi[INVESTIGATOR_467052], or 2) serological evidence of infection (e.g. seroconversion) with a 
respi[INVESTIGATOR_467053](s). In a case where t wo or more 
pathogens are identified in the same specimen, each pathogen will be considered to represent a 
separate infection (e.g., 2 pathogens as 2 events, 3 pathogens as 3 events) for that study 
participant for that time -point.  Sequential detection of t he same pathogens by [CONTACT_467260] 21 days apart will be considered separate 
infections.   
F2 Study Outcome Measurements:  
2.a  Measurement of the Protective Effects:  
• Investigators will compare the incidence rates of LCI, ARI, ILI, LCRI, and LDRI among HCPs 
who were randomized to wear respi[INVESTIGATOR_467054].  
  
• Investigators will examine the relationship between incidence and possible risk factors, 
including compliance, attitudes and opi[INVESTIGATOR_466963]. The 
analysis plan will account for the frequency and level of risk associated with 
nonocc upational exposures.  
2.b  Incidence Determination  
• Investigators will determine incidence rates of LCI among HCPs in outpatient setting.  
  
• Investigators will determine incidence rates of ARI, ILI, LCRI, and LDRI among HCPs in 
outpatient setting.  
  
F3 Effect Size  
This study is powered to detect a statistically significant difference between two randomized 
intervention arms, where the primary outcome is laboratory -confirmed influenza.  We aim to 
detect a 25% reduction (i.e., a relative risk of 0.75) in th e incidence of laboratory confirmed 
influenza among subjects wearing an N95 respi[INVESTIGATOR_467055] a medical 
mask.  These figures were chosen by [CONTACT_467261][INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   41  competition with each other, including (a) the anticipated mean incidence of laboratory 
confirmed ILI virus infection in all study locations, (b) level(s) at which one intervention is 
considered superior to another from a scientific perspective, and (c) the level(s) at which one 
intervention is  considered superior to another from an ethical perspective, such that study 
discontinuation becomes necessary.  Clinicians and clinical scientists in the Infectious Diseases 
and Occupational Medicine communities were informally surveyed for their opi[INVESTIGATOR_467056], such that one device would be considered better 
than another.  Most clinicians reported 15 -25% would be necessary to change practice.  
  
F4 Sample Size Determination and Power  
We chose the size of our sample based upon the expected attack rate of our primary outcome 
(lab-confirmed influenza) in our population.  We estimate that over a year, 20% of unvaccinated 
individuals in the medical mask group will experience laboratory conf irmed influenza.  We 
assume that 65% of our population will be vaccinated. Among vaccinated individuals in the 
medical mask group we assume that vaccine is 65% effective in preventing influenza infection. 
Vaccine efficacies at the higher end of what has be en seen (86% in health care workers) will lead 
to a reduction in the yearly attack rate to 8.8%, and efficacy on the lower end of what has been 
seen (51% in the general population) will lead to an increased yearly attack rate of 13.4%. This 
variation is sm aller than what we might expect due to variations in the severity of influenza 
epi[INVESTIGATOR_467057], and falls within the range of potential outcomes we consider in 
our sensitivity analysis (Table 5).  
  
Hence, we expect a yearly attack rate of 11. 55% {11.55% = 0.35*0.2+0.65*(1 -0.65)*0.2}. Based 
on this yearly attack rate, we expect a 4 -year attack rate of 38.80% {38.80%=1 -(1- 
(0.35*0.2+0.65*0.35*0.2))4}. We aim to detect a 25% reduction (i.e., a relative risk of 0.75 within 
each season) in the inci dence of laboratory confirmed influenza among subjects wearing an N95 
respi[INVESTIGATOR_467055] a medical mask.   
  
We estimate the sample size needed to detect a significant difference in the incidence of 
laboratory confirmed influenza using  the approach described by [CONTACT_467262]. The sample size is 
given by   
  
2 
 0(1
 0)
 1(1
 1) 
 pn
2*(z
/2 
z
) 2(DEFF )  
(
0 
 1) 
  
where p=the number of clusters (to be calculated)             n=number of people in each cluster 
(estimated from the units targeted for inclusion to be  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  42  16)             z
 /2=1.96 for an 
alpha=0.05              z
 =0.84 for 
beta=0.8  
            
 0=cumulative proportion with lab confirmed influenza over four seasons in group 1   
(medical mask group) (assumed to be 0.388 for LCI)  
            
 1=cumulative proportion with lab confirmed influenza in group 2 (   
N95 respi[INVESTIGATOR_467058]) (assumed to be 0.3 04 for LCI)  
DEFF=design effect (calculated to be 2.5)  
  
The Design effect is calculated as:  
  
1
(n
1)  
  
where 
  is the intra -class correlation coefficient (assumed to be 0.1) and n is the average 
number of people in each cluster.  The design effect pr ovides an adjustment for the correlation 
of outcomes within clusters.   
  
Using the above assumptions, we estimate that we need 157 independent clusters (clinics) with 
a median size of [ADDRESS_598804] a relative risk of 0.75 between N95 and m edical 
masks at preventing laboratory -confirmed influenza infection.  Using this model, the total 
number of individuals participating each season would need to be 2506, with total 
personseasons accumulated over the course of the study of 10,024.  For our s econdary outcome 
of laboratory confirmed respi[INVESTIGATOR_4375] (LCRI), the total number of individuals participating 
each season would need to be 1,276, with total person -seasons accumulated over the course of 
the study of 5,104. (See Table 6). We expect som e loss to follow -up (20 -25%) and thus would 
target clusters of [ADDRESS_598805] descriptive statistics will be used to describe baseline characteristics and follow -up 
measures, both overall, and within each group. Summary statistics such as means, medians, and 
ranges will be produced for all measured continuous variables. Frequencies will be computed for 
all categorical and ordinal variables. Graphical methods including stem -and-leaf diagrams and 
box plots will be used to examine distributions, identify potential i nfluential points, and guide 
the choice of transformations if warranted.   
  
Raw incidence calculations  
Using the outcome data discussed above, we will obtain estimates of the following quantities for 
all study participants and for each of the two study g roups:  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   43  • the incidence of laboratory -confirmed influenza (rate across the whole season),  
• the incidence of acute respi[INVESTIGATOR_4375] (rate by [CONTACT_9702] -weeks),  
• the incidence of influenza -like illness (rate by [CONTACT_9702] -weeks),  
• the incidence of laboratory -confirmed respi[INVESTIGATOR_4375] (rate by [CONTACT_9702] -weeks),  
• the incidence of laboratory -detected respi[INVESTIGATOR_4416] (rate by [CONTACT_9702] -weeks).  
  
Incidence comparison between study groups  
To compare the above incidence rates among HCPs who were randomized to w ear respi[INVESTIGATOR_467059], we will fit two different types of models.    
  
Logistic regression model  
A dichotomous variable will indicate whether or not a subject became infected with 
laboratory confirmed influenza during the entire influenza season. We will use logistic regression 
to model the difference in seasonal influenza infection between the N95 and medical mask 
groups, using generalized estimating equations (GEE) to account for cluster -specific correlation.  
If Yij is an indicator of whether subject i in group j developed laboratory -confirmed influenza, 
and  
MASK ij is an indicator of which mask the individual wore, then we would fit a version of this 
model  
logit
 Pr(Y ij =1  MASK ij)
[ADDRESS_598806] i in group j, and Nij is the total person -
time contributed, we model the expected number of illnesses as follows:  
log
 E
Dij  MASK ij
  logN ij 
 [ADDRESS_598807] up -to-date guidance issued by [CONTACT_467263] (CDC) and local policies at e ach study institution, at a 
minimum. This may result in cross -overs (e.g., wearing an N95 instead of a MM) which will be 
accounted for in an intention -to-treat analysis after study termination.  
  
The characteristics at the time of randomization for those participants without complete 
followup will be examined. To assess the potential biases introduced by [CONTACT_467264][INVESTIGATOR_13530], a comparison of withdrawal rates and time to withdrawal will be 
included as an ancillary analysis to the primary outcome comparison.  The processes are further 
explained in the analysis plan.  
  
F7 Planned sensitivity analyses  
7.a  Potential outcome analysis for laboratory -confirmed influenza  
To account for the unavoidable additional uncertainty regardi ng the missing data from our 
primary outcome, we will conduct a sensitivity analysis that randomly assigns binary outcomes 
to participants who did not complete the study. Specifically, we will create a two -dimensional 
grid on which we vary the influenza at tack rates in participants who dropped out of the study for 
both the MM and N95 arm, separately. We will fix the MM dropout attack rate between half 
and twice the observed MM attack rate, based on complete data. We will fix the N95 dropout 
attack rate betw een half and twice the observed N95 attack rate, based on complete data. By 
[CONTACT_467265], and for each combination, calculating the 
adjusted odds ratio (averaged across n=50 imputed datasets for each point on the grid), we w ill 
observe the sensitivity of our results to values of the missing data.  
  
7.b  Analysis of differential withdrawal  
The characteristics at the time of randomization for those participants without complete 
followup will be examined. To assess the potenti al biases introduced by [CONTACT_467264][INVESTIGATOR_13530], a comparison of withdrawal rates and time to withdrawal will be 
included as an ancillary analysis to the primary outcome comparison.  
  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598808] Keepi[INVESTIGATOR_007]   
  
G1 Confidentiality and Security  
  
Data Management and Privacy:     
Data will be entered into a password protected database with unique identifiers assigned to  
each study participant. Paper data collection instruments will be stored in a locked filing  cabin et.  
The data will be entered into a secure database. The specific database/data collection  system 
used may vary at each site due to site -specific privacy/database/IRB guidelines.   However, all 
data collected (i.e. surveys, specimen collection data) will b e standardized.  JHU has  been 
identified as the data collection center and will serve as a clearinghouse for data while the  study 
active (i.e., recruiting participants). Once participant recruitment interaction is complete,  
REDCap and cluster data will be securely moved to and stored at the UTSW, which will become  
one of the data management centers along with UF. After all data are collected and all analyses  
completed, linkage between participants and their unique identifier will be destroyed. During  
the course of the study, protected health information that is collected will be disclosed only to  
study personnel, unless otherwise required by [CONTACT_2371]. All personnel have taken (and will continue  
to maintain) required training for HIPAA protection and researc h ethics.    
  
A tracking system using coded identifiers will be implemented to facilitate tracking of sample  
compliance and sample movement between study sites, laboratories, and/or other pertinent  
locations. Coded identifiers will be matched year -to-year to link participants’ data. This  
information will be stored and accessed in compliance with federal and study site requirements.     
  
  
G2 Case Report Forms and Source Documents  
All subject -specific data recorded in diaries, forms or other record (includi ng infection status) 
will be de -identified and kept confidential.    
G3 Data Management   
Study data will be collected and managed using an electronic database which is a secure, 
webbased application designed exclusively to support data capture for researc h studies. This 
application provides: 1) an intuitive interface for data entry (with data validation); 2) audit trails 
for tracking data cleaning and export procedures; 3) automated export procedures for seamless 
data downloads to common statistical packag es (SPSS, SAS, Stata, R); 4) procedures for 
importing data from external sources; and 5) advanced features, such as branching logic and 
calculated fields.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598809] at UT  
Southwestern.    
  
Data storage facilities managed by [CONTACT_467266] (IR) Department at UTSW will 
house the ResPECT database. The facilities agreement with UTSW’s IR provides for an enterprise 
class data center equipped with uninterruptible power supplies (UPS) with automatic generator 
backup power in the e vent of a utility failure. In addition to state -of-the-art network security, 
the facility provides excellent physical security with [ADDRESS_598810]. Each user account has rights that can be granted or denied including: 
data import, data export, data comparison, data logging, file repository access, user rights 
assignment, data access groups assignment, lock/unlo ck records, and super user. In addition, 
they can be granted read, edit or no data entry rights for each data entry form.    
  
The standard REDCap audit trail cannot be disabled. REDCap records all data activity, including 
the access username, timestamp, a nd a detailed description of the action. In compliance with 
FDA [ADDRESS_598811] has been e -signed, then it denotes that its data has been both locked (to 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   47  prevent further changes) and authorized (i.e. by a user with e-signature [CONTACT_467316]). In addition 
to e-signatures, a required “reason for change” can be enabled which requires the user to enter 
a description of the reasons for the changes being made. The e -signature [CONTACT_467317]'s data audit trail.  
H  Limitations  
  
There are several possible limitations for this study:   
(1) Available scientific literature supports a wide spectrum of respi[INVESTIGATOR_467060].  Our screening tool may miss persons who are infected with influenza or other respi[INVESTIGATOR_467061]. However , the presence of 
asymptomatic HCPs with respi[INVESTIGATOR_467062].    We 
also hope to capture a significant portion of asymptomati c disease through serological testing 
for influenza titers, and by [CONTACT_467267][INVESTIGATOR_467063], with analysis of these stored samples carried out should funding be made available.  
However, currently only samples f rom participants who meet the criteria of being symptomatic 
with ILI will undergo analysis by [CONTACT_76851].  
  
Still, as some organisms may be less likely to cause signs and symptoms, infections from these 
specific organisms may be more difficult to documen t.    
  
(2) Self reporting of symptoms in the daily diary may under or overestimate illness especially 
among HCPs where there is a culture of “presenteeism.”   
  
(3) Compliance with not only respi[INVESTIGATOR_467064], but with other 
behaviors such as hand hygiene and isolation, could all be important effect modifiers and could 
bias or confound results towards or away from the null.  However, we would exp ect that the use 
of these normal protective measures would not be impacted by [CONTACT_15365].   
  
(4) We are including HCP populations that have a high rate of influenza vaccination that will 
require an increased sample size (accounted for in the calculations) usi ng the conservative 
influenza incidence rates in this protocol.    
  
(5) We are limited by [CONTACT_467268].   We will attempt to obtain swabs from upper 
respi[INVESTIGATOR_467065].   
  
(6) Because we are having subjects wear personal protective equipment while at work, but 
not at home or in the community, it is possible that non -occupational exposures could nullify 
("wash -out") any otherwise detectable differences in study arms.  T he probability of a Type I 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  48  (false positive) epi[INVESTIGATOR_467066] 24 hours per day for the study duration.  However, we will be 
assessing the level of risk exposure at home (Appendix D) that will allow us to account for to 
potential risk of infection outside of the workplace.  
  
(7) Some subjects will probably choose to be compliant with guidelines, while some of their 
colleagues are non -compliant.  All workers will be re quired to comply with the minimum 
requirements of the CDC guidelines and OSHA regulations.  Since those wearing medical masks 
may not be complying with existing federal and institutional guidelines, it stands to influence 
other workers to do the same.  Fur ther, the presence of our study stands to raise awareness 
about the importance of wearing respi[INVESTIGATOR_467067], possibly introducing bias 
toward the null (Hawthorne effect).  Such a "minority of compliance" could introduce error into 
our analys es, including sample size under -estimation.  
  
(8) Only two medical mask models are used.  The models used in this study exhibit better 
capture efficiency than most medical masks.  Thus, other models of medical masks may not 
perform as well as this model and t hus the data may not be generalizable to all hospi[INVESTIGATOR_467068].  
  
I  Anticipated Products and Impact  
  
I1  New Knowledge  
• An assessment of the incidence rate of organism specific respi[INVESTIGATOR_467069].  
• An analysis to determine the most effective respi[INVESTIGATOR_467070].  
• In the event of a large -scale respi[INVESTIGATOR_467071], an analysis to 
determine the more effective respi[INVESTIGATOR_467072] .  
I2  Publications and Reports   
• A publication in peer -reviewed medical journal – submission fall ~ 2017 – describing the 
absolute and relative effectiveness of respi[INVESTIGATOR_467064].  
• A publication in peer -reviewed medical journal – submission winter ~[ADDRESS_598812] of pathogens on HCPs in 
outpatient settings.  
• A publication in peer -reviewed medical journal – submission winter ~2017 describing 
the knowledge, attitudes and beliefs of  HCPs in outpatient settings about respi[INVESTIGATOR_467073].  
• A report gauging national respi[INVESTIGATOR_467074], including resource 
and financial costs, that grow out of the study results  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   49  • A report that  projects the development of evidence based guidelines that grow out of 
the study results for prevention of respi[INVESTIGATOR_4416].  
  Additional publications 
may follow.   
  
  
I3  Significance  
  
This study will be among the first attempts to determine the best facial protective equipment to 
use in a seasonal influenza outbreak, epi[INVESTIGATOR_466892].  This evidence -based 
information is needed to inform policy makers and administrators on how to prepare for these 
events.  
J  Study Administration  
  
At this time, nine institutions have been identified as participating centers: the Johns Hopkins  
Health System (JHHS) in Baltimore, MD; Denver Health Medical Center, in Denver, CO, and  
Children’s Hospi[INVESTIGATOR_20161], in Aurora, CO; the Department of Veterans Affairs sites in Denver,  
CO, Washington, DC, [LOCATION_001], NY, and Houston, TX; the University of [LOCATION_005], Amherst,  
MA; and University of [LOCATION_007] Southwestern, Dallas, TX .  UTSW will serve as the study  
administrative site and house the samples and data for further analyses, and UF will also house  a 
copy of the study data on an encrypted external hard drive. The transitions were made due to  
investigators moving to sites and are pro viding coordinating and supporting functions.  
Additional sites will be assessed by [CONTACT_467227] (Appendix K) and must have an adequate 
number of outpatient visits/clinics (at least 25 that employ 20 or more HCPs), history of 
collaboration with ot her sites on large clinical trials, and research infrastructure experience with 
clinical studies.  We aim to recruit at least 500 participants per study site, per influenza season.  
Depending on the capability of selected study sites to accrue subjects, up  to 10 (ten) sites may 
be included altogether.    
J1  Organization and Participating Centers  
1.a  Study Site: Johns Hopkins Health System, Baltimore -Washington Region  
  
JHHS includes 4 acute care hospi[INVESTIGATOR_600]:  (1) JHH, (2) Bayview Medical Center (BMC), (3)  Howard 
County General Hospi[INVESTIGATOR_307], and (4) Suburban Hospi[INVESTIGATOR_307]; and a network of urgent care facilities and a 
group of outpatient primary care clinics organized under the umbrella of the Johns Hopkins 
Community Physicians.  For this proposed study the primary sites will be the JHHS and BMC that 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598813] metropolitan area in Maryland (population of 
1,024,645).  Forty -seven percent of the population is African -American, and 52% is Caucasian.   
Only 9% of the population is ove r 65 years of age.  One fifth of the population qualifies for 
Medicaid.  We will also be approaching the network of 18 primary care facilities that constitute 
the Johns Hopkins Community Physicians.  These facilities are located in 11 counties, providing a  
variety of primary care services to communities in and around Baltimore, Washington DC, and 
across the state of Maryland.   
  
JHHS provides medical care to patients regardless of payer status and serves patients of both 
sexes and all races. Johns Hopkins H ospi[INVESTIGATOR_77690] a 1026 bed hospi[INVESTIGATOR_467075] a pediatric 
hospi[INVESTIGATOR_307] (Johns Hopkins Children’s Center), a 63 -bed oncology unit (The Johns Hopkins Weinberg 
Oncology Center) and 8 ICUs.  Johns Hopkins Bayview Medical Center (JHBMC), a [ADDRESS_598814] County Emergency Departments, the Bayview Pediatric Department, 
JHHS clinics located in Green Spring, MD and White Marsh, MD, interested departments in JHH’s 
Outpatient Center, and the Patient  First Clinics associated with the Johns Hopkins Health 
System.   
  
Resources at the Johns Hopkins Health System study site:   
  
JHHS’s Hospi[INVESTIGATOR_467076] (HEIC) is responsible for surveillance of 
healthcare -associated infections and epi[INVESTIGATOR_124367] - important organisms (MRSA, VRE, 
influenza, RSV, etc.), prevention and control of communicable disease exposures, investigation 
and control of outbreaks, development of hospi[INVESTIGATOR_467077] e spread of 
healthcare -associated infections and epi[INVESTIGATOR_124367] -important organisms. All are infectious 
diseases -trained hospi[INVESTIGATOR_467078], healthcare economics 
and healthcare -associated infections.   
  
Charlotte A.  Gaydos, MS, MPH, DrPH will now serve as the site PI [INVESTIGATOR_467079],  
following [CONTACT_467328]’s departure to UTSW. [CONTACT_467329] is a Professor and Director of the  
Infectious Diseases STD Lab at Johns Hopkins University School of Medicine. She advised the 
study team on the appropriate handling of specimens and continues to advise on aspects of  
virology pertinent to the project. She has been responsible for the virological testing performed  
at JHU and will be overseeing the transfer of samples to UTSW.   
  
Derek A. Cummings, PhD, who will supervise and conduct statistical and epi[INVESTIGATOR_467080], 
is an Adjunct Professor in the Department of Epi[INVESTIGATOR_467081].  He is also a Preeminence Professor in the Depart ment of Biology and in the 
Emerging Pathogens Institute, at the University of [LOCATION_012].  [CONTACT_467330]' interests are in 
bridging theoretical work on infectious disease dynamics, field work on infectious diseases and 
public health responses to infectious dis ease outbreaks. He conducts research on spatial 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598815]. Cummings ha s also 
worked to characterize transmission of multiple emerging pathogens including MERS -CoV, 
pandemic influenza, chikungunya and Ebola.  
  
DCC:  Initially at JHHS, the DCC for the ResPECT study includes a strong research group led by [CONTACT_467269] M anager, a research coordinator, and research assistants.  The group has a 
long history of implementing interventions within the healthcare setting.  They have 
collaborated with the CDC and VHA and completed many projects designed to reduce the risk of 
heal thcare -associated infections including clinical trials. This research group would be 
responsible for distributing the study materials and training the various participating sites on the 
conduct of the ResPECT clinical trial.   
  
NOTE: The DCC will be moved  to UTSW following the move of one of the co -PIs.    
  
Surveillance data including the status of respi[INVESTIGATOR_467082]. The system contains information on demographics, length of stay, DRG’s, ICD -[ADDRESS_598816].  
Each system has limited access and significant security. In addition, surveillance for 
epi[INVESTIGATOR_467083]/tracking/chart review systems in the JHHS.  This 
system of healthcare information tools allow for efficient research and clinical accuracy across 
the many sites within the Hopkins network.  These sys tems include (but are not limited to) 
Theradoc
  software (Theradoc Corporation, Salt Lake City, Utah), the Johns Hopkins Hospi[INVESTIGATOR_467084] (Electronic Patient Record), Eclipsys
 /Allscripts
 , the JHH POE (Provider Order Entry  
System), the Johns Hopkins Adjuste d Clinical Groups Case Mix System, and the CDC Biosense 
System.  If necessary, data for this project will be collected based on the systems and software 
available at each research site.  
  
Occupational Health Services (OHS) is integrated across JHHS.  Each  site is staffed by a CRNP 
manager and nurses. As part of the respi[INVESTIGATOR_467085], these personnel test ill HCPs with 
nasopharyngeal (NP) swabs.  NP swabs are performed routinely on ill HCPs who present to work 
during the respi[INVESTIGATOR_467086].  NP  swabs are available during the day at OHS and in the 
emergency department in the evenings and on weekends. Investigators may pursue access to 
both to the results of these NP swab studies, performed per JHHS usual procedures, and to the 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  52  results of the resp iratory specimen collection performed as part of the experimental studies 
described in this protocol.  
  
1.b  Study Administration:  National Personal Protective Technology 
Laboratory, National Institute for Occupational Safety and Health, CDC  
Lewis Radon ovich, MD, formerly the Director of the VA’s National Center for Occupational  
Health and Infection Control COHIC, a Senior Physician Scientist and Medical Officer at the 
National Personal Protective Technology Laboratory at NIOSH, who has served as Co -PI [INVESTIGATOR_467087].    
1.c Study Administration: North [LOCATION_012] Foundation for Research and Education 
(NFFRE):   
  
A not -for- profit  education foundation based in Gainesville, [LOCATION_012], established in 1997 to 
administer and facilitate research funded from non -VA sources.  The Executive Director of 
NFFRE, will be responsible for managing and distributing the non -VA funds to their respecti ve 
locations.    
  
1.c  Study Administration: Veterans Health Administration Network of 
Medical Facilities:   
On a nationwide scale, VA’s health care system now includes [ADDRESS_598817] scan, radioimmunoassay, and improvements in 
artificial limbs.  Throu gh VA's Cooperative Studies Program, researchers conduct multicenter 
clinical trials to investigate the best therapy for various diseases affecting large numbers of 
veterans.    
  
 The 1400 medical facilities in the national VA healthcare system are decent ralized into 21 
Veterans Integrated Service Networks (VISNs), each representing a geographic portion of the 
nation.  Regional Network offices help integrate the activities of the medical facilities included in 
each VISN.  Local medical center leadership is  primarily responsible for the activities at each 
hospi[INVESTIGATOR_467088].    
  
Almost 5.[ADDRESS_598818] 
medical education and health professions training program in the [LOCATION_002].  VA facilities are 
affiliated with 107 medical schools, 55 dental schools and more than 1,200 other schools across 
the country.  Ea ch year, about 90,000 health professionals are trained in VA medical centers.  
More than half of the physicians practicing in the [LOCATION_002] had some of their professional 
education in the VA health care system.   
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   53  1.d  Study Site: VA [LOCATION_001] Harbor Healthcare System, [LOCATION_001] NY   
Setting:  VA [LOCATION_001] Harbor Healthcare System (NYHHS) is the first Veterans Health  
Administration (VHA) site and overall the second site to join the Respi[INVESTIGATOR_467089] (ResPECT) Study.  It joins Johns Hopkins University (JHU) which served 
as the pi[INVESTIGATOR_467090] 1 year.   
Organization:  VA NYHHS is a level 1A VHA facility.  It consists of two tertiary care me dical 
centers located in Manhattan and Brooklyn and a Community Living Center located in St. Albans, 
Queens.  VA NYHHS also operates four Community Based Outpatient Clinics (CBOCs) located in 
Harlem, downtown Brooklyn, [LOCATION_001] and Staten Island which serv e [LOCATION_001], Kings, Queens 
and Richmond Counties. The Veteran population in this catchment of the [LOCATION_001] -New Jersey 
Veterans Integrated Service Network #3 (VISN -3) is approximately 186, 869.   
VA NYHHS operates [ADDRESS_598819]. Albans provides Primary Care and a limited number of 
specialty care clinic services (Mental Health, Dermatology, Optometry, Cardiology, Urology, 
Podiatry, and Dental). The CBOC in Staten Island provides Primary Care, Mental Health, 
Optometry and Podiatry services.  The CBOCs in Harlem, lower Manhattan, and downtown 
Brooklyn provide Primary Care and Mental Health clinics.  
VA [LOCATION_001] Harbor’s two major academic affiliations are N ew York University (NYU) Medical 
Center and SUNY Downstate Medical Center.  It provides funding for 270 medical residents, as 
well as other disciplines, including dental, optometry, podiatry, psychology, physician assistants, 
nursing, pharmacy, social work , Dietician, Respi[INVESTIGATOR_467091].  In addition, 
approximately 850 medical students rotate through the Brooklyn and NY campuses annually.   
In fiscal year 2010, VA [LOCATION_001] Harbor Healthcare System Research Program had 199 both 
human and a nimal research projects and a budget of ~$6.0 million.  Important areas of research 
include cardiovascular, hematology/oncology, cancer, infectious diseases including AIDS/HIV, 
mental health, substance abuse, rehabilitation engineering/ prosthetics, pulmon ary, renal, 
geriatrics and optometry as well as clinical trials and co -operative studies.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  54  In Fiscal Year 2010 VA NYHHS treated 50,705 unique patients and had 7115,382 outpatient 
visits.  It provided 72,374 hospi[INVESTIGATOR_467092] (Br ooklyn and [LOCATION_001]); 
50,047 days of care in the Community Living Center and 24,031 days of care in its Residential 
Rehabilitation programs.    
  
VA NYHHS employs approximately 3,450 full time employee equivalents (FTEE).  While some of 
the Medical Staff a ttending and all of its resident physicians are part -time and rotate at the 
affiliated hospi[INVESTIGATOR_600], the vast majority of its primary care physicians and all of its nursing and 
support personnel are full -time employees.  
  
Resources Available:     
Michael S. S imberkoff, M.D. serves as the site PI [INVESTIGATOR_467079].  He retired from the 
position of Executive Chief of Staff, VA NYHHS on July 1, 2016.  He is now a volunteer member of 
the Infectious Diseases Section, Medical Staff of the [LOCATION_001] Campus, VA NYH HS and Professor 
of Medicine, NYU School of Medicine.  [CONTACT_467331] is Board Certified in Internal Medicine and 
Infectious Diseases (ID).  He has extensive experience in infectious diseases research, VA 
Cooperative Studies (served as Study Chairman for 2  CSPs and as site PI [INVESTIGATOR_467093] 2 others) as well as clinical infectious diseases.  He has been the 
facility PI [INVESTIGATOR_467094] (VACS) since it was initiated in 1993.  Prior to his 
appointment as Chi ef of Staff, he served as Chief, Infectious Diseases, Chairman of the Infection 
Control Committee, and ACOS, R&D at VA NYHHS.   
  
VA NYHHS has Employees Health Services at its Brooklyn, NY, and St. Albans campuses.  It also 
has active Infection Control pro grams and practitioners at each of these sites. Infection Control 
reports through an Infection Control Nurse Manager to the Associate Director of Patient Care 
Services (Chief Nurse) and to the Chairman, Infection Control Committee.    
  
VA NYHHS has well equipped and staffed Microbiology Laboratories at its Brooklyn and NY 
campuses.  Both laboratories are equipped to perform some molecular testing for respi[INVESTIGATOR_46264].  Both are prepared to expand molecular testing should funding bec ome available.  
  
VA NYHHS has Employees Health Services at its Brooklyn, NY, and St. Albans campuses.  It also 
has active Infection Control programs and practitioners at each of these sites. Infection Control 
reports through an Infection Control Nurse Man ager to the Associate Director of Patient Care 
Services (Chief Nurse) and to the Chairman, Infection Control Committee.    
  
VA NYHHS has well equipped and staffed Microbiology Laboratories at its Brooklyn and NY 
campuses.  Both laboratories are equipped t o perform some molecular testing for respi[INVESTIGATOR_46264].  Both are prepared to expand molecular testing should funding become available.  
  
1.e  Study Site: VA Eastern Colorado Healthcare System, Denver CO   
  
Setting: VA-ECHCS is a tertiary care medical center serving veterans residing in Colorado, 
Wyoming, and Montana, and the second Veterans Affairs medical center to join the ResPECT 
study.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   55    
Organization: VA -ECHCS provides comprehensive care to 75,000 veterans, including com munity 
based primary care and a full range of referral services.  It includes an acute care medical center 
with a full range of inpatient tertiary care service, on site primary and specialty care clinics, an 
active Emergency Department, two nursing homes i n Denver and Pueblo, and nine community 
based outpatient clinics (CBOCs). There are CBOCs located in the Denver metropolitan area, 
Colorado Springs, and Pueblo that well serve as study clinics. VA -ECHCS employs approximately 
[ADDRESS_598820]. Bessesen has worked closely with the Nurse Executive, who also supports the 
participation  of nurses in the study.  
  
Resources available: Mary Bessesen, M.D. will serve as the site principal investigator [INVESTIGATOR_467095] - 
ECHCS. She is the hospi[INVESTIGATOR_467096], Chief of the Infectious Diseases section and a VA  
Merit funded investigator at VA -ECHCS. She has served as site director for multicenter studies of 
Clostridium difficile epi[INVESTIGATOR_180446], C. difficile treatment and S. aureus 
bacteremia epi[INVESTIGATOR_419854]. She supervises a staff of four infection control 
practitioners, a s well as a full -time nurse study coordinator and 2 RAs to complete the necessary 
protocol activities.  
1.f  Study Site: VA Michael E. DeBakey Medical Center, Houston TX  
Medical Care: The Michael E. DeBakey VA Medical Center (MEDVAMC) serves as the primary 
health care provider for more than 120,[ADDRESS_598821] -Traumatic Stress Disorder Clinic; a Network Poly trauma Center; an 
award -winning Cardiac and General Surgery Program; a Liver Transplant Center; a VA Epi[INVESTIGATOR_467097]; a VA Rehabilitation Research of Excellence focusing on mild to moderate 
traumatic brain injury; and one of the VA’s six Park inson’s Disease Research, Education, and 
Clinical Centers. Including the outpatient clinics in Beaumont, Conroe, Lufkin, and Galveston, 
MEDVAMC outpatient clinics logged almost one million outpatient visits in fiscal year 2009.  
Teaching Hospi[INVESTIGATOR_307]: Nearly 3 ,500 health care professionals provide high -quality care to our 
Veterans. For more than 50 years, the MEDVAMC has provided clinical training for health care 
professionals through our major affiliate, Baylor Colleg e of Medicine  *.  MEDVAMC now 
operates the largest VA residency program with more than 251 slots. Each academic year, more 
than 1,972 students are trained through 144 affiliation agreements with institutions of hi gher 
learning in 19 states. Health care students from fields such as nursing, dietetics, social work, 
physical therapy, and a wide variety of medical specialties receive training here each year. This 
responsibility serves to enhance the quality of care pro vided to our Veterans. As a member 
institution of the [LOCATION_007] Medical Center  * (TMC) since 1985, the MEDVAMC staff serves on 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598822] received national awards and honors including 
accreditation from Joint Commission  for hospi[INVESTIGATOR_307], long -term care, behavioral health care, and 
substance abuse.  
Modern Facility: Located on a [ADDRESS_598823] Injury Center, and a 120 -bed transitional 
care unit for long -term care. An automated, computer -controlled transport system delivers 
food, laundry, and supplies throughout the building. The six -story granite building is designed 
with four exterior sections and four atriums that contain patio gardens, wheelchair basketball 
courts, and a rehabilitation pool.  
Research & Development: Supported with more than $16 million annually, research conducted 
by M EDVAMC staff ensures Veterans access to cutting -edge medical and health care technology. 
With 729 active research projects, the MEDVAMC Research & Development (R&D) Program is an 
integral part of the medical center’s mission and plays a very important role  in the health care 
Veterans receive. The production of new knowledge, techniques, and products has led to 
improved prevention, diagnosis, treatment, and control of disease.   
  
Resources Available:  Maria C. Rodriguez -Barradas, M.D. will serve as the site Principal  
Investigator (PI) for the ResPECT Study.  She is the Director for the HIV Program and Professor of 
Medicine, Baylor College of Medicine.  As Director for the HIV Program, she is responsible for all 
medical staff activities at the HIV -ID outpatie nt clinic at MEDVAMC, as well as in charge of the  
Infectious Diseases Fellows Program within the VA.  [CONTACT_26429] -Barradas is Board Certified in 
Internal Medicine and Infectious Diseases (ID).  She has extensive experience in infectious 
diseases researc h, including participation in VA Cooperative Studies (site PI [INVESTIGATOR_467098]), in NIH 
funded clinical trial networks (CPCRA, INSIGHT) as well as PI [INVESTIGATOR_467099].   She 
has been the facility PI [INVESTIGATOR_467094] (VACS) since it wa s initiated in 1993. 
MEDVAMC has an active Infection Control program and [CONTACT_26429] participates in Infection 
Control activities as required.  MEDVAMC has well equipped and staffed Microbiology 
Laboratories as well as an Infectious Diseases Research Lab oratory. Both laboratories are 
equipped to perform molecular testing for respi[INVESTIGATOR_467100].  Both are prepared to 
expand molecular testing should funding become available.  
  
1.g  Study Site: VA Washington DC Medical Center, Washington, DC  
  
Setting: Washington DC VA Medical Center (DC VAMC) is one of the four Veterans Health 
Administration (VHA) sites for the Respi[INVESTIGATOR_466877] (ResPECT) 
Study.  The DC VAMC joined the ResPECT Study as a site in the fall of 2012.  
  
Organization :  DC VAMC is one of the most visible and dynamic facilities in the VA system. This 
tertiary care teaching facility provides acute general and specialized services in medicine, 
surgery, neurology and psychiatry, and also has a large long -term care facility on site. The 
Medical Center has a satellite Substance Abuse Clinic and three Vet Centers and a number of 
Community Based Outpatient Clinics.  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   57  The Medical Center's staff of 1,[ADDRESS_598824] of Columb ia 
and portions of Virginia and Maryland. The DC VAMC cares for over 50,000 Veterans with more 
than 500,000 outpatient visits each year. The DC VAMC is the only VA medical center with three 
medical school affiliations – George Washington, Georgetown and Ho ward Universities. It is also 
affiliated with many other colleges and universities in such areas as pharmacy, rehabilitation 
medicine, biomedical engineering, dietetics, social work, nursing and medical center 
management.  
  
The DC VAMC has a multi -million dollar research program that supports more than 100 
investigators and 300 active research projects. Areas of research include mental health, 
substance abuse including alcoholism, hypertension, cardiovascular disease, 
hematology/oncology, infectious  diseases including HIV/AIDS, pulmonary, nephrology, 
neurology, and war -related injuries.  
  
The DC VAMC is part of the VA Capi[INVESTIGATOR_467101] (VISN 5), which was established in  
October 1995, and serves Veterans from economically and demographical ly diverse areas within 
Maryland, the District of Columbia, and portions of Virginia, West Virginia, and Pennsylvania.  
  
Resources Available:   Cynthia L. Gibert, MD, MSc will serve as the site PI [INVESTIGATOR_467102].   
[CONTACT_467332] is Professor of Medicin e, George Washington University School of Medicine and  
Health Sciences.  At the Washington DC Veterans Affairs Medical Center, she is the Director of 
Special Projects in the Medical Service, an attending physician in the Infectious Diseases Section 
and a member of the IRB. For more than ten years she was the Assistant Chief of Infectious 
Diseases and the Director of the Infectious Diseases Clinic. [CONTACT_467332] is also a Senior Medical 
Adviser to the Veterans Affairs Office of Public Health. For [ADDRESS_598825] of NIH -funded clinical research in HIV/AIDS. Currently, she is the site PI [INVESTIGATOR_467103]-sponsored Veterans Aging Cohort Study. She served as the site PI [INVESTIGATOR_467104] a VA 
CSP-sponsored study. She is also a site  investigator for the NIAID -funded DC Center for AIDS 
Research (D -CFAR) being overseen by [CONTACT_467270]/AIDS Institute. [CONTACT_467333] is a member of the VA taskforce for multidrug resistant organisms – that has defined VA 
policy for bot h methicillin -resistant Staphylococcus aureus as well as Clostridium difficile . She is a 
fellow of both the American College of Physicians and the Infectious Diseases Society of 
America.  She is board certified in both Internal Medicine and Infectious Dise ases.   
  
The Washington DC VAMC has an active Infection Control program and with four infection 
control practitioners.  The Infection Control staff reports through the Infection Control Nurse 
Manager to the Medical Center Director and to the Chairman, Inf ection Control Committee.  The 
Medical Center has a well -equipped and staffed Microbiology Laboratory.   The laboratory is 
equipped to perform some molecular testing for respi[INVESTIGATOR_467105].  There is also a robust 
Occupational Health Service.   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  58    
1.h  Study Site: Denver Health & Hospi[INVESTIGATOR_54686], Denver CO   
Setting:  Denver Health and Hospi[INVESTIGATOR_54686] (DHHA), is a regional, academic, level -one trauma 
center for the Rocky Mountain Region, and overall the third site to join the Respi[INVESTIGATOR_467106] (ResPECT) Study.  It joins Johns Hopkins University (JHU) 
which served as the pi[INVESTIGATOR_467107] 1 year.  
  
Organization:  DHHA serves the city and county of Denver, CO, and the Rocky Mountain Region.  
DHHA integrates acute hospi[INVESTIGATOR_467108], primary, and acute care services.  DH employs approximately 5,[ADDRESS_598826] care providers and serve special populations such as 
the poor, uninsured, mentally ill, pregnant teens, persons addicted to alcohol and other 
substances, victims of violence, the  homeless, and those with AIDS and tuberculosis.    
  
DHHA operates 477 acute hospi[INVESTIGATOR_84335], and is one of the state’s busiest hospi[INVESTIGATOR_467109] 25,000 admissions annually.  DHHA’s major academic affiliation is the University of 
Colorado Anschutz Me dical Campus.  Denver Health’s Community Health Services manages 
more than 355,000 outpatient visits annually, from eight family health centers located 
throughout Denver neighborhoods, and 13 school -based health centers in Denver Public 
Schools, offering o n-site medical care to elementary, middle and high school students, while 
DHHA’s Emergency Department (Adult and Pediatric) and Adult Urgent Care Center manages 
more than 106,000 visits annually.    
  
Resources Available:  Connie S. Price, MD will serve as  the site PI [INVESTIGATOR_467110].  She is 
the Chief Medical Officer at DHHA, and Assistant Professor of Medicine at the University of 
Colorado, School of Medicine.  [CONTACT_231497] is board -certified in infectious diseases and medical 
microbiology.  Her resear ch and clinical interest focuses in healthcare epi[INVESTIGATOR_467111]. She is an independently funded investigator who has 
served on numerous AHRQ task orders:  As a task order lead for PBRN Task Order #16:  Reducing 
Inap propriate Prescribing of Antibiotics by [CONTACT_467271]; as a Principle Investigator  
(with [CONTACT_156761]) on AHRQ (ACTION) Task Order 8 - Improving the Measurement of Surgical Site  
Infection (SSI) Risk Stratification and Outcome Detection; as a Principle Investigator on AHRQ 
(ACTION) Task Order 7 - Reducing Hospi[INVESTIGATOR_467112] (HAI):  Improving Patient Safety 
through Implementing Multidisciplinary Interventions in the Safe ty Net; a Consultant on PBRN 
Task Order #4: Management by [CONTACT_467272] -Acquired, Methicillin -Resistant Staphylococcus Aureus (CA -MRSA) Infections; a 
Coinvestigator on  Task Order #[ADDRESS_598827] of  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   59  Dire ctors of the Society of Healthcare Epi[INVESTIGATOR_128456].  She also serves on the Colorado 
Healthcare Associated Infections advisory committee for public reporting of healthcare 
associated infections for Colorado.  
  
DHHA Division of Infectious Diseases will also employ 3.25 FTEs for the duration of this study to 
complete necessary protocol activities.  DHHA also has an active Infection Control program and 
practitioners.  
1.i  Study Site: Children’s Hospi[INVESTIGATOR_20161], Denver, CO   
Organization: Children’s  Hospi[INVESTIGATOR_20161] (Children’s Colorado) has defined and delivered 
pediatric health care excellence for more than 100 years. Founded in 1908, Children’s Colorado 
is a leading pediatric network entirely devoted to the health and well -being of children. 
Cont inually recognized as one of the nation’s outstanding pediatric hospi[INVESTIGATOR_341118] U.S. News &  
World Report and ranked 9th on its Best Children’s Hospi[INVESTIGATOR_600] 2016 -17 Honor Roll, Children’s 
Colorado is known both for its nationally and internationally recognized medical, research and 
education programs, as well as the full spectrum of everyday care for kids throughout Colorado 
and surrounding states. Children’s Colorado  is recognized for excellence in nursing from the  
American Nurses Credentialing Centers and has been designated a Magnet® hospi[INVESTIGATOR_200323] 2005. 
With more than 1,000 health care professionals representing the full spectrum of pediatric 
specialties, the netw ork for Children’s Colorado includes [ADDRESS_598828] with Children’s Colorado on 
Facebook and Twitter (@ChildrensColo).   
  
Resources Available: Ann-Christine Nyquist, MD, MSPH will serve as the site Principal  
Investigator (PI) for the Res PECT study. She is the Medical Director of Infection Prevention and  
Control Program and the Medical Director for Occupational Health at Children’s Hospi[INVESTIGATOR_467113]. [CONTACT_467334] is board -certified in Pediatrics and Pediatric Infectious Diseases. She is a   
Professor in the Department of Pediatrics, Sections of Infectious Diseases and Epi[INVESTIGATOR_467114] a secondary appointment in the 
Colorado School of Public Health in the Department of Community and Beha vioral Health.  Her 
research and clinical interest focuses in healthcare epi[INVESTIGATOR_623], influenza, vaccinations and 
methods to prevent nosocomial infections. [CONTACT_467334] served as Co -Principal Investigator [INVESTIGATOR_467115] C. Shepard Award for the Best Manuscript 
in 2006 in the Category of Prevention and Control -. From 2005 -2009 she served as the site 
Principal investigator [INVESTIGATOR_467116]: the Training Program for Clinical and Translational Research and 
Group Education. Nationally, [CONTACT_467334] serves on American Academy of Pediatrics Committee 
on Infectious Diseases and the Society for Healthcare Epi[INVESTIGATOR_128456]  
(SHEA) Pediatric Leadership Council Chair. She was an Invited Expert, representing Pediatric  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  60  Infectious Diseases Society, Department of Health and Human Services (HHS) Progress Toward  
Eliminating Healthcare -Associated Infections meeting. In [ADDRESS_598829] and her team 
recently received Children’s Hospi[INVESTIGATOR_20161] [ADDRESS_598830] hospi[INVESTIGATOR_467117].   
  
Children’s Hospi[INVESTIGATOR_467118]’s Clinical Research Organization (CCRO) for 
the duration of the study to complete the necessary protocol activities. Children’s Hospi[INVESTIGATOR_467119] 1.[ADDRESS_598831] and 2.0 FTE Administrative Support. The Children’s Clinical Research 
Organization (CCRO) at the Children’s Hospi[INVESTIGATOR_467120], facilities and personnel to support the conduct and facilitation  of clinical trials, 
including study start -up, execution and close -out. The mission of the CCRO is to improve the 
health of children by [CONTACT_467273]; as well as innovative opportunities 
to advance the diagnosis, treatment and prevention of pediatric diseases and their sequelae.   
  
The CCRO team is made up of a dedicated group of clinical research professionals, including 
clinical researc h coordinators, regulatory professionals, financial administrators and 
management team. Services include: Study coordination: start -up and initiation, patient 
screening and recruitment, consenting, patient management, identification and reporting of 
advers e events, phlebotomy and drug administration (as appropriate and according to 
licensure), monitoring of patient compliance, data entry and query response, coordination of 
preparation for sponsor monitor visits, specimen processing and shipment, collaborati on and 
coordination of ancillary services, project management, budget development and negotiation, 
collaboration with Office of Research Services contracting team and IRB submission and 
continuing review.   
  
l.l   Study Site: Statistical Support: Universi ty of Massachussetts, Amherst,  
MA  
UMass Amherst, the flagship campus of the University of [LOCATION_005] system, sits on nearly  
1,[ADDRESS_598832] Library 
System provides support for research through collections in the 28 -story W.E.B. Du Bois Librar y 
and two science libraries. Numerous periodical indexes and full text databases may also be 
accessed electronically. The Five College online catalog provides electronic access to library 
catalog records at the University and the surrounding four colleges (Amherst, Hampshire, Mount 
Holyoke and Smith colleges). Reference librarians are available in person, online, and by 
[CONTACT_756].  
The Reich Laboratory ( http://reichlab.io ) is the research lab of [CONTACT_467335] at U. Mass.  In 
addition to [CONTACT_467336], it also houses [CONTACT_467337] C. Brown.  [CONTACT_467336] is [CONTACT_46792]'s primary 
mentor, in the Department of Biostatistics and Epi[INVESTIGATOR_623]. [CONTACT_46792] has her own desk space 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598833]. Brown has a 15.6 GiB Intel® Core™ i7 -4790 CPU @ 3.60GHz × 8 
desktop computer with 3.9 TB of disk space. This machine is connected to the Department’s 
Local Area Network (LAN). The LAN enables secure hard disk space for research  projects that is 
accessible by [CONTACT_467274] -up daily.  
The School of Public Health and Health Sciences (SPHHS) is comprised of approximately 50 
fulltime faculty members, including six epi[INVESTIGATOR_467121]. SPHHS maintains 
micro computer research rooms for faculty, staff and students. Fourteen PC compatible 
microcomputers, a file server, a  scanner and two laser printers are connected to the 
Department’s Local Area Network (LAN). The LAN enables secure hard disk space for res earch 
projects that is accessible by [CONTACT_467274] -up daily. The following software 
packages have been installed on the LAN: SAS System 9.1 for Windows, Stata 9, SAS callable 
SUDAAN, Minitab 13.1 for Windows, SPSS 14, Microsoft Office XP, Dream weaver MX, Endnote  
6.0, NCSS 2001, Nud*ist N6, and Adobe Acrobat.  
Resources Available: Nicholas Reich, PhD, is a biostatistician whose research operates at the 
interface of biostatistics and epi[INVESTIGATOR_623]. He has broad experience as a collaborating and 
independent biostatistician across many different biomedical and global health research set tings. 
His areas of research focus have been on developi[INVESTIGATOR_467122], and developi[INVESTIGATOR_467123]. He received doctoral training in Biostatist ics and post -doctoral training in 
Infectious Disease Epi[INVESTIGATOR_467124]. He has 
served as the statistician for the ResPECT Study since its inception.  
  
l.m   Study Site Administration and DCC: University of [LOCATION_007] Southwestern 
Medical Center, Dallas TX   
  
UT Southwestern is a prominent medical education and biomedical research institution in the  
[LOCATION_002]. It is located in the Southwestern Medical District, a 1,000 pl us-acre campus in  
Dallas  incorporating three degree -granting institutions - UT Southwestern Medical School, UT  
Southwestern Graduate School of  Biomedical Sciences, UT Southwestern School of Health  
Professions – along with four affiliated hospi[INVESTIGATOR_600]: Parkland Hospi[INVESTIGATOR_307] , Children’s Health ℠, Zale 
Lipshy University Hospi[INVESTIGATOR_307], and William P. Clements Jr. University Hospi[INVESTIGATOR_307]. One of the largest 
medical schools in the country, UT Southwestern annually trains about 3,700 medical, graduate, 
and health professions students, residents, and postdoctoral fellows each year. Ongoing support 
from federal agencies, such as the National Institutes of Health , along with foundations, 
individuals, and corporations, provides approximately $422.6 million per year to fund more than  
5,700 research projects. UT Southwestern faculty physicians provide patient care at UT  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  62  Southwestern University Hospi[INVESTIGATOR_600] & Clinics, Parkland Health & Hospi[INVESTIGATOR_48214], Children’s 
Medical Center, [LOCATION_007] Scottish Rite Hospi[INVESTIGATOR_7722] , VA North [LOCATION_007] Health Care System , and 
other affiliated hospi[INVESTIGATOR_467125]. Faculty and residents care for more than 100,000 
hospi[INVESTIGATOR_467126] 2.2 million outpatient visits a year, providing 
more than $106.7 million in unreimbursed clinical service s annually.  
  
The Division of Infectious Diseases includes 24 full time faculty members, 9 of whom are faculty 
preceptors. There is ample administrative support for the training program within the division 
which includes: 1) Division Administrator, who ma nages and directs the administrative and 
business functions of the Division and also coordinates grant submissions, budget monitoring, 
and personnel; 2) Division Accountant, who monitors budgets and provides monthly reports to 
PIs in the division; 3) Grant s and Contracts Specialist, who prepares grant applications and 
progress reports for all divisional grants; and 4) Fellowship Coordinator, who oversees 
administrative duties of both the fellowship and T32 grant trainees. The Division of 
Epi[INVESTIGATOR_623], organ ized within the Department of Internal Medicine, was founded by [INVESTIGATOR_124]. 
Robert Haley in 1983 and since has served a leading role in organizing and managing large 
multidisciplinary studies spanning the range of research from basic mechanistic to clinical and 
population studies. The UT Southwestern Department of Clinical Sciences is a multidisciplinary 
department which encourages clinical research and provides an academic, educational, and 
cultural home for clinical investigators across all departments and discip lines of the University. 
The DCS has the following 5 divisions staffed by [CONTACT_456250] -time faculty: Outcome's and Health Services 
Research, Biostatistics, Biomedical Informatics, Community Health Sciences, and Behavioral and 
Communication Sciences.  
    
Resources  Available: Trish M. Perl, MD, MSc, serves as a co -PI [INVESTIGATOR_467110].   
She supervised the Johns Hopkins University sites while a faculty member there and the DCC.   
She continues to supervise the overall conduct of the study. She is the Chief of In fectious  
Diseases at UT Southwestern Medical Center where she is the Jay P Sanford Professor of 
Medicine.   She has extensive experience in clinical trials and is an expert in in health 
careassociated infections, antimicrobial -resistant organisms, emerging pathogens, and infection 
prevention.  She is an Adjunct Professor of Medicine in the School of Medicine and recently left  
Johns Hopkins. Previously, she served for [ADDRESS_598834] 
outbreak investigation – an encephalopathy caused by [CONTACT_467275] – was published in the 
New England Journal of Medicine .  
  
l.n   Study Site: Statistical and Epi[INVESTIGATOR_467127]: University of [LOCATION_012]   
  
The University of [LOCATION_012] (UF)  is an American public university that sits on a 2,000 -acre campus in 
Gainesville, [LOCATION_012]. The University of [LOCATION_012] is divided into 16 colleges and more than 150 
research,  service and education centers, bureaus and institutes, offering more than 100 
undergraduate majors and 200 graduate degrees. The University of [LOCATION_012] is one of the nation's 
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598835] research universities. The University of [LOCATION_012] was awarded $678 million  in research 
expenditures, more than all other [LOCATION_012] universities combined, in sponsored research in 2009 - 
10.  
  
University of [LOCATION_012] Health has two campuses in Gainesville and Jacksonville. It includes two 
teaching hospi[INVESTIGATOR_467128] s, as well as the colleges of Dentistry, Medicine, 
Nursing, Pharmacy, Public Health and Health Professions, and Veterinary Medicine, including a 
large animal hospi[INVESTIGATOR_3491] a small animal hospi[INVESTIGATOR_307]. The system also encompasses six UF research 
institutes: the Clinical and Translational Science Institute, the Evelyn F. and William L. McKnight 
Brain Institute, the Genetics Institute, the UF Health Cancer Center, the Institute on Aging and 
the Emerging Pathogens Institute. UF Health is the only academic health cen ter in the United 
States with six health -related colleges on a single, contiguous campus.  
  
Resources Available: Derek Cummings, PhD, MHS, MS, is an infectious diseases epi[INVESTIGATOR_467129]’s Preeminence Program, through which he serves as a full profe ssor for the 
department of biology and the Emerging Pathogens Institute. Prior to his arrival at the 
University of [LOCATION_012] he worked for the school of public health at Johns Hopkins University, 
where he was an associate professor in the school’s department  of epi[INVESTIGATOR_623]. Cummings’ 
research focuses on identifying the factors that influence the spread of infectious diseases in 
order to develop strategies to control and curb their proliferation. Cummings’ work with 
emerging pathogens spans several nations, i ncluding southern China, Thailand, Liberia, Senegal, 
and Saudi Arabia. Though he has examined a variety of diseases, the bulk of his research has 
focused on the dengue virus and influenza.  
  
In southern China he studied influenza A and patterns of transmi ssion between rural and urban 
areas. In Saudi Arabia he studied Middle East Respi[INVESTIGATOR_23223] (MERS). In Senegal he 
studied transmission of the dengue virus in non -human primate species – baboons, red 
monkeys, and green monkeys. Cummings has conducted e xtensive research on pathogens in the 
[LOCATION_002] as well. He was the pr[INVESTIGATOR_2993]cipal [INVESTIGATOR_2993]vestigator [INVESTIGATOR_2993] a study of seasonal shifts in 
transmission of influenza A, influenza B, and respi[INVESTIGATOR_4345] (RSV) in Pi[INVESTIGATOR_9109], 
Pennsylvania.   
  
ADDITIONAL STUDY  SITES  
Since it is not possible to predict the location of the future outbreaks, despi[INVESTIGATOR_179799] “seasonal,” 
multiple sites from across the U.S. will be identified for participation.  In order to optimize the 
use of funding, several criteria will be used to guide t he selection process (Appendix K).  
 Ideally, study sites would have the following characteristics:  
• Site has at least 25 clinics (EDs, outpatient clinics, etc.) that employ [ADDRESS_598836] fewer clinics that are easily divisible into 25 separate work environments, with 
16 or more people working in each work environment.    
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  64  (This is based on 400 participants per site, per year.) 
  Site needs to have a track record of research.  
• Site needs to have an active research staff that can conduct the study without undue 
delay.    
• The site needs to show past ability to do collaborative research.  
• Site should have a track record of clinical trials.  
• Site should have a history of collaborative research efforts with one of the Principal 
Investigators  
• Site should have a pediatric component in their set of possible study locations (because 
the incidence of infectious diseases is highest in these settings).  This criterion would not 
apply to VA study sites.  
• Active respi[INVESTIGATOR_467130]  
  
J2  Funding Source and Conflicts of Interest  
Two US Federal Government Agencies provided most of the funding for this project. Together, 
the Centers for Disease Control (National Institute of Occupational Health and Safety) and the 
Veterans Health Administration (Office of Public Health and Environmental Hazards) h ave 
expressed commitment to approximately $10M.  It is well -understood by [CONTACT_467276] $10M could be required to reach the primary 
endpoint, especially if the incidence of measured outcomes happens to be relat ively low in the 
study -site locations when data is collected.  However, in a setting with high -than -usual counts of 
influenza or ILI, the primary endpoint could be achieved in less than a 4 -year period as 
described.   If accessible funding draws low, a gro up of key CDC decision -makers will determine 
whether to continue pursuing some or all of the study endpoints, and how. The Biomedical  
Advanced Research and Development Authority (BARDA) provided an additional $350,[ADDRESS_598837], financial or otherwise.   
  
J3  Committees/Science Board  
While many of the key questions about the design and conduct of this clinical trial have been 
answered, a variety of questions and issues will be raised duri ng the course of the study.  To 
ensure that each question or issue receives impartial and equitable attention from the  
Investigators, an independent Science Board (SB) will be developed.  The Members of this Board, 
each an eminent scholar and/or opi[INVESTIGATOR_1649] l eader, will offer their personal opi[INVESTIGATOR_467131].  
Any changes made by [CONTACT_467277]’s IRB, the IRB at NIOSH, and the local IRBs for each site 
before the changes are implemented in the conduct of the study.    
  
In contrast to the narrow focus of the Data Safety Monitoring Board (DSMB), topi[INVESTIGATOR_467132] a wide variety of scientific, sociological, 
economical or political topi[INVESTIGATOR_1102]. Members of the SB may change over the course of the Study.    
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598838] Members:   
  
Michael Bell, MD – Centers for Disease Control  
Arnold  Monto, MD – University of Michigan School of Public Health  
David Weissman, MD – Centers for Disease Control/ National Institute for Occupational Safety 
and Health  
Mark Loeb, MD – McMaster University  
  
Trish M. Perl, MD, MSc – University of [LOCATION_007] Southw estern  
Lew Radonovich, MD – Centers for Disease Control and Prevention  
  
K  Publication Plan   
As this is a  large, multicenter study, authorship rules need to be defined in advance.  All 
publications of information or data related to this project will come under this rule.  Publications 
by [CONTACT_467278]'s part of the study should involve 
collaboration with the other pa rticipating investigators and the ResPECT Study Consortium and 
should include input from the principal investigator(s), and his or her colleagues. Such input 
should be reflected in publication authorship, and agreement regarding order of authors’ names 
should be tentatively established before drafting the manuscript. Additionally, publications must 
comply with confidentiality obligations owed to the sponsor.  
  
The members of the ResPECT Study Consortium must have the opportunity to review and 
comment on all proposed abstracts, manuscripts, or presentations regarding this study ideally 
60 days prior to submission for publication/presentation. During this [ADDRESS_598839] be deleted prior to submission. If reasonably 
requested, members of the Consortium will take reasonable ste ps to expedite the review 
process to meet publication deadlines. Submission may be made upon notification by [CONTACT_467279]/or 
information identified by [CONTACT_467280]. The ResPECT Study 
Consortium also has the right to publish the results of this study.  
All manuscripts submitted for publication must have “The ResPECT Study Consortium” listed in 
the authorship section.  The members of the ResPECT Study C onsortium will be identified under 
acknowledgements at the end of the manuscript.    
  
  
L  References  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  66  Askarian M, Mirzaei K, Honarvar B, Etminan M, Araujo MW. Knowledge, attitude and practice 
towards droplet and airborne isolation precautions among dental health care professionals in 
Shiraz, Iran. J Public Health Dent.  Winter 2005;65(1):[ADDRESS_598840] Dis.  Jan 9 2009.  
  
Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respi[INVESTIGATOR_244089] (SARS) coronav irus and environmental contamination in SARS outbreak units. J Infect 
Dis. May 1 2005;191(9):[ADDRESS_598841] Dis.  Apr 2007;7(4):257 -265.  
  
Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health 
care settings. Clin Infect Dis. Oct 15 2003;37(8):1094 -1101.  
  
Centers for Disease Control. 2009 H1N1 Flu. 2009; http://www.cdc.gov/H1N1FLU/ . Accessed 
5/6/2009, 2009.  
  
CDC 2007. Centers for Disease Control and Prevention. 2007 guideline for isolation precautions:  
preventing transmission of infectious agents in healthc are settings, 2007.  Available at: 
http://www.CDC.gov/hicpac/2007IP/2007ip_appendA.html. Accessed 3/14/2018 .  
  
Centers for Disease Control. CDC H1N1 Flu. Interim guidance on Infection Control Measures for  
2009 H1N1 Influenza in Health Care Workers: A Randomized Trial . 2009; 
http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm . Accessed October 21, 2009.  
  
CDC 2010. Centers for Disease Control and Prevention.  Updated Guidance: Prevention 
Strategies for Seasonal Influenza in Healthcare Setting, June 22, 2010.  Available at:  
https://www.gpo.gov/fdsys/pkg/FR -2010 -06-22/html/2010 -[ZIP_CODE].htm .  Accessed 3/14/2018.   
  
Centers for Disease Control. MERS -CoV.  Interim Infection Prevention and Control  
Recommendations for Hospi[INVESTIGATOR_467133] 
(MERS -CoV). https://www.cdc.gov/coronavirus/mers/infection -prevention -control.html . 
Accessed May 9, 2017.   
  
Chia SE, Koh D, Fones C, et al. Appropriate use of personal protective equipment among 
healthcare workers in public sector hos pi[INVESTIGATOR_467134]. Occupational and Environmental Medicine.  Jul 2005;62(7):473 -477.  
  
Chor JS, Ngai KL, Goggins WB, et al. Willingness of Hong Kong healthcare workers to accept 
prepandemic infl uenza vaccination at different WHO alert levels: two questionnaire surveys. 
BMJ .  
2009;339:b3391.  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   67    
Chung JS, Ling ML, Seto WH, et al. Debate on MERS -CoV respi[INVESTIGATOR_467135]: surgical mask 
or N95 respi[INVESTIGATOR_13530]? Singapore Med J  2014;55(6):[ADDRESS_598842] Control . Aug 
1997;25(4):[ADDRESS_598843] infection in the Uni ted States. Arch Intern Med . Feb 24 2003;163(4):487 -
494.  
  
Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human 
immunodeficiency virus: an outbreak of infection at a residential facility in [LOCATION_001] City. Clin 
Infect Dis . Jun 15  2001;32(12):1784 -1791.  
  
Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak 
controllable. Proc Natl Acad Sci U S A . Apr 20 2004;101(16):6146 -6151.  
  
Gala CL, Hall CB, Schnabel KC, et al. The use of eye -nose gog gles to control nosocomial 
respi[INVESTIGATOR_227235]. JAMA . 1986;256(19):[ADDRESS_598844]/universal infection control pr ecautions. J Clin Nurs.  Jan 
2008;17(2):[ADDRESS_598845]. Am J Med . Jun 28 1985;78(6B):32 -37.  
  
Gershon RR, Karkashian CD, Vlahov D, et al. Compliance with universal precautions in 
correctional health care facilities. J Occup Environ Med . Mar 1999;41(3):[ADDRESS_598846] Control . Aug 1995;23(4):225 -236.  
Hall C, Douglas R. Modes of transmission of respi[INVESTIGATOR_4345]. J Pediatr . 
1981;99(1):100103.  
  
Hall CB, Douglas RG, Jr., Geiman JM. Possible transmission by [CONTACT_467281][INVESTIGATOR_151495]. J Infect Dis . 1980;141(1):98 -102.  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  68  Hall CB, Geiman JM, Douglas RG, Jr., Meagher MP. Control of nosocomial respi[INVESTIGATOR_467136]. Pediat rics. 1978;62(5):728 -732.  
  
Hammond JS, Eckes JM, Gomez GA, Cunningham DN. HIV, trauma, and infection control: 
universal precautions are universally ignored. J Trauma . May 1990;30(5):555 -558; discussion 
558-561.  
  
Hansen S, Stamm -Balderjahn S, Zuschneid I, et al. Closure of medical departments during 
nosocomial outbreaks: data from a systematic analysis of the literature. J Hosp Infect . Apr 
2007;65(4):[ADDRESS_598847] J. Personal correspondence. 2009.  
  
LY Hsu. Respi[INVESTIGATOR_467137] -CoV: acc eptable risk -benefit determination. Singapore 
Med J  2014; 55(6):293.   
  
Institute of Medicine. Preparing for an influenza pandemic: Personal protective equipment for 
healthcare workers. Washington, DC: Institute of Medicine;2008.  
  
Jefferson T, Foxlee R,  Del Mar C, et al. Interventions for the interruption or reduction of the 
spread of respi[INVESTIGATOR_4398]. Cochrane Database Syst Rev . 2007(4):CD006207.  
  
Jefferson T, Foxlee R, Del Mar C, et al. Physical interventions to interrupt or reduce the spread of 
respi[INVESTIGATOR_4398]: systematic review. BMJ . Jan 12 2008;336(7635):[ADDRESS_598848] . 
1977;71(5):576 -579.  
  
Karanfil LV, Conlon M, Lykens K, et al. Reducing the rate of nosocomially transmitted respi[INVESTIGATOR_14256] [published erra tum appears in Am J Infect Control 1999 Jun;27(3):303]. Am J 
Infect Control . 1999;27(2):[ADDRESS_598849]: a review of the 
literature. PharmacoEconomics . 2008;26(11):[ADDRESS_598850] of influenza and influenza -like illness on productivity and 
healthcare resource utilization in a working population. Occupational medicine (Oxford, 
England) . Feb 1998;48(2):85 -90.  
  
Kelen GD, DiGiovanna TA, Celentano DD, et al. Adher ence to Universal (barrier) Precautions 
during interventions on critically ill and injured emergency department patients. J Acquir 
Immune Defic Syndr . 1990;3(10):987 -994.  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   69  Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I. Estimation of influenza vaccine effectiveness 
from routine surveillance data. PLoS One . 2009;4(3):e5079.  
  
Lane DJ, Pace B, Olsen GJ, Stahl DA, Sogin ML, Pace NR. Rapid determination of 16S ribosomal  
RNA sequences for phylogenetic analyses. Proceedings of the National Academy of Sciences of 
the [LOCATION_002] of America 82(20):[ADDRESS_598851] . Mar 2008;136(3):299 -308.  
  
Loeb M, Dafoe N, Mahony J, et al. Surgical Mask vs. N95 Respi[INVESTIGATOR_467138]: A Randomized Trial. JAMA . Oct [ADDRESS_598852] Dis . 2009;15(2):233 -241.  
  
MacIntyre CR, Wang Q, Cauchemez S et al. A cluster randomized clinical trial comparing fit 
tested and non -fit-tested N95 respi[INVESTIGATOR_467139]. Influenza & Other Respi[INVESTIGATOR_467140]  2011;5(3):170 -179.  
MacIntyre CR, Wang Q, Seale H et al. A randomized clinical trial of three options for N95 
respi[INVESTIGATOR_467141] h ealth workers. American Journal of Respi[INVESTIGATOR_696] & Critical Care 
Medicine 2013;187(9):[ADDRESS_598853], Jr., Saxman PR, Farris RJ et al. The RDP -II (Ribosomal 
Database Project). Nucleic Acids Research  29(1):173 -4, 2001.  
  
  
Madan AK, Rentz DE, Wahle MJ, Flint LM. Noncompliance of health care workers with universal 
precautions during trauma resuscitations. South Med J . Mar 2001;94(3):[ADDRESS_598854]: a 
randomised, controlled trial. BMC Med Res Methodol . 2007;7:30.  
  
McLellan RK, Schusler KM. Guide to the medical evaluation for respi[INVESTIGATOR_466915]. Beverly Farms, 
MA: OEM Press; 2000.  
Moore D, Gamage B, Bryce E, Copes R, Yassi A. Protecting heal th care workers from SARS and 
other respi[INVESTIGATOR_13531]: organizational and individual factors that affect adherence to 
infection control guidelines. Am J Infect Control . Mar 2005;33(2):[ADDRESS_598855] Control Hosp 
Epi[INVESTIGATOR_5541] . May 1995;16(5):[ADDRESS_598856] Dis J . Sep 1999;18(9):811 -815.  
  
National Institute of Allergy and Infectious Diseases. Common Cold  2007.  
  
[LOCATION_001] City Department of Health and Mental Hygiene. NYC DOHMH Pandemic Influenza 
Preparedness and Response Plan 2006.  
  
North [LOCATION_012]/South Georgia Veterans Health System. Nort h [LOCATION_012]/South Georgia Veterans 
Health System Infection Control Manual 2009.  
  
Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V et al. Streptococcus pneumoniae 
coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS O NE [Electronic 
Resource] 2009; 4(12):e8540.  
  
Pi[INVESTIGATOR_184423] D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospi[INVESTIGATOR_307] -wide programme to improve 
compliance with hand hygiene. Infection Control Programme. Lancet . Oct 14 
2000;356(9238):1307 -1312.  
  
Radonovich LJ, Jr., Cheng J, Shenal BV, Hodgson M, Bender BS. Respi[INVESTIGATOR_467142]. JAMA . Jan 7 2009;301(1):[ADDRESS_598857] health -care workers from 
airborne infectious disea ses? Respir Care . Dec 2008;53(12):1660 -1664.  
  
Radonovich LJ, Jr., Perl TM, Davey V, Cohen H. Preventing the Soldiers of Health Care From 
Becoming Victims on the Pandemic Battlefield: Respi[INVESTIGATOR_467143]. Disaster Med Publ ic Health Prep . Sep 29 2009.  
  
Randolph AG, Reder L, Englund JA. Risk of bacterial infection in previously healthy respi[INVESTIGATOR_14256] -infected young children admitted to the intensive care unit. Pediatric Infectious 
Disease Journal  2004; 23(11):9 90-994.  
  
Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter 
increase in mortality in the [LOCATION_002], 1959 -1999. Am J Epi[INVESTIGATOR_5541] . Sep 1 
2004;160(5):492502.  
  
Rengasamy S, Eimer BC, Shaffer RE. Comparison of nano particle filtration performance of 
NIOSH -approved and CE -marked particulate filtering facepi[INVESTIGATOR_467144]. Ann Occup Hyg . Mar 
2009;53(2):[ADDRESS_598858] 
Dis. Mar 2002;2(3):[ADDRESS_598859] affected during the 
spring 2009 H1N1 pandemic? Disaster Med Public Health Prep . Mar;4(1):[ADDRESS_598860] 2002;23(10):[ADDRESS_598861] Control Hosp Epi[INVESTIGATOR_5541] . Mar 
2005;26(3):[ADDRESS_598862] in 
prevention of nosocomial t ransmission of severe acute respi[INVESTIGATOR_7686] (SARS). Lancet . 
May 3 2003;361(9368):1519 -1520.  
  
Shine K. Personal correspondence. September 10, 2009.  
  
Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for Isolation Precautions: 
Preventin g Transmission of Infectious Agents in Health Care Settings. Am J Infect Control . Dec 
2007;35([ADDRESS_598863] 2):S65 -164.  
  
Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL et al. The fundamental link 
between pneumococcal carriage and disease. [Re view]. Expert Review of Vaccines  2012; 
11(7):841 -855.  
  
Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE. Effectiveness of N95 
respi[INVESTIGATOR_467145]: a sys tematic review and meta -analysis. [Review]. CMAJ Canadian Medical Association 
Journal 2016;188(8):567 -574.  
  
Suwantarat, Nuntraa,b; Api[INVESTIGATOR_467146], Anuchac. Current Opi[INVESTIGATOR_133746] : 
August 2015 - Volume 28 - Issue 4 - p 349 –[ADDRESS_598864] Dis . Nov 
2006;12(11):[ADDRESS_598865] Rev . 2006;3:CD005187.  
  
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respi[INVESTIGATOR_467147]. JAMA . Jan 8 2003;289(2):[ADDRESS_598866] MC, Chinn S, Ste rne JA, Burney PG. Methods for evaluating area -wide 
and organisation -based interventions in health and health care: a systematic review. Health 
Technol Assess . 1999;3(5):iii -92.  
  
van der Sande M, Teunis P, Sabel R. Professional and home -made face masks r educe exposure to 
respi[INVESTIGATOR_467148]. PLoS ONE . 2008;3(7):e2618.  
  
Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA 
sequences into the new bacterial taxonomy. Applied & Environ mental Microbiology  
73(16):5261 -7, 2007.  
  
Weber TP, Stilianakis NI. Inactivation of influenza A viruses in the environment and modes of 
transmission: a critical review. J Infect . Nov 2008;57(5):[ADDRESS_598867] Control Hosp Epi[INVESTIGATOR_5541] . Nov 2000;21(11):730 -732.  
  
Weiss MM, Weiss PD, Weiss DE, Weiss JB. Disrupting the transmission of influenza a: face masks 
and ultraviolet light as control measures. Am J Publi c Health . Apr 2007;[ADDRESS_598868] 1:S32 -37.  
  
Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for 
phylogenetic study. Journal of Bacteriology  173(2):697 -703, 1991.  
Wertheim HF, Melles DC, Vos MC, van LW, van BA, Verbrugh HA et al.  The role of nasal carriage 
in Staphylococcus aureus infections. [Review] [184 refs]. The Lancet Infectious Diseases  2005; 
5(12):751 -762.  
  
Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza 
vaccine in health  care professionals: a randomized trial. JAMA . Mar 10 1999;281(10):[ADDRESS_598869] Cont rol Hosp 
Epi[INVESTIGATOR_5541] . Jul 1990;11(7):351 -356.  
  
World Health Organization. Infection prevention and control fo epi[INVESTIGATOR_901] - and pandemic -prone 
acute respi[INVESTIGATOR_467149]: World Health Organization; June 2007.  
  
World Health Organization. Infection prevention and control during health care for probable or 
confirmed cases of Middle East respi[INVESTIGATOR_6507] (MERS -CoV) infection: World 
Health Organization, 2015.   
  
Yassi A, Bryce E, Moore D, et al. Protecting the Faces of Health Care Workers: Knowledge gaps 
and research priorities for effective protection against occupationally -acquired respi[INVESTIGATOR_467150]. Journal of Infection Control and Hospi[INVESTIGATOR_467151] . 2004;28:171 -177.  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   73  Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respi[INVESTIGATOR_467152]. N Engl J Med . Apr 22 2004;350(17):1731 -1739.   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  74  M Attachments   
M1  Tables  
  
  
     
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  
  
  
  
  
   75    
  
Table1  Protocol Activities by [CONTACT_467282]-Study Period   Intervention Period (weeks)      Post -Study 
Period   
Week   ≥5 weeks before study 
begins   1  2  3  4  5  6  7  8  9  10  11  12-16  ≥[ADDRESS_598870] -study 
survey   
Specimen 
Collection   B  R  R  R  R  R  R  R  R  R  R  R  R  B  
Key:  
B = Blood Draw        
I = Randomized Intervention FPE   
R= Upper Respi[INVESTIGATOR_92814], randomized and triggered as indicated.     
L = Weekly diary and Daily Exposure forms, and Symptomatic Event Report form if needed.   
O =FPE and Hand Hygiene Observation Forms       
Study is projected to last 20 weeks during the height of viral respi[INVESTIGATOR_431883], as determined by 
[CONTACT_467283]/incidence of RPI, but may be modified according to incidence rates. Intervention Period 
could be shorter than [ADDRESS_598871] a minimum of 12 weeks.  
-NA_00031266 412-386-
6478  
 The Respi[INVESTIGATOR_466878], PI, 214 -648-9022, Lew Radonovich, PI,  
  
  
Table2 Case Definition* of Acute Respi[INVESTIGATOR_467153] (T > 37.8° C)  
   Tachypnea (Respi[INVESTIGATOR_13581] > 25)  
   Coryza  
   Lymphadenopathy                
Symptoms   
  Vomiting/Nausea  
  Diarrhea  
  Cough  
   Sputum Production   
   Fatigue   
   Malaise  
   Headache  
   Sore Throat  
   Dyspnea  
   Chills  
   Sweats  
   Arthralgias/Myalgias/Body Aches  
  Other Gastrointestinal Symptoms  
*An acute respi[INVESTIGATOR_467154] :  
 The presence of any sign(s) OR two symptom(s) listed above.  
 Positives must represent a change from baseline   
  
  
  
  
  
  
  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598872] of potential ILI pathogens  
  
□ Influenza A □ 
Influenza B  
□ Respi[INVESTIGATOR_467155] A □ 
Respi[INVESTIGATOR_467155] B  
□ Parainfluenza virus Type 1  
□ Parainfluenza virus Type 2  
□ Parainfluenza virus Type 3  
□ Parainfluenza virus Type 4(a)  
□ Parainfluenza virus Type  4 (b)  
□ Human Metapneumovirus  
□ Adenoviruses   
□ Coronavirus OC43  
□ Coronavirus NL63  
□ Coronavirus 229E  
□ Coronavirus HKU1  
□ Human Rhinovirus  
□ Cocksackie/echoviruses  
□ Bocavirus  
□ Bordetella pertussis  
□ Streptococcus pneumonia  
□ Steptococcus pyogenes   
□ Staphylococcus aureus  
□ Hemophilus influenza  
□ Other microbial respi[INVESTIGATOR_467156] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  78 Table4 Power analysis of the sensitivity to the 4 -year attack rate:  
Power analysis of the sensitivity to the 4 -year attack rate for the primary outcome (laboratory 
confirmed influenza) and secondary outcomes (ILI, ARI). The power to detect a relative -risk of 
0.75 between the N95 group and the medical mask group and the rel ative -risk that can be 
detected with 80% power are shown for scenarios representing the low and high end of 
reasonable attack rates in the medical mask (i.e., the control) group. For all calculations the 
twosided Type I error probability is 0.05.  
  
    
  Low Attack Rate Scenario   High Attack Rate Scenario   
Outcome   S.M. Attack  
Rate  Power  Detectable RR   
(RR=0.75)  (80% Power)  S.M. Attack  
Rate  Power  Detectable RR   
(RR=0.75)  (80% Power)  
Primary   0.2  43%  0.62  0.5  93%  0.80  
ILI  0.15  33%  0.56  0.4  82%  0.76  
ARI  0.5  93%  0.80  0.95  100%  0.94  
LCRI   0.3  91%  0.79  0.7  100%  0.90  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  79 Table5 Sample size and power calculations for primary and secondary outcome.  
  
This table shows the total person -seasons of observation required for the primary outcome (LCI) 
and a secondary outcome (LCRI), assuming a four -year study. The annual attack rate for the 
medical mask (MM) group is calculated for LCI based on assumed vaccin ation rates and efficacy.  
  
  
M.1.a.i.[IP_ADDRESS].1   LCI  M.1.a.i.[IP_ADDRESS].2   LC 
RI  
M.1.a.i.[IP_ADDRESS].3   Annual 
attack rate,  
SM group  M.1.a.i.[IP_ADDRESS].4   0.1 
2  M.1.a.i.[IP_ADDRESS].5   0. 
25  
M.1.a.i.[IP_ADDRESS].6   Cumula 
tive 4 -year 
attack rate,  
SM group  M.1.a.i.[IP_ADDRESS].7   0.3 
9  M.1.a.i.[IP_ADDRESS].8   0. 
68  
M.1.a.i.[IP_ADDRESS].9   Detecta 
ble relative risk  M.1.a.i.[IP_ADDRESS].10   
0.7 
5  M.1.a.i.[IP_ADDRESS].11   0. 
75  
M.1.a.i.[IP_ADDRESS].12   Median 
cluster size  M.1.a.i.[IP_ADDRESS].13   16  M.1.a.i.[IP_ADDRESS].14   16  
M.1.a.i.[IP_ADDRESS].15   ICC  M.1.a.i.[IP_ADDRESS].16   0.1  M.1.a.i.[IP_ADDRESS].17   0. 
1  
M.1.a.i.[IP_ADDRESS].18   Total 
personseasons 
of observation  M.1.a.i.[IP_ADDRESS].19   10, 
024  M.1.a.i.[IP_ADDRESS].20   5, 
104  
    
  
M2  Appendices   
 Appendix  A   Cluster Randomization Scheme   
    
        
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, 214 -648-9022, Lew Radonovich, PI, 412 -386-6478  
  80 M.2.a.i.[IP_ADDRESS].1     Cluster A FPE  Cluster B FPE  
M.2.a.i.[IP_ADDRESS].2  Week  
1  M.2.a.i.[IP_ADDRESS].3  Not yet 
randomized  M.2.a.i.[IP_ADDRESS].4  Not yet 
randomized  
M.2.a.i.[IP_ADDRESS].5  Week  
2  M.2.a.i.[IP_ADDRESS].6  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].7  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].8  Week  
3  M.2.a.i.[IP_ADDRESS].9  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].10  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].11  Week  
4  M.2.a.i.[IP_ADDRESS].12  N95 
Respi[INVESTIGATOR_467157]  
M.2.a.i.[IP_ADDRESS].13  Week  
5  M.2.a.i.[IP_ADDRESS].14  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].15  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].16  Week  
6  M.2.a.i.[IP_ADDRESS].17  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].18  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].19  Week  
7  M.2.a.i.[IP_ADDRESS].20  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].21  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].22  Week  
8  M.2.a.i.[IP_ADDRESS].23  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].24  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].25  Week  
9  M.2.a.i.[IP_ADDRESS].26  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].27  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].28  Week  
10  M.2.a.i.[IP_ADDRESS].29  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].30  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].31  Week  
11  M.2.a.i.[IP_ADDRESS].32  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].33  Medical  
Mask  
M.2.a.i.[IP_ADDRESS].34  Week  
12-16  M.2.a.i.[IP_ADDRESS].35  N95 
Respi[INVESTIGATOR_13521]  M.2.a.i.[IP_ADDRESS].36  Medical  
Mask  
 Appendix  B   Recruitment Flyer  
  
The Respi[INVESTIGATOR_466877] (ResPECT)   
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [ADDRESS_598873]? 
We are investigating what type of facial protective equipment is more effective in preventing flu 
and other respi[INVESTIGATOR_467158]. Help us find the a nswer!  Earn up to $599 for your 
time and participation in our research study!  
  
Open to outpatient healthcare workers over the age of 18.  We will be visiting your clinic for 
enrollment soon.  
  
Questions?  
  
Please call the ResPECT Team at [PHONE_9774]/pager [PHONE_9775]  
OR  
email us at [EMAIL_8934]  
  
 
        
[ADDRESS_598874] Study    
8   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598875] Study    
1   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598876] Study    
4   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598877] Study    
7   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598878] Study    
0   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598879] Study    
3   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598880] Study    
6   [PHONE_9774], [PHONE_9775]    
[ADDRESS_598881] Study    
9   [PHONE_9774], [PHONE_9775]    
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  82  Name: _________________________  
 Appendix  C    Inclusion/Exclusion Screening     
Inclusion/Exclusion Screening     
Inclusion/Exclusion Screening Form      
Yes        No                                       
1. Are you 18 years or older?  □  □  
2. Do you have daily face -to-face (within 6 feet) contact [CONTACT_467284]?  □  □  
3. Are you willing to wear either an N95 respi[INVESTIGATOR_466922] a medical/surgical mask 
when coming into contact [CONTACT_467285]/confirmed respi[INVESTIGATOR_467159]?  □  □  
4. On average, do you work at least 24 hours per week in a clinic setting?  □  □  
  
a. If yes , on average, how many hours per week do you have patient 
contact (within 6 feet of patients) at this clinic?  
b. If no , on average, how many hours a week do you work in the clinic in 
which you were recruited for this study?       
    
_____________  
  
_____________  
5. During the intervention period (flu -season), will you be working at only one 
clinic or emergency department?  
              
            (If no, ask details, record in notes, and report to PI)     □           □  
  
  
_____________  
6. (N/A for women): If you have facial hair, are you willing to shave it off and keep 
it off, so that you can be fit tested for and wear a mask or respi[INVESTIGATOR_467160] 
16-week study period?  □  □  
  
7. Can you wear a respi[INVESTIGATOR_467161]?   □  □  
8. Are you able to walk (or minimally exert yourself) for [ADDRESS_598882]?  
  □  □  
    
    
9. (N/A for men): Are you currently pregnant or attempting to become pregnant?                                                                                             □  □  
  
  
  
Exclusion based on PI [INVESTIGATOR_467162]: __________________________________________________________  
  
Notes:  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.1611  
  
  83  _____________________________________________________________________________________  
_____________________________________________________________________________________  
______________ ____________________________________________  
Name: _________________________  
 Appendix  D   Baseline Survey  
  
  
This information will be kept confidential.  We are collecting this information for your participant 
payments and to contact [CONTACT_467286].  
  
Contact [CONTACT_7171]   
  
1. What is your first name?    ________________________________________________ ___________  
  
2. What is your last name?    __________________________________________________________  
  
3. What is your date of birth?  _________________________  
  
4. What is your address?  
_______________________________________________________________  
  
                       _________________________ ______________________________________  
  
5. What is your daytime phone number?   _____________________________________________   
  
6. What is your evening phone number?   ____________________________________________ _  
  
7. What is your email address?    ____________________________________________________  
(It is important that you use the same email for all documents related to the study)  
  
8. What is the best way to contact [CONTACT_10825] (day/evening phone, pager, email, text, social media etc.)?          
______________________________________  
  
9. Have you been a participant in the ResPECT Study in the past?    □Yes   □ No   
  
If yes, please choose the year(s) where you have participated:   
  
Johns Hopkins  
 □ 2010 -2011    □ Other (site and year):_________________________________  
□ 2011 -2012            ________________________________ 
□ 2012 -2013           _____________________ ___________  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  84  □ 2013 -2014  
  
10. At which clinic or Emergency Department are you employed?  
 __________________________________________________________________________________   
  
Name: _________________________  
  
11. Has your name [CONTACT_467318]?      □Yes   □ No   
  
If yes, what was your name [INVESTIGATOR_111480]? _________________________________  
  
12. Do you anticipate any changes that could affect your eligibility for the ResPECT Study over the 
next year? (i.e. third trimester of pregnancy, change in work location, etc.)      □Yes  □ No   
If yes, explain (this information is completely confidential and will not be shared with your employer or other 
staff members):  
_____________________________________________________________________________________ 
_____________________________________________________________________________________   
  
Demographic Infor mation  13.   
What is your gender?  
  □ Female  □ Male   
  
14. What is your ethnicity?  
  □ Hispanic or Latino  
  □ Non -Hispanic or non -Latino  
    
15. What is your race? (Check all that apply)                       
 □ Black or African American     □ Caucasian/White    □ American Indian/Alaskan Native     
□ Asian   □Native Hawaiian or other Pacific Islander   □ More than one race    □ 
Other (please list) ______________________  
  
16. What is your job/role at this institution?   
□ MD/DO – House Staff   □ MD/DO - Fellow or Faculty  
□ Dentist      □ Physician Assistant/Nurse Practitioner       
□ Nursing Staff      □ Clinical Technician (ED, Dental, Dialysis, Radiology, etc.)  
□ Medical Student    □ Clinical Support (CMA, CNA, Dental, etc.)  
□ Nursing Student      □ Patient Support Assistant/Care Worker/Care Assistant   
□ Administrative/Clerical  □ Environmental Services/Housekeepi[INVESTIGATOR_007]   
□ Registration/Reception  □ Respi[INVESTIGATOR_696]/Physical/Occupational Therapi[INVESTIGATOR_541]   
□ Social Worker/Pastoral Care   □ Paramedic  
□ Other________________________________  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.1611  
  
  85  17. Not including yourself, please provide the following information about the members of your 
household. If none, please enter “0”.   
Age of household 
members  # of household 
members  # of immunocompromised 
household  members  # of household members 
who received seasonal  # of household 
members  
 (does not include 
you!)  (chemotherapy, transplant, 
steroids, etc.)  flu vaccine (since July  
2014)   diagnosed with 
influenza A  
(since July 2014)  
0–5 years          
6-24 years          
25-64 years          
65+ years          
  
  
The following questions pertain to you.   Yes  No  
18. Do you smoke tobacco?      
a. If yes, how many times do you smoke tobacco (cigarettes, pi[INVESTIGATOR_5836], cigars) in a day?  
□ <5    □ 5 -10     □ 11 -20    □ >[ADDRESS_598883] any of the following conditions?    
a. COPD (Chronic obstructive pulmonary disease)      
b. Asthma      
c. Other respi[INVESTIGATOR_3765]       
i. If yes, please specify _________________________    
d. Heart disease (i.e. severe congestive heart failure, angina)      
ii. If yes, please specify _________________________    
e. Neurologic disease (i.e. stroke, MS)      
iii. If yes, please specify _________________________    
f. Other systemic disease (i.e. rheumatoid arthritis, lupus) iv.  If yes, 
please specify _________________________    
    
  
20. Do you use any of the following medications regularly?    
a. Albuterol/ventolin      
b. Inhaled medication       
c. Antipyretics (i.e. Tylenol, Ibuprofen, Aspi[INVESTIGATOR_248])       
d. Immunosuppressants (i.e. oral corticosteroids, antibodies)      
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  86  e. Steroid nasal sprays      
21. Do you wear or use any of the following?       
a. Glasses (prescription or non -prescription)      
b.    Contacts       
22. (N/A for men) Are you currently pregnant or are you attempting to become pregnant ?       
a.    If currently pregnant, what trimester? _________________________     
    
 Appendix  E   Pre-Study Survey   
    
Vaccination   
  
1) Have you had a lab -confirmed or physician -diagnosed case of influenza between July 2014 
and today?  
a) If yes, approximately when?            Date:  
2) Did you receive a vaccination for influenza between July 2014 and today?  
a) If yes, approximately when?           Date:   
b) If yes, what type of vaccine did you receive?  
 □ Injectable (killed) vaccine   □ Inhaled/nasal (live, attenuated) vaccine 3) Did you 
receive a vaccination for pertussis (often included with vaccinations for diphtheria and 
tetanus, also known as the DTaP or Tdap) between July 2014 and today?   
 a) If yes, approximately when?           Date:   
  
Knowledge   
  
1. If a patient came in w ith the following symptoms, I would use the following personal protective 
equipment (PPE)…  (Check all that apply)  
    
                Today’s Date: ____/___/____  
    (MM/DD/YEAR)  
Study Subject ID: ____________  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.1611  
  
  87  Symptoms  Hand 
hygiene  Gowns  Gloves  Eye protection/ 
face shield  Medical/ 
surgical 
masks  N95  
respi[INVESTIGATOR_467163]’t know   
Fever, cough, sore 
throat  □  □  □  □  □  □  □  
Bloody/ productive 
cough, chest pain, 
fever, weight loss  □  □  □  □  □  □  □  
Itchy rash and blisters  □  □  □  □  □  □  □  
Sore throat, runny 
nose, sneezing, mild 
cough   □  □  □  □  □  □  □  
Diarrhea, vomiting, 
stomachache    □  □  □  □  □  □  □  
Dry, uncontrollable 
cough   □  □  □  □  □  □  □  
Immuno - 
compromised patient 
(chemotherapy, 
transplant patient, 
steroid therapy)   □  □  □  □  □  □  □  
2. If I needed to perform a nebulizer treatment on a patient with respi[INVESTIGATOR_467164] -like 
symptoms, I would use the following PPE… (Check all that apply)   
Hand 
hygiene  Gowns  Gloves  Eye protection/ face 
shield  Medical/ surgical masks  N95 respi[INVESTIGATOR_467163]’t 
know  
□  □  □  □  □  □  □  
  
  
Behaviors   
  
  
  
Medical/surgical mask  
  
3. I wear a medical/surgical mask during my work shift…  
 (If never, skip to question 6)  
      □ All patients                  □ Immunocompromised patients   

The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  88        □ Patients with respi[INVESTIGATOR_467164] -like illness   □ Other? ________________________       
□ Patients with confirmed influenza A  □ I never plan to wear medical/surgical       
 mask     
4. I wear a surgical/medical mask when required by [CONTACT_160572]…  
 (i.e. wh en in contact [CONTACT_4490] a patient on droplet isolation)  
 □ Never   □ With some patient contacts  □ With every patient contact    
  
5. When I do wear a medical mask, I do so…  
 Please rank the following reasons in order of importance:  
 (1 = most important, 2 = im portant, 3 = less important, 4 = least important):  
____  To avoid getting a respi[INVESTIGATOR_4416]  
____ To keep from spreading respi[INVESTIGATOR_467165]  
____ To keep from spreading respi[INVESTIGATOR_467166] I live with  
____ B ecause I am required to wear mask by [CONTACT_467287], Occupational Health, or clinic policy   
  
6. The following reasons may deter me from wearing a surgical/medical mask…  
(Check all that apply)  
□ Uncomfortable          □ Difficulty breathing     
□ Interferes with communication    □ Masks are unavailable       
□ Masks don’t protect from infection      □ No need to wear a mask         
 □ Wear N95 instead        □ Other ______________   
  
  
  
N95 Respi[INVESTIGATOR_13521]   
7. I wear an N95 respi[INVESTIGATOR_467167]…  
(If  never, skip to question 10)   
      □ All patients                  □ Immunocompromised patients   
      □ Patients with respi[INVESTIGATOR_467164] -like illness   □ Other? ________________________  
      □ Patients with confirmed influenza A  □ I never plan to wear medical/surgical      
mask  
8. I wear an N95 respi[INVESTIGATOR_467168]…   
(i.e. when in contact [CONTACT_4490] a patient on droplet isolation)   

The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.1611  
  
  89   □ Never       □ With some patient contacts  □ With e very patient contact   
    
9. When I do wear an N95 respi[INVESTIGATOR_13521], I do so…   
Please rank the following reasons in order of importance   
(1 = most important, 2 = important, 3 = less important, 4 = least important):  
____  To avoid getting a respi[INVESTIGATOR_4416]  
____ To keep from spreading respi[INVESTIGATOR_467165]  
____ To keep from spreading respi[INVESTIGATOR_467166] I live with  
____ Because I am required to wear respi[INVESTIGATOR_467169], Occupational Health, or clinic policy        
  
10. The following reasons may deter me from wearing an N95 respi[INVESTIGATOR_13521]…  
 (Check all that apply)  
 □ Uncomfortable          □ Difficulty breathing     
 □ Interferes with communication    □ Respi[INVESTIGATOR_467170]      
 □ Respi[INVESTIGATOR_467171]’t protect from in fection       □ No need to wear a respi[INVESTIGATOR_13521]        
 □ Wear masks instead       □ Other ______________________  
  
11. When were you last fit -tested to wear an N95 respi[INVESTIGATOR_467172] a healthcare setting?  
□ Within 1 year (12 months)        □ Within 2 -5 years        □ Greater than 5 years        □ Never               
 □ Don’t know    
Attitudes/Beliefs   
  
12. Do you think medical/surgical masks or N95 respi[INVESTIGATOR_467173]? (Check all that apply)   
  
         Mask   N95  
Effective  □  □   
Necessary  □  □   
Not effective or 
necessary  □  □   
Other measures (hand 
hygiene, cough 
etiquette) are more 
important  □  □   
  
  
13. Wearing a medical/surgical mask or an N95 respi[INVESTIGATOR_467174](s) on 
patient interaction:   (Check all that apply)   
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  90    
                  Mask          N95  
Makes communicating difficult  □  □   
Increases patients’ fear of infection  □  □   
Increases patients’ concern/confusion 
about lack of FPE consistency  □  □   
Decreases patients’ fear of infection  □  □   
Has little or no effect on patient 
interaction  □  □   
  
Appendix  F   Daily Exposure Form (Monday, Tues, etc.)  
  
If you have developed respi[INVESTIGATOR_696]/flu -like symptoms today, please contact [CONTACT_467288]:  
  
Phone: xxx -xxx-xxxx  
Email: [EMAIL_8935]    
Pager: xxx -xxx-xxxx   
  
Please complete the Daily Form each day regardless  of whether you work.  
  
REMINDER : Individuals with facial hair must continue to shave any facial hair during the study period.   
  
FPE = facial protective equipment (medical/surgical mask or N95 respi[INVESTIGATOR_13521])  
Please refer to the Symptomatic Event Report Form , Weekly Diary, or ResPECT business card for list of 
respi[INVESTIGATOR_696]/flu -like symptoms.  
  
1. This form is for XXX (date range) – did you work today or have a shift that started on this date?   
      □ Yes    □ No   
2. What shift is this in your work week starting M onday? (Please select one.)   
        □ First Work Day  
    □ Second Work Day       
□ Third Work Day    
□ Fourth Work Day  
□ Fifth Work Day  
□ Sixth Work Day  
□ Seventh Work Day  
3. Did you feel sick or have any respi[INVESTIGATOR_467164] -like symptoms on this work date?   
 □ Yes    □ No  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.[ADDRESS_598884] Study Staff?      □ Yes    □ No  
b. If yes, did you remember to fill out a Symptomatic Event Form?  □ Yes    □ No      
                                                                                    
4. Were you in contact [CONTACT_467289] a 
respi[INVESTIGATOR_467164] -like illness on this work date?                                                  
 □ Yes    □ No  
a. If yes, what was the estimated duration ( in minutes) of contact [CONTACT_467290]?  
 □ <15 minutes    □ 15 -29 minutes   □ 30 -44 minutes     
 □ 45 -59 minutes         □ 1-2 hours                    □ >[ADDRESS_598885](s) occurred: (sele ct all that apply)  
 □ Within 6 feet    □ Further than 6 feet    □ In direct contact (e.g., touching)   
  
c. If yes, I wore Facial Protective Equipment (FPE):  
 □ None of the time  □ Part of the time       □ All of the time    □ Don’t know  
  
  
d. If yes, what type of FPE?    
 □ N95     □Medical/surgical mask   
4.  Estimate how often you performed hand hygiene before and after seeing each patient on this date:  
 □ Never       □ Some patient encounters      □ Most patient encounters       
 □ All patient encounters  □ Don’t remember            □ No patient encounters                          
  
5:  Estimate how often you wore a medical/surgical mask  on this date:  
□ Never           □ Some patient contacts       □ Most patient contacts      □ 
All patient contacts     □ Don’t remember  
  
6:   Estimate approximately how many total hours you wore a medical/surgical mask  on this date:                                          
□ Never     □ <15 minutes      □ 15 -29 minutes       □ 30 -44 minutes        □ 
45-59 minutes      □ 1-2 hours        □ >2hours      
  
7:  Estimate how often you wore an N95 respi[INVESTIGATOR_467175]:  
□ Never           □ Some patient contacts       □ Most patient contacts      □ 
All patient contacts     □ Don’t remember  
  
8:  Estim ate approximately how many total hours you wore an N95 respi[INVESTIGATOR_467175]:                                                        
□ Never     □ <15 minutes      □ 15 -29 minutes       □ 30 -44 minutes        □ 
45-59 minutes      □ 1-2 hours        □ >2h ours      
  
9:  On this work date, did you perform any of the following procedures?  If yes, write in the number of times 
performed and mark the type of protection worn during the procedure.  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  92  # of times     N95  Surgical  
Mask  Other  
PPE  None  
   Intubation*            
   Respi[INVESTIGATOR_696]/airway suctioning**            
   Nebulizer treatments***            
   Nasopharyngeal aspi[INVESTIGATOR_1516]****            
  
*placement of a flexible plastic tube into the trachea (windpi[INVESTIGATOR_5836]) to maintain an open airway or to serve as 
a conduit through which to administer certain drugs  
  
**removal of airway secretions by [CONTACT_4859] a suction catheter into the patient’s oral airway  and/or trachea  
  
***a drug delivery device used to administer medication in the form of a mist inhaled into the lungs  
  
****insertion of catheter or tube to suction mucus from patient’s nasal cavity, sometimes in addition to 
saline wash  
     
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.1611  
  
  93  Today’s Date: _____/__/_____  
               (MM/DD/YEAR)  
Study Subject ID: ____________  
  
 Appendix  G   Weekly Diary     
  
Phone: 410 -614-6206  
Email: [EMAIL_8934]    
Pager: [ADDRESS_598886] you experienced any of the following 
symptoms? (Please check all that apply.)  
       Date of Onset  
  Yes  No  Unsure  (MM/DD/YEAR)   
Fever (greater than 37.8oC or 100.1oF)  □   □  □   __/__/____  
Nasal congestion/runny nose(Coryza)  □   □  □   __/__/___  
Headache  □   □  □   __/__/____  
Sneezing   □   □  □   __/__/____  
Fatigue  □   □  □   __/__/____  
Dry cough  □   □  □   __/__/____  
Body aches (myalgias or arthralgias)  □   □  □   __/__/____  
General feeling of being sick (malaise)  □   □  □   __/__/____  
Sore throat  □   □  □   __/__/____  
Sputum  production  □   □  □   __/__/____  
Diarrhea  □   □  □   __/__/____  
Bloody sputum  □   □  □   __/__/____  
Chills  □   □  □   __/__/____  
Nausea/vomiting  □   □  □   __/__/____  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, [PHONE_9777]  
  
  94  Abnormal sweating  □   □  □   __/__/____  
Rapid breathing/shortness of breath 
(tachypnea >25)  □   □  □   __/__/____  
Swollen lymph nodes  
(lymphadenopathy)  □   □  □   __/__/____  
Other Gastrointestinal symptoms 
(please specify)  □   □  □   __/__/____  
Other (please specify)  □   □  □   __/__/____  
  
2. If you developed any of the above symptoms:   
Did you call the study coordinator?                       □ Yes    □ No  
 If NO, please contact [CONTACT_467291].   
 Did you receive an upper respi[INVESTIGATOR_269454]?              □ Yes    □ No   
  
3. In the last week, have you: (Please check all that apply)   
  Yes  No  Don’t 
remember  
  Had any problems with seasonal or chronic allergies?  □  □  □  
  Used any nasal sprays?    
               If yes, please specify:_________________  □  □  □  
  Taken any antihistamines or decongestants?  
               If yes, please specify:_________________  □  □  □  
  Taken any fever -reducing medication (Tylenol, Ibuprofen, Aleve, aspi[INVESTIGATOR_248])?                
If yes, please specify:_________________  □  □  □  
  Taken any immune -suppressing drugs?  
               If yes, please specify:_________________  □  □  □  
Been exposed to anyone with symptoms of a respi[INVESTIGATOR_4375] (please 
refer to list of symptoms above)  □  □  □  
  
4:  Were you in contact [CONTACT_467292][INVESTIGATOR_467164] -like illness this 
week?   
 □ Yes    □ No  
  
a.  If yes, how many?  __________            
a. If yes, what was the total duration  of contact [CONTACT_467293][INVESTIGATOR_467164] - like illness?   
 □ Never         □ <15 minutes       □ 15 -29 minutes              
□ 30 -44 minutes       □ 45 -59 minutes        □ 1-2 hours          □ 
>2 hours  
  
The Respi[INVESTIGATOR_466877] -NA_00031266 Trish 
Perl, PI, [PHONE_9776], Lew Radonovich, PI, 352. 376.[ADDRESS_598887] (or most of the contacts) were (select all that apply):  
    □ Within 6 feet    □ Further than [ADDRESS_598888]  
     □ In direct contact  (i.e. touched) the family member  
  
c. If yes, I wore FPE     
 □ None of the time  □ Part of the time     □All of the time  □Don’t know  
 □ If yes, what type of FPE?  □ N95   □Medical/surgical mask   
  
5. Do you remember a significant exposure to a person with respi[INVESTIGATOR_467164] -like symptoms on 
any day of this week?  
  
Monday 
(M/DD)  Tuesday 
(M/DD)  Wednesday 
(M/DD)  Thursday 
(M/DD)  Friday 
(M/DD)  Saturday 
(M/DD)  Sunday 
(M/DD)  
              
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
96  
        
  
6. Did you receive a vaccination for influenza this week?   
  
 □ Yes    □No   
  
a) If yes, approximately when?                                 Date: ____/____ /_____  
        (MM/DD/YEAR)    
  
b) If yes, which type of vaccine did you receive?  
  
 □ Injectable (killed) vaccine    □ Inhaled/nasal (live, attenuated) vaccine   
  
7. Did you receive a vaccination for pertussis (DTaP or Tdap) this week?  
  
 □ Yes    □No   
a) If yes, approximately when?                                 Date: ____/____ /_____  
        (MM/DD/YEAR)  
  
8. If you were absent from work this week as a result of any of the symptoms you experienced, 
how many days were you absent?  
  
 □ 1   □ 2   □ 3   □ 4   □ 5   □ 6   □ [ADDRESS_598889] -Study Survey  
  
  
Medical/surgical mask  
  
1:  In the future, I plan to use a medical/surgical mask when 
delivering healthcare to the following patients: (Check all that apply)  
□ All patients             □ Immunocompromised patients   
□ Patients with respi[INVESTIGATOR_467164] -like illness  □ Other? _________________________  
□ Patients with confirmed influenza A      □ I never plan to wear a medical/surgical mask  
  Today’s Date: ____/___/____  
    (MM/DD/YEAR)  
Study Subject ID: ____________  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
97  
  2:  If  you plan on wearing a medical/surgical mask in the future, please rank the following reasons in 
order of importance (1 = most important, 2 = important, 3 = less important, 4 = least important):  
  
____ To avoid getting a respi[INVESTIGATOR_4416]  
____ To keep  from spreading respi[INVESTIGATOR_467165]  
____ To keep from spreading respi[INVESTIGATOR_467166] I live with  
____ Required to wear mask by [CONTACT_467287], Occupational Health, or clinic policy   
  
3:  Which of the following stateme nts most reflects your future plans for medical/surgical mask use?   
□ I will wear a mask more often than before        
 □ I will wear a mask as often as before     
 □ I will wear a mask less often than before      
□ Don’t know   
  
4:  If you will not use a medical/surgical mask in the future, check all the reasons that apply  
  
□ Uncomfortable          □ Difficulty breathing     
□ Interferes with communication    □ Masks are unavailable       
□ Masks don’t protect from infection     □ No need to wear a mask         
□ Wear N95 instead       □ Other ______________________  
  
5:  How often during the course of the study were you unable to wear the medical/surgical mask due 
to discomfort?  
 □ Always  □ Often   □ Rarely    □ Never   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
98  
    
  
  
N95 respi[INVESTIGATOR_13521]  
  
6:  In the future, I plan to use an N95 respi[INVESTIGATOR_467176]:  
  
□ All patients           □ Immunocompromised patients   
□ Patients with respi[INVESTIGATOR_467164] -like illness   □ Other ____________________  □  
Patients with confirmed influenza A     □ I never wear a respi[INVESTIGATOR_13521]  
  
7:  If  you plan on wearing an N95 respi[INVESTIGATOR_467177], please rank the following reasons in order of  
importance (1 = most important, 2 = important,  3 = less important, 4 = least important):  
  
____ To avoid getting a respi[INVESTIGATOR_4416]  
____ To keep from spreading respi[INVESTIGATOR_467165]  
____ To keep from spreading respi[INVESTIGATOR_467166] I live with  
____ Require d to wear mask by [CONTACT_467287], Occupational Health, or clinic policy  
  
8:  Which of the following statements most reflects your future plans for N95 respi[INVESTIGATOR_466915]?  
□ I will wear a respi[INVESTIGATOR_467178]        
□ I will wear a respi[INVESTIGATOR_467179]    
□ I will wear a respi[INVESTIGATOR_467180]     □ 
Don’t know   
  
9:  If you will not use an N95 respi[INVESTIGATOR_467177], check all the reasons that apply.  
  
 □ Uncomfortable        □ Difficulty breathing     
 □ Interferes with communication  □ Respi[INVESTIGATOR_467170]      
 □ No need to wear a mask    □ Respi[INVESTIGATOR_467171]’t protect from infection  
  □ Wear mask instead    □ Other   ___________________________  
  
10:  How often were y ou unable to wear the N95 respi[INVESTIGATOR_467181]?  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
99  
    
 □ Always  □ Often   □ Rarely  □ Never   
  
11: Did you receive a vaccination for influenza between July 2012 and today?  
 □ Yes    □No   
  
a. If yes, approximately when?                 Date: ____/____ /____  
(month)  (day)   (year)  
  
b. If yes, which type of vaccine did you receive?  
  
 □ Injectable (killed) vaccine    □ Inhaled/nasal (live, attenuated) vaccine  
  
12: Did you receive a vaccination for pertussis (often included with vaccinations for diphtheria and 
tetanus, also known as the DTaP or Tdap) between July 2014 and today?   
 □ Yes    □No  
  
 a) If yes, approximately when?           Date: __________________ ___________  
  
  
     
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
100  
    
Appendix  I  Hand Hygiene and FPE Observation Form  
  
  
  
  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
[ADDRESS_598890] been excluded from the study based on your answers to an exclusion/inclusion 
survey.  You may have been disqualified for one or more of the fo llowing reasons:  You are a part -time 
worker; an N95 respi[INVESTIGATOR_467182] a qualitative fit test; you are 
unable to wear an N95 respi[INVESTIGATOR_467183] a trained clinician; you have facial hair which interferes with the efficacy of the 
N95 respi[INVESTIGATOR_13521]; you are in your third trimester of pregnancy (due to possible changes in the shape of 
your face); you have a medical condition that makes yo u more susceptible to influenza -related 
complications or unable to wear a mask;  a member of the study staff has deemed you unfit for the 
study.  
Regardless of why you were excluded from the study, there are a number of precautions 
you  
can take, as a healthcare worker, to greatly reduce the risk of infection.     
  
• Wash your hands frequently, especially before and after having contact 
[CONTACT_4490] a patient.  If soap and water are not immediately available, use an 
alcohol -based hand rub such as Purell.  
      
• Get the flu vaccine, as well as the H1N1 vaccine, if possible.  Both vaccines 
come in an inactivated shot form and a live, attenuated nasal mist.    
  
• Cover your mouth and nose when sneezing or coughing.  This should 
ideally be done into a t issue, but if one is not available, use the bend in 
your arm.  
  
• Use personal protective equipment such as gloves and appropriate facial or 
respi[INVESTIGATOR_467008].   
  
• Consult the Occupational Health department for any additional 
information about how to p rotect yourself from influenza and respi[INVESTIGATOR_467184], it is important that, if possible, you wear appropriate 
facial or respi[INVESTIGATOR_467185].  An N95 respi[INVESTIGATOR_467186].  If you are unable to wear an N95 respi[INVESTIGATOR_13521], you should consult the Occupational Health 
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
102  
  department; you may be able to use a medical mask or other form of FPE.  It is extremely important that 
you are vaccinated with the seasonal vaccine, whi ch includes the pandemic H1N1 strain.  If you are 
concerned about the risks of being vaccinated, please call Johns Hopkins Infection Control at [ADDRESS_598891], it is recommended 
that you re ceive the seasonal vaccine.    
  
  
  
  
 Appendix  K   Certification Criteria for Study Sites  
  
• Minimum of 24 clinics/clusters employing a median of at least [ADDRESS_598892] fewer clinics that are easily divisible into 24 
separate work environments, with 16 or more people working in each 
environment  
• History of collaboration with other sites on large clinical trials  
• Research infrastructure experience with clinical studies  
• Active research staff to conduct the study  
• High interest level and enthusiasm of HCP participants  
• High number of patients who present for healthcare with a diagnosable 
respi[INVESTIGATOR_4375]  
• Outpati ent/primary care facilities  
• Track record of collaborative research  
• Site is preferred to have a track record of clinical trials  
• Site is preferred to have a pediatric component in their set of possible 
study locations (because the incidence of infectious diseases is highest 
in these settings).  This criterion would not apply to VA study sites.  
• Active respi[INVESTIGATOR_467187]  L  Study Timeline  
  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
102  

 
  
             The Re spi[INVESTIGATOR_466877] – Perl, Radonovich  
   
105  
  Today’s Date:     ____/___/____   
      
    (MM/DD/YEAR)  
Study Subject ID: ____________ Study Site: ______________   
  
 Appendix  M   Amended Fit Testing Medical Questionnaire     
Reference: Appendix C to Sec. 1910.134: OSHA Respi[INVESTIGATOR_467011] (Mandatory)    
  
ResPECT Study Questionnaire   
  
  
Please answer the following questions.  
  
1. Have you been fit tested within the past 6 months?     Yes ________    No ________  
2. If you have been fit tested within the past [ADDRESS_598893] or gained 10% or more  of your 
total body weight after the fit test?     Yes ________   No _________  
  
To the employer: Answers to questions in Section 1, and to question 9 in Section 2 of Part A, do not require a 
medical examination.   
  
To the employee:   
  
Can you read (cir cle one): Yes/No   
  
Your employer must allow you to answer this questionnaire during normal working hours, or at a time and 
place that is convenient to you. To maintain your confidentiality, your employer or supervisor must not look at 
or review your answers, and your employe r must tell you how to deliver or send this questionnaire to the 
health care professional who will review it.   
  
Part A. Section 1. (Mandatory) The following information must be provided by [CONTACT_467294][INVESTIGATOR_141876] r (please print).   
  
1. Today's date: _______________________________________________________   
  
2. Your name: __________________________________________________________   
  
3. Your age (to nearest year):_________________________________________   
  
4. Sex (circle o ne): Male/Female   
  
5. Your height: __________ ft. __________ in.   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
106  
    
6. Your weight: ____________ lbs.   
  
7. Your job title: _____________________________________________________   
  
8. A phone number where you can be reached by [CONTACT_467295] 
(include the Area Code): ____________________   
  
      
9. The best time to phone you at this number: ________________   
  
10. Has your employer told you how to contact [CONTACT_467296] (circle one):         Yes  No   
  
11. Have you worn a respi[INVESTIGATOR_13521] (circle one):      Yes  No   
  
If "yes," what type(s):_________________________________ __________________________ 
_____________________________________________________________   
  
Part A. Section 2. (Mandatory) Questions [ADDRESS_598894] be answered by [CONTACT_467297][INVESTIGATOR_13521] (please circle "y es" or "no").   
  
1. Do you currently  smoke tobacco,   
or have you smoked tobacco in the last month:       Yes  No   
  
2. Have you ever had  any of the following conditions?   
a. Seizures (fits):             Yes  No  
b. Diabetes (sugar disease):           Yes  No  
c. Allergic reactions that interfere with your breathing:     Yes  No  
d. Claustrophobia (fear of closed -in places):       Yes  No  
e. Trouble smelling odors:           Yes  No  
3. Have you ever had  any of the following pulmonary or lung problems?   
a. Asbestosis:             Yes  No  
b. Asthma:              Yes  No  
c. Chronic bronchitis:           Yes  No  
d. Emphysema:             Yes  No  
e. Pneumonia:             Yes  No  
f. Tuberculosis:             Yes  No  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
107  
  g. Silicosis:              Yes  No  
h. Pneumothorax (collapsed lung):         Yes  No  
i. Lung cancer:             Yes  No  
j. Broken ribs:             Yes  No  
k. Any chest injuries or surgeries:         Yes  No  
l. Any other lung problem that you've been told about:     Yes  No  
4. Do you currently  have any of the following symptoms of pulmonary or lung illness?   
a. Shortness of breath:           Yes  No  
b. Shortness of breath when walking fast on level   
 ground or walking up a slight hill or incline:       Yes  No  
c. Shortness of breath when walking with other   
 people at an ordinary pace on level ground:       Yes  No  
d. Have to stop for breath when walking   
at your own pace on level ground:         Yes  No e.  
 Shortness of breath when washing or dressing yourself:   Yes  No  
f. Shortness of breath that interferes with your job:     Yes  No  
g. Coughing that produces phlegm (thick sputum):     Yes  No  
h. Coughing that wakes you early in the morning:     Yes  No  
i. Coughing that occurs mostly when you are lying down:    Yes  No  
j. Coughing up blood in the last month:       Yes  No  
k. Wheezing:             Yes  No  
l. Wheezing that interferes with your job:       Yes  No  
m. Chest pain when you breathe deeply:       Yes  No  
n. Any other symptoms that you think may be   
 related to lung problems:          Yes  No  
5. Have you ever had  any of the following cardiovascular or heart problems?   
a. Heart attack:             Yes  No  
b. Stroke:              Yes  No  
c. Angina:              Yes  No  
d. Heart failure:             Yes  No  
e. Swelling in your legs or feet (not caus ed by [CONTACT_270876]):     Yes  No  
f. Heart arrhythmia (heart beating irregularly):      Yes  No  
g. High blood pressure:           Yes  No  
h. Any other heart problem that you've been told about:    Yes  No  
6. Have you ever had  any of the following cardiovascular or heart symptoms?   
a. Frequent pain or tightness in your chest:       Yes  No  
b. Pain or tightness in your chest during physical activity:    Yes  No  
c. Pain or tightness in your chest   
 that interferes with your job:         Yes  No  
d. In the past two years, have you noticed your   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
108  
  heart skippi[INVESTIGATOR_467188] a beat:         Yes  No e.  
 Heartburn or indigestion that is not related to eating:    Yes  No  
f. Any other symptoms that you think may be related   
g. to heart or circulation problems:         Yes  No  
  
7. Do you currently  take medication for any of the following problems?   
a. Breathing or lung problems:         Yes  No  
b. Heart trouble:             Yes  No  
c. Blood pressure:             Yes  No  
d. Seizures (fits):             Yes  No  
8. If you've used a respi[INVESTIGATOR_13521], have you ever had  any of the following problems? (If you've never used a 
respi[INVESTIGATOR_13521], check the following space and go to question 9:)   
a. Eye irritation:             Yes  No  
b. Skin allergies or  rashes:           Yes  No  
c. Anxiety:              Yes  No  
d. General weakness or fatigue:         Yes  No  
e. Any other problem that interferes   
 with your use of a respi[INVESTIGATOR_13521]:         Yes  No  
  
9. Would you like to talk to the health care professional  who will  review this questionnaire about your   
answers to this questionnaire:           Yes  No   
     
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
[ADDRESS_598895] Study Staff as soon as possible.  
  
Phone: [ADDRESS_598896] ID: ______________  
Email: [EMAIL_8934]        Study Site: ___________________  
Pager: 410 -434-0821     
  
Today’s date: _____/ ___/____   
    (MM/DD/YEAR)  
Complete the Symptomatic Event Report Form and Remember to contact [CONTACT_467298]:    
  
1. Please complete the following table if you have experienced anyone of the following 
symptoms? (Please check all that apply.)  
       Date of Onset   
   Yes  No  Unsure   (MM/DD/YEAR)   
Fever (greater than 37.8oC or 
100.1oF)  □  □  □  __/__/____    
Nasal congestion/runny 
nose(Coryza)  □  □  □  __/__/___   
Headache  □  □  □  __/__/____   
Sneezing   □  □  □  __/__/____   
Fatigue  □  □  □  __/__/____   
Dry cough  □  □  □  __/__/____   
Body aches (myalgias or arthralgias)  □  □  □  __/__/____   
General feeling of being sick 
(malaise)  □  □  □  __/__/____   
Sore throat  □  □  □  __/__/____   
Sputum  production  □  □  □  __/__/____   
Diarrhea  □  □  □  __/__/____   
Bloody sputum  □  □  □  __/__/____   
Chills  □  □  □  __/__/____   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
110  
  Nausea/vomiting  □  □  □  __/__/____   
Abnormal sweating  □  □  □  __/__/____   
Rapid Breathing/shortness of breath 
(tachypnea >25)  □  □  □  __/__/____   
Swollen lymph nodes 
(lymphadenopathy)  □  □  □  __/__/____   
Other Gastrointestinal symptoms 
(please specify)  □  □  □  __/__/____   
Other (please specify)  □  □  □  __/__/____   
  
  
  
  
2.) If you answered yes to any one of the above symptoms, did you take any of the following 
actions?  
  
a)  Seek medical help from a   
  
MD/Provider      □ Yes    □No   
Emergency Department   □ Yes    □No   
Occupational Health Services  
  
b)  Take medication  
  □ Yes    □No   
Tylenol    □ Yes   □No     
Ibuprofen   □ Yes    □No    
Aleve    □ Yes    □No    
Aspi[INVESTIGATOR_248]   □ Yes    □No     
Oseltamivir   □ Yes    
  □No     
3.) If you answered YES to any of the above symptoms, are your symptoms still present?   
  
 □ Yes    □No  
  
If no, when did your symptoms end? __/__/____   
  
  
    
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
[ADDRESS_598897] promptly report to the IRB, in writing, any unanticipated side 
effects, hazards, or other problems involving risks to subjects or others.    Promptly report all 
adverse events considered to be related to research procedures t o the Steering Committee.  Please 
fax to Jenna Los at 410 -614-6207.  
  
M.2.a.i.[IP_ADDRESS].61  Date:   
M.2.a.i.[IP_ADDRESS].62  Principal Investigator:  [INVESTIGATOR_467189], Trish  
M.2.a.i.[IP_ADDRESS].63  Protocol#:  NA_00031266  
M.2.a.i.[IP_ADDRESS].64  Protocol Title:  The Respi[INVESTIGATOR_467190]  
 M.2.a.i.[IP_ADDRESS].65  Research Coordinator(s):  M.2.a.i.[IP_ADDRESS].66  Phone:  M.2.a.i.[IP_ADDRESS].67  Fax:  
 Jenna Los  410-614- 410- 
   6206  614- 
   6207  
  
  
Report Type:   Initial     Follow -up  
Subject Identifier # ( study ID number, do not list medical record number or other personal identifier ): AE 
Date:    
AE Description (brief):    
  
  
  
  
  
Is the adverse event a previously described complication that is listed in the “Risk” secti on of 
the Investigator’s Brochure    Yes      No  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
112  
  This is a (an):   
  
M.2.a.i.[IP_ADDRESS].68    
Unanticipated/Unexpected 
Event    
M.2.a.i.[IP_ADDRESS].69   (Any untoward event 
that is not identified with 
the current  The opi[INVESTIGATOR_467191]:  
  
M.2.a.i.[IP_ADDRESS].72  
 Unrelated  
M.2.a.i.[IP_ADDRESS].73  
not related Possibly  Probably 
related  
M.2.a.i.[IP_ADDRESS].[ADDRESS_598898]  
   
Study ID: __________________    Study Site: ____________________  
 Consent obtained:     Yes      No Date of consent:  ____/_____/________   
                                       (MM/DD/YEAR)      
 Reviewed & entered in RedCap:    
  
• Baseline survey:    Yes     No  
  
• Inclusion/exclusion criteria:    Yes     No   investigator brochure or  
study protocol)    
  
M.2.a.i.[IP_ADDRESS].70      Serious Adverse Event      
M.2.a.i.[IP_ADDRESS].[ADDRESS_598899]  ( 
medical occurrence that  
results in death, is life  - 
threatening, requires  
patient hospi[INVESTIGATOR_059],  
prolongs existing  
hospi[INVESTIGATOR_059], results in  
persistent or significant  
disability/incapacity, or is  
a  congenital abnormality)    
  M.2.a.i.[IP_ADDRESS].75    Related    
M.2.a.i.[IP_ADDRESS].76    Other:              
  
  
________________________________________           _________________    
I NVESTIGATOR SIGNATURE                 [CONTACT_81619]    
( Sub - investigator may sign if the investigator is unavailable (i.e. out of the country  )   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
113  
    
o Eligible?    Yes     No   o   
 If eligible, date enrolled (date emailed by [CONTACT_412860]):  _____/______/_______  
  
• Site assignment:    N95     Medical Mask  
• If N95, complete Amended Fit Test Questionnaire .   
  
o Fit test qx reviewed (signed & dated) by [CONTACT_467299]: Yes  No  o Fit 
testing:   
  
 Qualitative   Quantitative  
       
 Pass    Fail      Date of testing:  ____/_____/________   
                                                                       (MM/DD/YEAR)      
o Successfully fit -tested for the following respi[INVESTIGATOR_13521]: _____________  
  
• Vendor form reviewed and submitted:    Yes     No     On file from prior year   
  
o Initial payment: $______.00  & Date Submitted: ____/_____/________   
                                             
 [If only submitting final payment] Emailed participant earning status: ____/_____/______  
 o Final 
payment: $______.00  & Date submitted: ____/_____/________   Withdrawn?     
  
• If yes, date withdrawn:  _____/______/_______   
                                             (MM/DD/YEAR)           
  
• If yes, reason withdrawn (list option #): _______  
  
  
Option 1: No longer eligible due to change in work location  Option 6: Does not believe seeing enough flu to be helpful  
Option 2: Lack of time/schedule conflicts       Option 7: No reason given  
Option 3: Swab discomfort        Option 8: Other (please describe):   
Option 4: Can't Keep up with Surveys      Option 9: Administrative Withdrawal  - Team removed  
Option 5: Mask Discomfort        due to lack of completion     
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
[ADDRESS_598900] Evaluation Form   
  
NAME_________________________________________  DATE________________  
             (PLEASE PRINT CLEARLY )  
  
CLINIC NAME___________________________________    
  
HAS SUBJECT EATEN WITHIN THE LAST 15 MINUTES ? (CIRCLE ONE )      YES   NO  
COULD THE SUBJECT TASTE SACCHARIN ?  (CIRCLE ONE )         YES   NO*  
* IF NO, REFER FOR QUANTITATIVE TESTING   
  
RESPI[INVESTIGATOR_467192]:    ⁬ N95        ⁬ ELASTOMERIC   ⁬ (OTHER SPECIFY )_________   
MANUFACTURER         ⁬ 3M    ⁬ KIMBERLY CLARK⁬        (OTHER SPECIFY )_________   
STYLE:      ⁬ 1870     ⁬ 1860          ⁬             (OTHER SPECIFY )_________   
SIZE:          ⁬ SMALL      ⁬ MEDIUM      ⁬ LARGE                    N/A  
  
ADEQUACY OF RESPI[INVESTIGATOR_467193] ?        (CIRCLE ONE )  YES   NO MASK 
POSITIONED PROPERLY ?       
  -FIT ACROSS NOSE BRIDGE ?         (CIRCLE ONE ) YES   NO    -CHIN 
PROPERLY PLACED ?            (CIRCLE ONE ) YES   NO STRAPS 
POSITIONED PROPERLY ?  
  -LOWER AROUND NECK ?         (CIRCLE ONE ) YES   NO  
  -UPPER AT CROWN OF HEAD ?      (CIRCLE ONE )  YES   NO  
            
CHALLENGE EXERCISES               PASS    FAIL   /                 
2ND MODEL : PASS    FAIL  
NORMAL BREATHING                 ⁬ ⁬    
DEEP BREATHING                      
    
TURNING HEAD (SIDE TO SIDE )                   
MOVING HEAD (UP & DOWN )        
TALKING                        
    
BENDING (AT WAIST /KNEE BENDS )             
NORMAL BREATHING      ⁬                  
  
  
  
FIT TEST RESULTS :  (CIRCLE ONE )    PASS    FAIL                    
             
             
                  
             
             
                            
        ⁬⁬ 
        ⁬⁬   
                 
        ⁬⁬ 
        ⁬⁬   
        ⁬⁬   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
115  
    
NOTES :  _______________________________________________________   
  
  
HSE  STAFF:  ____________________________DATE___________________   
     
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
116  
   Appendix  R   Supplies for Take -Home Kits  
  
In order to comply with Dangerous Goods and Hazardous Materials Shippi[INVESTIGATOR_467194], the 
kits will include materials for specimen collection, triple packaging and proper labeling, and 
instructions to complete collection and shippi[INVESTIGATOR_007]:  
  
  
1. Specimen Tubes (Primary Packaging)  
a. UTM Tube and [ADDRESS_598901] Bags (for Secondary Packaging)  
3. Absorbent Sheets (for Secondary Packaging)  
4. FedEx Padded Envelope (for Outer Packaging)  
a. FedEx Small Pak  
b. Inside Dimensions: 12 -3/4” x 10 -1/4”  
5. FedEx Box (for Outer Packaging)  
a. FedEx Small Box  
b. Inside Dimensions: 12 -1/4” x 10 -7/8” x 1 -1/2”  
6. FedEx UN3373 Pak (for Outer -Outer Packaging)  
a. UN 3373 Pak  
b. Inside Dimensions: 18” x 13 -1/2”  
7. Barcode identifier labels (tracking purposes)  
8. ‘Shippi[INVESTIGATOR_467195]’ instructions (Appendix S)  
9. ‘At-Home Symptomatic Upper Respi[INVESTIGATOR_467196]’ (Appendix T)  
10. ‘Take -Home Kit Packaging Information’ (Appendix U)  
11. ‘For Any Questions Regarding This Package Or Its Contents’ contact [CONTACT_467300]  
12. 12. Swab Delivery Form and separate envelope with line indicated “For Personnel Use Only” 
for lab to indicate date and time of receipt (Appendix X).  
    
  
 Appendix  S   Shippi[INVESTIGATOR_467197]? Articles or substances which are capable of posing a significant 
risk to health, safety or to property when transported by [CONTACT_94269].  
What are hazardous materials? A substance or material that has been determined by [CONTACT_467301] T to be capable of posing an unreasonable risk to health, safety, and property.  
• Hazardous materials are organized into nine primary hazard classes, however, this 
study will be dealing solely with Class 6.2 (Infectious Substances.) o Class 6.2 
includes two  sub-categories: Category A are the most virulent agents and Category 
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
117  
  B are potentially pathogenic substances.  Take -home kits will be shipped under a 
Category B classification with the label UN3373.  
There are steep penalties for non -compliance with hazar dous materials regulations.  
Packaging:  
• Triple Packaging is used in sending any biological substance. Triple packaging 
contains: primary receptacle leak -proof (liquids), leak -proof secondary packaging 
and durable outer packaging. Triple packaging must always be used whether 
shippi[INVESTIGATOR_467198] A, B, or Exempt substances.  
• Marking and labeling for Category B biological substances requires a diamond -on-
point label with UN3373 with the words “Biological substance, category B” 
adjacent. It must also include the name, address, and phone number of a 
responsible person, either on the package or the waybill.  
Category B Infectious Substances:    
• Can never  be ta ken aboard an aircraft in carry -on or checked baggage, nor on your 
person.  
• May be transported in your private vehicle or in any other private motor vehicle, 
provided they meet the appropriate packaging requirements.  
Specific Security Procedures:  
• All pac kages of hazardous materials intended for shipment should be kept in a 
secure area until collection by [CONTACT_467302].  
• Do not leave a package unattended in an unlocked area.  
• If left in a locked area where others have access, sure they are known to you and 
reliable.    
  
Appendix  T   At-Home Symptomatic Upper Respi[INVESTIGATOR_467199].  
  
At-Home Symptomatic NASAL  Swab Directions  
 Considerations :   
   
When possible, do your swab before starting antibiotic therapy or use of antihistamines. Antibiotics may 
suppress growth of infecting agent, causing a false negative culture.  
  
Swab Directions:    
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
118  
  1. Blow your nose to remove excess mucous.   
2. Remove cap from t he tube & place cap upside down on a clean surface.  
a. Open plastic swab package at the end nearest to the handle (Photo 
Companion 1, Figure 1).  
  
3. Take swab by [CONTACT_467303] (be sure not to touch any part of the swab below the 
breakpoint). Tilt head back slightly & insert swab approximately 2 cm (¾ inches) 
into one naris, rotate against the anterior nasal mucosa.   
a. Rotate for 3 seconds to ensure swab  contains both cells, as well as 
mucosa (Photo companion 1, Figure 2, & 3).   
  
4. Place the swab inside the tube until the end touches the bottom.  
a. Bend the swab shaft against the side of the tube to remove the 
handle at the breaking point (Photo companio n 1, Figure 4).  
  
5. Cap specimen swab collection tube and continue to Throat Swab          Directions.  
  
Photo Companion 1: At-Home Symptomatic Nasal Swab  
Directions   
 
  
Figure 1  :     
  
  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
119  
     
At-Home Symptomatic THROAT  Swab Directions   
Swab Directions :  
   
1. Position yourself in front of a well -light mirror so that your oral cavity (mouth & 
throat) is well defined.   
  
2. Remove cap from the tube & place cap upside down on a clean surface.   
  
3. Open plastic swab package at the end nearest to the handle (Photo companion 1, 
Figure 1).  
   
4. Take one (unused) swab by [CONTACT_467303] (be sure not to touch any part of the swab 
below the  breakpoint).  
  
Figure 2  :      Figure 3  : 
  
  
Figure 4  :     
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
120  
  5. Breathe deeply and flex tongue towards the bottom of your mouth (to avoid 
contact [CONTACT_467304]).   
  
a. Guide the swab to the posterior pharynx (back of throat), taking care not to 
touch tongue, cheeks, and uvula (Photo companion 2, Figures 1 & 2).   
  
b. Swab vigorously while saying “Ah.” (This lifts the uvula and decreases the 
gag reflex.) Swab area from right tonsillar area across posterior pharynx 
(back of throat) to left tonsillar area and across to right tonsillar area.  
  
c. In addition, areas of inflammation, ulceration, exudation, or with white 
patches should be touched. Rub vigorously, not gently, to remove 
organisms adhering to the mucosal membrane.  
  
6. Do not touch swab tip after removal.  
  
7. Place the swab inside the same tube  until the end touches the bottom   
a. Bend the swab shaft against the side of the tube to remove the handle at 
the breaking point (Photo companion 1, Figure 4)   
  
8. Cap the specimen swab collection tube tightly.  
  
9. Peel off one barcode and place it on tube.  
  
10. Read “Shippi[INVESTIGATOR_467200]” handout.   
  
  
Photo Companion 2: At-Home Symptomatic Throat Swab 
Directions  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
121  
    
  
  
Great job taking your own throat swab!  
  
  
  
  
  
 Appendix  U   Take -Home Kit Packaging Information   
Please follow the instructions below to ship your collected nose and throat 
swabs.  
  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
122  
  1.) Insert swabs into specimen tube.  
Specimen tube with screw -top containing  nose and 
throat swabs, labeled with your barcode ID , is  your 
“primary packaging”.  Proper labeling of swab tube:   
  
  [ADDRESS_598902] bag along with  
the specimen swab collection  
tube    
See Step 4    
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
123  
    
  
Remaining labels should be included in bag with tube, but not peeled off backing.  
  
Swab Delivery Form should be completed from the link in your weekly email.   
  
2.) Place the specimen tube inside the biohazard bag with absorbent sheet.  
  
Biohazard bag with absorbent sheet is your “secondary packaging  
  
3.) Place the remaining 4 (not peeled off the backing) 
specimen barcode ID labels in biohazard bag with specimen 
tube.  
  
4.) Place biohazard bag (“secondary packaging”) into FedEx padded envelope.  
Then place this envelope into FedEx box.   
  
The FedEx box will be your “outer packaging”.   
5.) Insert the ‘For Any Questions’ contact [CONTACT_467305].   
  
6.) Seal the FedEx® corrugated cardboard box with its contents.  
  
7.) Seal the orange FedEx UN 3373 Pak.   
FedEx® UN 3373 Pak [intended for Biological Substance, 
Category B (UN 3373) specimens] is an extra layer, an 
“outer -outer packaging,” used because it already comes 
with the required hazardous materials labels.  
  
8.) Keep your prepared FedEx® package in a secu re area until collection by 
[CONTACT_467306].  
  
  
The padded  envelope provides protection.    
  
  
  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
124  
    
9.) Call [PHONE_9778] to schedule a FedEx Express pi[INVESTIGATOR_467201]. In 
case needed by [CONTACT_467307], the account number is xxx -xxx-x (located on the 
pre-printed waybill).   
  
10.) Complete online  your “Swab Delivery Form.”  
  
Biological samples cannot be put into a FedEx Drop Box.  
 Appendix  V   Participant Correspondence Email Templates  
  
Mass ResPECT Recruitment Email   
  
Greetings from the ResPECT study!   
  
We are recruiting healthcare workers from your place of work for a 19 week study researching 
the effectiveness of surgical masks vs. N95 respi[INVESTIGATOR_467202] (RPI). If you choose to part icipate in this study, you will be 
randomly assigned to wear either a surgical mask or an N95 respi[INVESTIGATOR_467203]. Your experiences will be shared with us via weekly surveys as 
well as randomized anonymous c ompliance observations made by [CONTACT_467308].   
  
Participants will:  
  
• complete a baseline and pre -study survey  
• submit to 2 blood draws (at the beginning and end of study) as well as 2 combined nasal and 
throat swabs  
• be fit -tested if necessary (if working at an N95 -assigned site)  
• be expected to wear their assigned facial protective equipment (FPE) when in close contact 
[CONTACT_467309]  
• Surveys:  
o Weekly Diary  for each week of the study o Daily (Monday, 
Tues day, etc.) Forms  for each day of the week  o Symptomatic 
Event Report Form if you become ill   
• be randomly observed by [CONTACT_467310]  
• be asked to inform study staff if you are on vacation, are sick, or are otherwise unavailable 
during a week of the study  
• be asked to complete a post -study survey after the end of the study  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
[ADDRESS_598903] 
who works a minimum of 24 hours per week at the assigned study site and is willing and able to 
comply with the study requirements, as outlined above.  
  
Participants can receive a maximum of $599.00 compensation for partaking in the study.  The 
rate of compensation is based directly on the participant’s completion of study requirements 
(surveys, diaries, blood draws and specimen collections.)  
  
Please call or e -mail us if you are interested in participating in our study, or if  you have any 
questions.  Also, be sure not to miss our first recruitment/information session at your site on 
[date for that site ]!  
  
For more information, please see our Facebook page at www.facebook.com/RespectStudy  
  
Sincerely,  
[see signature [CONTACT_467319]]  
  
ResPECT Ineligible Email Template:   
  
Dear [First Name [CONTACT_2385]; automatically generated by [CONTACT_467311]],  
  
Thank you for your interest in the ResPECT Study!  Unfortunately, you are ineligibl e to join our 
study so we won’t be able to include you at this time.  If you have any questions, please feel 
free to contact [CONTACT_467312].  
  
Thank you,  
[See Signature [CONTACT_5628]]  
  
  
ResPECT Initial Welcome E -mail   
  
  
Dear [First Name [CONTACT_467320]; automatically generated by [CONTACT_467311]],  
  
Thank you for agreeing to participate in the ResPECT Study! You will fill out a series of surveys 
throughout the intervention period.  Links for the new surveys will be emailed to you each 
week, as well as any surveys that were left incomplete from the pre vious week.  
  
Please click the link below to access your Pre -Study Survey so that we can get some 
information about you before the intervention period of the study begins:  
  
LINK HERE  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
126  
    
Thank you,  
[Signature [CONTACT_467321]]  
  
Respect Week [week number] Survey Email Template   
  
Dear ____,  
  
Welcome to Week [ADDRESS_598904]!  
  
Please use the links below to complete the appropriate forms for this week.    
These links are unique to YOU and should not be forwarded to others.    
If you  are unable to open these links or have questions, please notify the ResPECT team in your 
area.  
  
Week 2 Forms:  
  
Monday (Week 2) [Required regardless of days worked ]  
Tuesday (Week 2) [Required regardless of days worked]  
Wednesday (Week 2) [Required regardless of days worked]  
Thursday (Week 2) [Required regardless of days worked]  
Friday (Week 2) [Required regardless of days worked]  
Saturday (Week 2) [Required regardless of days worked]  
Sunday (Week 2) [Required regardl ess of days worked]  
  
Weekly Diary (Week 2) [Required regardless of days worked]  
  
Symptomatic Event Report Form 1 (Week 2) [only if you have symptoms] 
Symptomatic Event Report Form 2 (Week 2) [only if you have symptoms]  
  
Swab Delivery Form – Take -Home  Kit [only if instructed to use your take -home kit]  
  
**********************************************************  
In this section, you will find your INCOMPLETE forms from last week (Week 1); they will not be 
available again, so please complete them as so on as possible:  
  
Monday  (Week 1)  [Required regardless of days worked]   
Tuesday  (Week 1)  [Required regardless of days worked]   
Wednesday  (Week 1)  [Required regardless of days worked]   
Thursday  (Week 1)  [Required regardless of days worked]   
Friday  (Week 1)  [Required regardless of days worked]   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
127  
  Saturda y  (Week 1)  [Required regardless of days worked]   
Sunday  (Week 1)  [Required regardless of days worked]   
  
Weekly Diary (Week 1)  [required ]  
  
Symptomatic Event Report Form 1 (Week 1)  [only if you have symptoms] Symptomatic 
Event Report Form 2 (Week 1)  [only if you have symptoms]  
  
Swab Delivery Form – Take -Home Kit [only if instructed to use your take -home kit]  
  
********************************************************** 
Thank you  for your continued participation!  
[Signature [CONTACT_467321]]  
  
Survey and Week Info to Participants   
  
Hello ResPECT Study Participants!   
  
Now that we have started our study, we realize there is some confusion about filling out the 
surveys and what a “sur vey week” consists of.  Please note that you will be emailed survey links 
late Sunday/early Monday that will be for the week beginning  on that Monday.  For example, 
the links sent late last night are for the work week starting today through Sunday ( Week 1 = 
Date – Date ).  
  
There are 3 categories of Forms sent in each weekly email:  
• You should fill out your Daily Exposure Form at the end of every day whether or not you 
work..    
• A Symptomatic Event Form  should be filled out whenever you feel sick and may need to 
be swabbed, as soon as possible after feeling sick (so if you feel sick today, please do 
not wait until Friday to fill out this form or contact [CONTACT_220872]).    
• The Weekly Diary  should only be fil led out after  you have finished all your work shifts 
for that week.  It will cover the time period from when you receive the email until your 
last work shift that week or Sunday evening, whichever comes first.  We are working on 
resetting the surveys that were submitted today in error.  
  
For your convenience, here are all the time periods (Mon -Sun) covered by [CONTACT_95842]:  
• Week 1 :  date - date  
[…..]   
• Week 16 :  date - date  
• FINAL STUDY ITEMS (after intervention period ends) : post -study survey, blood draw # 2  
  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
128  
  [Signature [CONTACT_467321]]  
  
Study Activation to Champi[INVESTIGATOR_467204]!   
  
The ResPECT Study is activating on <day, date>  and you can expect to see more staff than 
usual wearing masks. We are asking that all participants wear masks anytime they are within 6 
feet of patients with respi[INVESTIGATOR_1856], so please feel free to remind staff you know to be 
participating (or any of your staff as it is good infection control practice!) to wear their masks 
at the appropriate time.   
  
You can also expect to see us periodically during the 16 weeks – we will be there doing 
compliance checks, swabs, and replenishing masks. On the week when your site is chosen for 
swabs, we will let you know in advance when you expect us.   
  
Thank you again for agreeing to assist the study this flu season!!!   
  
[Signat ure Line Info]  
  
Study Activation to Participants   
  
Hello ResPECT Study Participants!   
  
It is time to start wearing masks  – we are activating the study on <day, date>!!!  Please 
remember to wear your masks when within 6 feet of patients with respi[INVESTIGATOR_13521] y symptoms and 
make sure to do your daily and weekly surveys! You will receive a weekly email with a link to 
that week’s surveys.   
  
A couple reminders about the take -home swab kits :   
  
• Please call us if you plan to use a take -home kit and/or submit a sy mptomatic event form. 
We will then determine if we would like you to take a sample at home.  
• There are 2 swabs required for each sample: 1 nasal and 1 throat; instructions are provided 
in the take -home kit and you can always call us for clarification  
• For the nasal swab, please make sure you insert the swab 2 -3 centimeters inside your 
nostrils! We realize it will be uncomfortable, but we need you to do your best to get us 
good samples.   
• If you are sick on the weekend (Friday through Sunday) please wait until Monday to do 
your swab. FedEx doesn’t pi[INVESTIGATOR_467205].   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
129  
    
[Signature [CONTACT_467321]]  
  
Symptomatic and Incompletes Info to Participants   
  
Hello  ResPECT Study Participants!   
  
Now that we are in Week 2, we have noticed some additional confusion over the surveys.   
Please recall from previous email that you will be emailed survey links late Sunday/early 
Monday that will be for the week beginning  on that Monday.  You should not complete your 
Weekly Diary  until you have stopped working for that week.  
  
In addition, the Symptomatic Event Forms  are only  if you feel sick and may need to be 
swabbed.  If you don’t feel sick, you don’t need to fill it out.  We gave you 2 each week in case 
you feel sick more than once that week.  You may also call the office or email us if you feel sick 
and want to know if you should swab yourself (or have  a Research Assistant come take one).  
  
You will now notice some “ Incompletes ” at the bottom of your list of Weekly Surveys.  These 
will only appear for the previous week (you get 2 weeks to complete your surveys and then 
they disappear).  Also make sure to complete 7 Daily Exposure Forms each week – this year 
you’re required to do all 7!!  
  
Thank you so much for your continued help,  
  
[Signature [CONTACT_467321]]  
  
Question #[ADDRESS_598905] Study Participants!   
  
The flu season has arrived and we have been following up on everyone’s submissions! Many of 
you have seen us recently for a swab because you’re ill, and many more of you have been 
confused when we ask about your symptoms.   
  
The problem across the board i s on the Daily Exposure form, Question #2 – which asks if you 
feel sick. Please be careful here; the question is not about the patients you were exposed to – it 
only wants to know about you.  Question #3 is about your patients and coworkers.  
  
We love hea ring from everyone, but whenever you say “Yes you’re having symptoms” (of any 
sort, including a headache) we get an automated notification. And then we worry that you’re 
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
130  
  sick! So please be extra careful on this form – it’ll save you the hassle of explainin g yourself to 
us every week.  
  
Thanks so much!   
[Signature [CONTACT_467321]]  
  
Swab Week to Champi[INVESTIGATOR_467206] <CHAMPI[INVESTIGATOR_467207]>!   
  
Your site has been selected to have nose -throat swabs done the week of <DATE to DATE>. We 
would like your assistance to make th is process as efficient as possible. If you could please send 
us schedules for the below participants and let us know of any schedule conflicts with site 
events we would greatly appreciate it! We have emailed the participants for their schedules, 
but your input is very valuable to us.   
  
We appreciate your help!!   
  
[Signature [CONTACT_467321]]  
  
Swab Week to Participants  
  
Hello XXXXX Site Participants!   
  
Congratulations! Your site has been selected to have nose -throat swabs done the week of 
<DATE to DATE>. We would like to visit your site <DATE> at <TIME>. If you will not be on site 
during this time, please send us your schedule as soon as possible so we can visit when you are 
working. It is very important that w e see you this week, so please consider droppi[INVESTIGATOR_467208]’t miss you.   
  
We look forward to seeing you <DATE>!!!  
  
[Signature [CONTACT_467321]]  
  
Week [ADDRESS_598906] Study Participants!   
  
We are nearing the half -way point for the study – which means your first payment is being 
tallied (YAY!). However – your payment is dependent on completion of surveys so in order 
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
131  
  to maximize your payment, the following forms need to be submitted to us by <INSERT  
DATE>.    Please go through your email and make sure you’ve submitted:  
  
1) Pre-Study Survey  
2) Weekly Diary – for each week, total of 6 (even if you did not work)   
3) Daily Exposure Survey  – for each day of the week (even if you do not work)  
  
We are re -sending the Pre -Study Survey to all participants – if you have not filled this out, 
please submit this as soon as possible!! You can check whether the survey is complete by 
[CONTACT_467313] – if you’ve submitted it, the link will not work.   
  
Remember: If you don’t submit all the surveys, you won’t get all your money! If you can’t find 
the emails, please let us know so we can resend them!!!   
  
Thanks and we look forward to your participation in the second half!   
  
[Signature [CONTACT_467321]]  
  
Fina l Blood Draw to Participants  
  
Hello XXXXX Site Participants!   
  
You’re almost finished!! Starting <date>, we will be visiting <CLINIC OR ED NAME> to collect the 
last blood draw from everyone. We would like to visit on <DATE> at <TIME>. If you will not b e 
on site during this time, please send us your schedule as soon as possible so we can visit when 
you are working. It is very important that we see you sometime between April 30th and May 
18th so you can get full participation credit for being in the study !!   
  
Please also remember to do the Post -Study Survey by [CONTACT_11712] 30th. We look forward to seeing you 
in the upcoming weeks!!!   
  
[Signature [CONTACT_467321]]  
  
End of Study to Participants   
  
Hello XXXXX Site Participants!   
  
You’re almost finished!! Starting April 30th, we will be visiting <CLINIC OR ED NAME> to collect 
the last blood draw from everyone. We would like to visit on <DATE> at <TIME>. If you will not 
be on site during this time, please send us your schedule as soo n as possible so we can visit 
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
132  
  when you are working. It is very important that we see you sometime between April 30th and 
May 18th so you can get full participation credit for being in the study!!   
  
Please also remember to do the Post -Study Survey by [CONTACT_11712] 30th. We look forward to seeing you 
in the upcoming weeks!!!   
  
[Signature [CONTACT_467321]]  
  
ResPECT Post -Study Email Template   
  
Dear ____,  
  
We would like to thank you so much for your participation in the ResPECT Study.  We would 
not have been successful or made any meaningful results without the participation of you and 
other healthcare workers like you.  
  
In order to receive your final stud y payment, you need to complete a final blood draw (if you 
haven’t already), as well as your final survey, the Post -Study Survey.  Please click below to 
access it:  
  
LINK HERE  
  
Thank you,  
[Signature [CONTACT_467321]]  
  
ResPECT Final Email Template   
  
Dear __ _,  
  
This email signifies that you have completed the ResPECT Study for this season!  Once again, 
we would like to thank you for all of your help in this research.  
  
We have submitted everyone’s final study payments to be processed. You should receive th is 
check (pro -rated based upon your amount of participation) in the next 2 -3 weeks; if you do not 
receive it in [ADDRESS_598907] you in tracking 
down the problem.  
  
Thank you again!  
[Signature [CONTACT_467321]]  
  
    
ResPECT Supplemental Vaccination Questions Email Template  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
133  
    
Dear [Participant Name] ,  
  
Thank you again so much for your participation in the ResPECT Study.  As we wind down this 
multi -year study, we realize that there were a couple additional questio ns we should have 
asked about other vaccinations you may have previously received.  
  
Please use the link below to access and answer these final couple questions (at the most, 
depending on responses, you could have 5 questions total):  
  
[Participant’s Lin k here]  
  
Thank you once again for your continued support and participation in this very important study.  
  
Sincerely,  
  
The ResPECT Study Team  
  
[site specific info]  
  
  
  
Signature [CONTACT_467322] (will be tailored to which arm the participant is recruited under:  Baltimore, 
Denver, Houston, [LOCATION_001], or Washington DC)   
  
The ResPECT Study Team  
Children’s Hospi[INVESTIGATOR_20161]: 720 -777-8864; [EMAIL_8936]  
Denver Health: 303 -436-4843; [EMAIL_8937] (Amy)  
Denver VA: 303 -399-8020 x6862; [EMAIL_8938]  
Houston VA: 713 -794-7224 or 713 -791-1414 x5458; [EMAIL_8939]  
Johns Hopkins: 410 -614-6206; [EMAIL_8934]  
[LOCATION_001]: 212 -686-7500  x4469 and 718 -836-6600 x6588; [EMAIL_8940]   
Washington DV VA: 202 -745-8457 [EMAIL_8941]   
  
[this part only for Weekly Emails]  
Reminder: Please contact [CONTACT_467314] -like symptoms and please  
wear your study -assigned m asks when interacting with patients with suspected influenza -like 
illness.      
  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
134  
   Appendix  W   Payment Schedule  
Study Requirement  Frequency  Payment 
Amount  Total  
Possible  
Payment  
Pre-study package:  
1. Pre-study attitudes, beliefs, and opi[INVESTIGATOR_467209] (Preliminary survey)  
2. Baseline survey (participant demographic 
information)  
3. Blood draw #1  1x (subject 
to being 
eligible to 
participate)  $ 55.00  $ 55.00  
Randomized nasal and throat swab set   2-3x   $60.00 (1st &  
2nd set)  
$59.00 (3rd 
set)  $120.00 - 
$179.00  
Weekly symptom diary  12-16x  $ 5.00 (each)  $ 60.00 - 
$80.00  
Daily Exposure Form  Every day 
during 
study 
period  $ 5.00  
(weekly)  $ 60.00 - 
$80.[ADDRESS_598908] -study package:  
1. Blood draw # [ADDRESS_598909] -study attitudes, beliefs, and 
opi[INVESTIGATOR_467009]  
  1x  $ 70.00  $ 70.00  
*Study Bonus:   Prorated according to participant 
completion of weekly symptom diaries and daily 
exposure forms.  1x  Up to $135.00  Up to 
$135.00  
        
    Maximum  
Total Study  
Payment  $500.00  
(12 wks)  or  
$599.00  
(16 wks)   
  
Payment Schedule:  There are two payment dates - the first payment will be distributed 
midway through the study period, and the second payment will be distributed at the end of the 
study period.  The first payment has a maximum of $175 and the second payment, which will 
include the bonus, has a maximum o f $325 if the study ends after 12 weeks and $[ADDRESS_598910] each participant’s completion of study 
requirements. Payment is capped at $[ADDRESS_598911] 
Research Office with any paym ent questions.   
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
135  
  Reminder:   Please contact [CONTACT_467315] 410 -614-6206 or [EMAIL_8934]  
if you experience ANY of the respi[INVESTIGATOR_696]/flu -like symptoms listed on the Symptomatic Event 
Form (symptoms also listed on weekly symptom diary and back  of ResPECT Study business 
card).    
 Appendix  X  Swab Delivery Form  
  
Swab Delivery Form                                       
  
Participant ID: ________  
  
1.) When did symptoms begin? (date and time)  
  
2.) When is pi[INVESTIGATOR_9696] -up scheduled? (date and time)  
  
a. What is the FedEx tracking number? (16 -digit field)  
  
Please remember to complete your Symptomatic Event Form online! Please contact [CONTACT_7477] 
[EMAIL_8942]  or XXX -XXX-XXXX with any questions or concerns.  
  
  
     
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
136  
    
 Appendix  Y  Patient -Based Observation  Form  
  
Please let us know…  
  
Were you given a face mask to wear today?    Yes______  No______  
  
Did you see your doctor, nurse, or other healthcare professional wear a face mask  
during your visit today?  If yes, please circle  the mask that most closely resembles what 
they wore.  
  
 
      
 
      
  
Mask unlike those 
above.   
Please describe mask:  
  
     
N95 Masks    
Medical Masks    
Other    
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
137  
    
  
Did you see your doctor, nurse, or other healthcare professional 
clean their hands during your visit today?   
  
Yes _____      No _____  
  
If yes, what did they use? Please indicate when  they used this method.  
  BEFORE your exam   AFTER your exam   
Sanitizing Gel       
Sanitizing Foam       
Soap and Water       
Thank you for answering our survey!    
  
Appendix Z HandyAudit Compliance Monitoring  
  
  
  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
[ADDRESS_598912] Study Facebook Page  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
139  
    
  
  

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
    
Appendix  BB  Mask Up Sample Poster  
  
 
  
WE WANT YOU  TO MASK UP!  
    

 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
    
136  
Today’s Date:  ____/___/____  
    (MM/DD/YEAR)  
Study Subject ID: ____________  
  
Appendix  CC  Supplemental Vaccination Questions   
  
1) Have you ever had measles?   
a) If yes, approximately when?   Date:   
  
2) Have you ever had varicella (aka chicken pox)?  a) If yes, 
approximately when?   Date:   
  
3) If you have not had measles or varicella (chicken pox) or you 
are unsure, have you ever received a vaccination for measles (often 
included with vaccinations for mumps, rubella, and sometimes 
varicella/chicken pox, known as MMR or MMRV)?   
a) If yes, what type  of vaccine did you receive?   
□ 2 doses as a child    □ 2 doses as an adult  
□ 1 dose as a child    □ 1 dose as an adult  
□ 0 doses as a child    □ 0 doses as an adult  
  
b) If yes, approximately when did you receive your dose(s)?    
Year of 1st dose:   
Year of 2nd dose:  
  
4) Have you ever received a pneumococcal vaccination (pneumonia)?  a) 
If yes, approximately when?   Date:   
  
5) Have you ever received a tuberculosis vaccination (this is not the same 
as the “TB skin test”)?   
a) If yes, approximately when?    Date:   
  
  
  
  
  
  
  
  
 
  
             The Respi[INVESTIGATOR_466877] – Perl, Radonovich  
   
    
  
  
137  